

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/12328 A2

- (51) International Patent Classification⁷: C07K 14/47
- (21) International Application Number: PCT/US01/24218
- (22) International Filing Date: 31 July 2001 (31.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/223,283 3 August 2000 (03.08.2000) US
60/279,763 28 March 2001 (28.03.2001) US
60/302,051 29 June 2001 (29.06.2001) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): CORIXA CORPORATION [US/US]; 1124 Columbia Street, Suite 200, Seattle, WA 98104 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): KING, Gordon, E. [US/US]; 15716 First Avenue N.W., Shoreline, WA 98177 (US). MEAGHER, Madeleine, Joy [US/US]; 507 N.E. 71st Street, #1, Seattle, WA 98115 (US). XU, Jiangchun [US/US]; 15805 S.E. 43rd Place, Bellevue, WA 98006 (US). SECRIST, Heather [US/US]; 3844 35th Avenue W., Seattle, WA 98199 (US).
- (74) Agents: POTTER, Jane, E., R. et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).
- Published:
— without international search report and to be republished upon receipt of that report
— with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (48) Date of publication of this corrected version: 30 May 2002
- (15) Information about Correction:
see PCT Gazette No. 22/2002 of 30 May 2002, Section II
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF COLON CANCER

(57) Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

H7

POS0-X30

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/012328 A3(51) International Patent Classification⁷: C12N 15/12,
C07K 14/47, G01N 33/574, C12Q 1/68, A61K 38/17

(21) International Application Number: PCT/US01/24218

(22) International Filing Date: 31 July 2001 (31.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/223,283 3 August 2000 (03.08.2000) US
60/279,763 28 March 2001 (28.03.2001) US
60/302,051 29 June 2001 (29.06.2001) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): CORIXA CORPORATION [US/US]; 1124 Columbia Street, Suite 200, Seattle, WA 98104 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): KING, Gordon, E. [US/US]; 15716 First Avenue N.W., Shoreline, WA 98177 (US). MEAGHER, Madeleine, Joy [US/US]; 507 N.E. 71st Street, #1, Seattle, WA 98115 (US). XU, Jiangchun [US/US]; 15805 S.E. 43rd Place, Bellevue, WA 98006 (US). SECRIST, Heather [US/US]; 3844 35th Avenue W., Seattle, WA 98199 (US).

(74) Agents: POTTER, Jane, E., R. et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:
20 February 2003

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 22/2002 of 30 May 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/012328 A3

(54) Title: COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF COLON CANCER

(57) Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

INTERNATIONAL SEARCH REPORT

International Classification No

PCT/US 01/24218

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 G01N33/574 C12Q1/68 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N G01N C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, EMBL, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL20 May 1999 (1999-05-20) "Homo sapiens mRNA; cDNA DKFZp586A1123 (from clone DKFZp586A1123); partial cds." Database accession no. AL050181 XP002195313 the whole document	1-17
X	WO 00 37643 A (MEAGHER MADELEINE JOY; CORIXA CORP (US); WANG TONGTONG (US); YUQIU) 29 June 2000 (2000-06-29) the whole document --- -/--	1-17

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 April 2002

Date of mailing of the international search report

19. 07. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bucka, A

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/24218

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J-M FRIGERIO ET AL: "Analysis of 2166 clones from a human colorectal cancer cDNA library by partial sequencing" HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 4, no. 1, 1995, pages 37-43, XP002111970 ISSN: 0964-6906 the whole document	1-17
A	--- WO 98 53319 A (KINZLER KENNETH W ;VOGELSTEIN BERT (US); UNIV JOHNS HOPKINS (US)) 26 November 1998 (1998-11-26) the whole document -----	1-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/24218

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 12, 13 and 17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-17 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claim 6 relates to a method using an agent that is defined by reference to a desirable characteristic or property, namely its ability to bind a polypeptide.

The claim covers all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to antibodies as mentioned in claim 5.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: claims 1-17 (all partially)

an isolated nucleic acid having the SEQ ID NO: 1, the protein encoded by said DNA, fusion proteins comprising this protein, expression vectors comprising the DNA sequence SEQ ID NO: 1, host cells transformed with this vector, antibodies directed against the protein encoded by SEQ ID NO: 1, oligonucleotides hybridizing to SEQ ID NO: 1, stimulated or expanded T cells, compositions and kits comprising said nucleic acids, proteins, antibodies and T cells, as well as the use of any of these compounds in methods for diagnosis and therapy of cancer, for the stimulation of an immune response and for stimulating and/or expanding T-cells

Inventions 2-1788: claims 1-17 (all partially)

idem as subject 1,
wherein invention NO: 2 is represented by SEQ ID NO: 2;
wherein each of the subsequent inventions 3 to 1787 is represented independently by the respective, subsequent SEQ ID;
and wherein invention No: 1788 is represented by the nucleotide sequence SEQ ID NO: 1788 and the deduced amino acid sequence SEQ ID NO: 1789

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/24218

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0037643	A	29-06-2000	US 6284241 B1	04-09-2001
			AU 2387900 A	12-07-2000
			EP 1144632 A2	17-10-2001
			WO 0037643 A2	29-06-2000
			US 2002076414 A1	20-06-2002
<hr/>				
WO 9853319	A	26-11-1998	AU 7499198 A	11-12-1998
			WO 9853319 A2	26-11-1998
<hr/>				

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number
WO 02/12328 A2

- (51) International Patent Classification⁷: C07K 14/47 (74) Agents: POTTER, Jane, E., R. et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).
- (21) International Application Number: PCT/US01/24218
- (22) International Filing Date: 31 July 2001 (31.07.2001) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/223,283 3 August 2000 (03.08.2000) US
60/279,763 28 March 2001 (28.03.2001) US
60/302,051 29 June 2001 (29.06.2001) US
- (71) Applicant (*for all designated States except US*): CORIXA CORPORATION [US/US]; 1124 Columbia Street, Suite 200, Seattle, WA 98104 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): KING, Gordon, E. [US/US]; 15716 First Avenue N.W., Shoreline, WA 98177 (US). MEAGHER, Madeleine, Joy [US/US]; 507 N.E. 71st Street, #1, Seattle, WA 98115 (US). XU, Jiangchun [US/US]; 15805 S.E. 43rd Place, Bellevue, WA 98006 (US). SECRIST, Heather [US/US]; 3844 35th Avenue W., Seattle, WA 98199 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF COLON CANCER

(57) Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

WO 02/12328 A2

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF COLON CANCER

INCORPORATION OF SEQUENCE LISTING ON CD-ROM BY REFERENCE

5 The Sequence Listing associated with this application is provided on CD-ROM in lieu of a paper copy under AI § 801(a), and is hereby incorporated by reference into the specification. Four CD-ROMs are provided containing identical copies of the sequence listing: CD-ROM No. 1 is labeled "COPY 1 – SEQUENCE LISTING PART," contains the file 547pc.app.txt which is 1.1 MB and created on July
10 31, 2001; CD-ROM No.2 is labeled "COPY 2 – SEQUENCE LISTING," contains the file 547pc.app.txt which is 1.1 MB and created on July 31, 2001; CD-ROM No. 3 is labeled "COPY 3 – SEQUENCE LISTING PART," contains the file 547pc.app.txt which is 1.1 MB and created on July 31, 2001; CD-ROM No. 4 is labeled "CRF Copy," contains the file 547pc.app.txt which is 1.1 Mb and created on July 31, 2001.

15 BACKGROUND OF THE INVENTION

Field of the Invention

 The present invention relates generally to therapy and diagnosis of cancer, such as colon cancer. The invention is more specifically related to polypeptides, comprising at least a portion of a colon tumor protein, and to polynucleotides encoding
20 such polypeptides. Such polypeptides and polynucleotides are useful in pharmaceutical compositions, *e.g.*, vaccines, and other compositions for the diagnosis and treatment of colon cancer.

Description of the Related Art

 Cancer is a significant health problem throughout the world. Although
25 advances have been made in detection and therapy of cancer, no vaccine or other universally successful method for prevention and/or treatment is currently available. Current therapies, which are generally based on a combination of chemotherapy or surgery and radiation, continue to prove inadequate in many patients.

 Colon cancer is the second most frequently diagnosed malignancy in the
30 United States as well as the second most common cause of cancer death. The five-year

survival rate for patients with colorectal cancer detected in an early localized stage is 92%; unfortunately, only 37% of colorectal cancer is diagnosed at this stage. The survival rate drops to 64% if the cancer is allowed to spread to adjacent organs or lymph nodes, and to 7% in patients with distant metastases.

5 The prognosis of colon cancer is directly related to the degree of penetration of the tumor through the bowel wall and the presence or absence of nodal involvement, consequently, early detection and treatment are especially important. Currently, diagnosis is aided by the use of screening assays for fecal occult blood, sigmoidoscopy, colonoscopy and double contrast barium enemas. Treatment regimens
10 are determined by the type and stage of the cancer, and include surgery, radiation therapy and/or chemotherapy. Recurrence following surgery (the most common form of therapy) is a major problem and is often the ultimate cause of death. In spite of considerable research into therapies for the disease, colon cancer remains difficult to diagnose and treat. In spite of considerable research into therapies for these and other
15 cancers, colon cancer remains difficult to diagnose and treat effectively. Accordingly, there is a need in the art for improved methods for detecting and treating such cancers. The present invention fulfills these needs and further provides other related advantages.

 In spite of considerable research into therapies for these and other cancers, colon cancer remains difficult to diagnose and treat effectively. Accordingly,
20 there is a need in the art for improved methods for detecting and treating such cancers. The present invention fulfills these needs and further provides other related advantages.

BRIEF SUMMARY OF THE INVENTION

 In one aspect, the present invention provides polynucleotide compositions comprising a sequence selected from the group consisting of:

- 25 (a) sequences provided in SEQ ID NO:1-1788;
 (b) complements of the sequences provided in SEQ ID NO:1-1788;
 (c) sequences consisting of at least 20, 25, 30, 35, 40, 45, 50, 75 and
 100 contiguous residues of a sequence provided in SEQ ID NO:1-1788;
 (d) sequences that hybridize to a sequence provided in SEQ ID
30 NO:1-1788, under moderate or highly stringent conditions;

(e) sequences having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to a sequence of SEQ ID NO:1-1788;

(f) degenerate variants of a sequence provided in SEQ ID NO:1-1788.

5

In one preferred embodiment, the polynucleotide compositions of the invention are expressed in at least about 20%, more preferably in at least about 30%, and most preferably in at least about 50% of colon tumor samples tested, at a level that is at least about 2-fold, preferably at least about 5-fold, and most preferably at least about 10-fold higher than that for normal tissues.

The present invention, in another aspect, provides polypeptide compositions comprising an amino acid sequence that is encoded by a polynucleotide sequence described above.

The present invention further provides polypeptide compositions comprising an amino acid sequence selected from the group consisting of sequences recited in SEQ ID NO:1789.

In certain preferred embodiments, the polypeptides and/or polynucleotides of the present invention are immunogenic, *i.e.*, they are capable of eliciting an immune response, particularly a humoral and/or cellular immune response, as further described herein.

The present invention further provides fragments, variants and/or derivatives of the disclosed polypeptide and/or polynucleotide sequences, wherein the fragments, variants and/or derivatives preferably have a level of immunogenic activity of at least about 50%, preferably at least about 70% and more preferably at least about 90% of the level of immunogenic activity of a polypeptide sequence set forth in SEQ ID NO:1789 or a polypeptide sequence encoded by a polynucleotide sequence set forth in SEQ ID NO:1-1788.

The present invention further provides polynucleotides that encode a polypeptide described above, expression vectors comprising such polynucleotides and host cells transformed or transfected with such expression vectors.

Within other aspects, the present invention provides pharmaceutical compositions comprising a polypeptide or polynucleotide as described above and a physiologically acceptable carrier.

Within a related aspect of the present invention, the pharmaceutical
5 compositions, *e.g.*, vaccine compositions, are provided for prophylactic or therapeutic applications. Such compositions generally comprise an immunogenic polypeptide or polynucleotide of the invention and an immunostimulant, such as an adjuvant.

The present invention further provides pharmaceutical compositions that
10 comprise: (a) an antibody or antigen-binding fragment thereof that specifically binds to a polypeptide of the present invention, or a fragment thereof; and (b) a physiologically acceptable carrier.

Within further aspects, the present invention provides pharmaceutical compositions comprising: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) a pharmaceutically acceptable carrier or excipient. Illustrative
15 antigen presenting cells include dendritic cells, macrophages, monocytes, fibroblasts and B cells.

Within related aspects, pharmaceutical compositions are provided that comprise: (a) an antigen presenting cell that expresses a polypeptide as described above and (b) an immunostimulant.

20 The present invention further provides, in other aspects, fusion proteins that comprise at least one polypeptide as described above, as well as polynucleotides encoding such fusion proteins, typically in the form of pharmaceutical compositions, *e.g.*, vaccine compositions, comprising a physiologically acceptable carrier and/or an immunostimulant. The fusions proteins may comprise multiple immunogenic
25 polypeptides or portions/variants thereof, as described herein, and may further comprise one or more polypeptide segments for facilitating the expression, purification and/or immunogenicity of the polypeptide(s).

Within further aspects, the present invention provides methods for stimulating an immune response in a patient, preferably a T cell response in a human
30 patient, comprising administering a pharmaceutical composition described herein. The patient may be afflicted with colon cancer, in which case the methods provide treatment

for the disease, or patient considered at risk for such a disease may be treated prophylactically.

Within further aspects, the present invention provides methods for inhibiting the development of a cancer in a patient, comprising administering to
5 patient a pharmaceutical composition as recited above. The patient may be afflicted with colon cancer, in which case the methods provide treatment for the disease, or patient considered at risk for such a disease may be treated prophylactically.

The present invention further provides, within other aspects, methods for removing tumor cells from a biological sample, comprising contacting a biological
10 sample with T cells that specifically react with a polypeptide of the present invention, wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the protein from the sample.

Within related aspects, methods are provided for inhibiting the development of a cancer in a patient, comprising administering to a patient a biological
15 sample treated as described above.

Methods are further provided, within other aspects, for stimulating and/or expanding T cells specific for a polypeptide of the present invention, comprising contacting T cells with one or more of: (i) a polypeptide as described above; (ii) a polynucleotide encoding such a polypeptide; and/or (iii) an antigen presenting cell that
20 expresses such a polypeptide; under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells. Isolated T cell populations comprising T cells prepared as described above are also provided.

Within further aspects, the present invention provides methods for inhibiting the development of a cancer in a patient, comprising administering to a
25 patient an effective amount of a T cell population as described above.

The present invention further provides methods for inhibiting the development of a cancer in a patient, comprising the steps of: (a) incubating CD4⁺ and/or CD8⁺ T cells isolated from a patient with one or more of: (i) a polypeptide comprising at least an immunogenic portion of polypeptide disclosed herein; (ii) a
30 polynucleotide encoding such a polypeptide; and (iii) an antigen-presenting cell that expressed such a polypeptide; and (b) administering to the patient an effective amount

of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient. Proliferated cells may, but need not, be cloned prior to administration to the patient.

Within further aspects, the present invention provides methods for
5 determining the presence or absence of a cancer, preferably a colon cancer, in a patient comprising: (a) contacting a biological sample obtained from a patient with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; and (c) comparing the amount of polypeptide with a predetermined cut-off value, and therefrom determining the presence
10 or absence of a cancer in the patient. Within preferred embodiments, the binding agent is an antibody, more preferably a monoclonal antibody.

The present invention also provides, within other aspects, methods for monitoring the progression of a cancer in a patient. Such methods comprise the steps of: (a) contacting a biological sample obtained from a patient at a first point in time
15 with a binding agent that binds to a polypeptide as recited above; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polypeptide detected in step (c) with the amount detected in step (b) and therefrom monitoring the progression of the cancer in the
20 patient.

The present invention further provides, within other aspects, methods for determining the presence or absence of a cancer in a patient, comprising the steps of: (a) contacting a biological sample, e.g., tumor sample, serum sample, etc., obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a
25 polypeptide of the present invention; (b) detecting in the sample a level of a polynucleotide, preferably mRNA, that hybridizes to the oligonucleotide; and (c) comparing the level of polynucleotide that hybridizes to the oligonucleotide with a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Within certain embodiments, the amount of mRNA is detected
30 via polymerase chain reaction using, for example, at least one oligonucleotide primer that hybridizes to a polynucleotide encoding a polypeptide as recited above, or a

complement of such a polynucleotide. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing an oligonucleotide probe that hybridizes to a polynucleotide that encodes a polypeptide as recited above, or a complement of such a polynucleotide.

- 5 In related aspects, methods are provided for monitoring the progression of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a polypeptide of the present invention; (b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; (c) repeating steps (a) and (b)
- 10 using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polynucleotide detected in step (c) with the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

- Within further aspects, the present invention provides antibodies, such as
- 15 monoclonal antibodies, that bind to a polypeptide as described above, as well as diagnostic kits comprising such antibodies. Diagnostic kits comprising one or more oligonucleotide probes or primers as described above are also provided.

- These and other aspects of the present invention will become apparent upon reference to the following detailed description. All references disclosed herein are
- 20 hereby incorporated by reference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF THE SEQUENCE IDENTIFIERS

SEQ ID NO:1	is the determined cDNA sequence for clone	'58123.1'
SEQ ID NO:2	is the determined cDNA sequence for clone	'58124.1'
SEQ ID NO:3	is the determined cDNA sequence for clone	'58125.1'
SEQ ID NO:4	is the determined cDNA sequence for clone	'58126.1'
SEQ ID NO:5	is the determined cDNA sequence for clone	'58127.1'
SEQ ID NO:6	is the determined cDNA sequence for clone	'58128.1'
SEQ ID NO:7	is the determined cDNA sequence for clone	'58130.1'
SEQ ID NO:8	is the determined cDNA sequence for clone	'58131.1'
SEQ ID NO:9	is the determined cDNA sequence for clone	'58132.1'
SEQ ID NO:10	is the determined cDNA sequence for clone	'58133.1'

SEQ ID NO:11	is the determined cDNA sequence for clone	'58135.1'
SEQ ID NO:12	is the determined cDNA sequence for clone	'58136.1'
SEQ ID NO:13	is the determined cDNA sequence for clone	'58138.1'
SEQ ID NO:14	is the determined cDNA sequence for clone	'58139.1'
SEQ ID NO:15	is the determined cDNA sequence for clone	'58141.1'
SEQ ID NO:16	is the determined cDNA sequence for clone	'58142.1'
SEQ ID NO:17	is the determined cDNA sequence for clone	'58143.1'
SEQ ID NO:18	is the determined cDNA sequence for clone	'58144.1'
SEQ ID NO:19	is the determined cDNA sequence for clone	'58148.1'
SEQ ID NO:20	is the determined cDNA sequence for clone	'58149.1'
SEQ ID NO:21	is the determined cDNA sequence for clone	'58150.1'
SEQ ID NO:22	is the determined cDNA sequence for clone	'58151.1'
SEQ ID NO:23	is the determined cDNA sequence for clone	'58153.1'
SEQ ID NO:24	is the determined cDNA sequence for clone	'58154.1'
SEQ ID NO:25	is the determined cDNA sequence for clone	'58155.1'
SEQ ID NO:26	is the determined cDNA sequence for clone	'58156.1'
SEQ ID NO:27	is the determined cDNA sequence for clone	'58159.1'
SEQ ID NO:28	is the determined cDNA sequence for clone	'58161.1'
SEQ ID NO:29	is the determined cDNA sequence for clone	'58163.1'
SEQ ID NO:30	is the determined cDNA sequence for clone	'58164.1'
SEQ ID NO:31	is the determined cDNA sequence for clone	'58165.1'
SEQ ID NO:32	is the determined cDNA sequence for clone	'58166.1'
SEQ ID NO:33	is the determined cDNA sequence for clone	'58167.1'
SEQ ID NO:34	is the determined cDNA sequence for clone	'58169.1'
SEQ ID NO:35	is the determined cDNA sequence for clone	'58170.1'
SEQ ID NO:36	is the determined cDNA sequence for clone	'58171.1'
SEQ ID NO:37	is the determined cDNA sequence for clone	'58172.1'
SEQ ID NO:38	is the determined cDNA sequence for clone	'58174.1'
SEQ ID NO:39	is the determined cDNA sequence for clone	'58176.1'
SEQ ID NO:40	is the determined cDNA sequence for clone	'58177.1'
SEQ ID NO:41	is the determined cDNA sequence for clone	'58178.1'
SEQ ID NO:42	is the determined cDNA sequence for clone	'58183.1'
SEQ ID NO:43	is the determined cDNA sequence for clone	'58185.1'
SEQ ID NO:44	is the determined cDNA sequence for clone	'58186.1'
SEQ ID NO:45	is the determined cDNA sequence for clone	'58189.1'
SEQ ID NO:46	is the determined cDNA sequence for clone	'58190.1'
SEQ ID NO:47	is the determined cDNA sequence for clone	'58194.1'
SEQ ID NO:48	is the determined cDNA sequence for clone	'58196.1'
SEQ ID NO:49	is the determined cDNA sequence for clone	'58203.1'
SEQ ID NO:50	is the determined cDNA sequence for clone	'58204.1'
SEQ ID NO:51	is the determined cDNA sequence for clone	'58205.1'
SEQ ID NO:52	is the determined cDNA sequence for clone	'58206.1'
SEQ ID NO:53	is the determined cDNA sequence for clone	'58208.1'
SEQ ID NO:54	is the determined cDNA sequence for clone	'58214.1'
SEQ ID NO:55	is the determined cDNA sequence for clone	'58215.1'
SEQ ID NO:56	is the determined cDNA sequence for clone	'58216.1'

SEQ ID NO:57	is the determined cDNA sequence for clone	'58218.1'
SEQ ID NO:58	is the determined cDNA sequence for clone	'69339.1'
SEQ ID NO:59	is the determined cDNA sequence for clone	'69340.1'
SEQ ID NO:60	is the determined cDNA sequence for clone	'69341.1'
SEQ ID NO:61	is the determined cDNA sequence for clone	'69342.1'
SEQ ID NO:62	is the determined cDNA sequence for clone	'69343.1'
SEQ ID NO:63	is the determined cDNA sequence for clone	'69344.1'
SEQ ID NO:64	is the determined cDNA sequence for clone	'69345.1'
SEQ ID NO:65	is the determined cDNA sequence for clone	'69346.1'
SEQ ID NO:66	is the determined cDNA sequence for clone	'69347.1'
SEQ ID NO:67	is the determined cDNA sequence for clone	'69348.1'
SEQ ID NO:68	is the determined cDNA sequence for clone	'69349.1'
SEQ ID NO:69	is the determined cDNA sequence for clone	'69350.1'
SEQ ID NO:70	is the determined cDNA sequence for clone	'69351.1'
SEQ ID NO:71	is the determined cDNA sequence for clone	'69352.1'
SEQ ID NO:72	is the determined cDNA sequence for clone	'69353.1'
SEQ ID NO:73	is the determined cDNA sequence for clone	'69354.1'
SEQ ID NO:74	is the determined cDNA sequence for clone	'69355.1'
SEQ ID NO:75	is the determined cDNA sequence for clone	'69357.1'
SEQ ID NO:76	is the determined cDNA sequence for clone	'69358.1'
SEQ ID NO:77	is the determined cDNA sequence for clone	'69360.1'
SEQ ID NO:78	is the determined cDNA sequence for clone	'69965.1'
SEQ ID NO:79	is the determined cDNA sequence for clone	'69966.1'
SEQ ID NO:80	is the determined cDNA sequence for clone	'69967.1'
SEQ ID NO:81	is the determined cDNA sequence for clone	'69969.1'
SEQ ID NO:82	is the determined cDNA sequence for clone	'69970.1'
SEQ ID NO:83	is the determined cDNA sequence for clone	'69971.1'
SEQ ID NO:84	is the determined cDNA sequence for clone	'69972.1'
SEQ ID NO:85	is the determined cDNA sequence for clone	'69974.1'
SEQ ID NO:86	is the determined cDNA sequence for clone	'69975.1'
SEQ ID NO:87	is the determined cDNA sequence for clone	'69976.1'
SEQ ID NO:88	is the determined cDNA sequence for clone	'69977.1'
SEQ ID NO:89	is the determined cDNA sequence for clone	'69978.1'
SEQ ID NO:90	is the determined cDNA sequence for clone	'69980.1'
SEQ ID NO:91	is the determined cDNA sequence for clone	'69981.1'
SEQ ID NO:92	is the determined cDNA sequence for clone	'69982.1'
SEQ ID NO:93	is the determined cDNA sequence for clone	'69983.1'
SEQ ID NO:94	is the determined cDNA sequence for clone	'69984.1'
SEQ ID NO:95	is the determined cDNA sequence for clone	'69985.1'
SEQ ID NO:96	is the determined cDNA sequence for clone	'69986.1'
SEQ ID NO:97	is the determined cDNA sequence for clone	'69987.1'
SEQ ID NO:98	is the determined cDNA sequence for clone	'69989.1'
SEQ ID NO:99	is the determined cDNA sequence for clone	'69990.1'
SEQ ID NO:100	is the determined cDNA sequence for clone	'69991.1'
SEQ ID NO:101	is the determined cDNA sequence for clone	'69992.1'
SEQ ID NO:102	is the determined cDNA sequence for clone	'69993.1'

SEQ ID NO:103	is the determined cDNA sequence for clone	'69994.1'
SEQ ID NO:104	is the determined cDNA sequence for clone	'69995.1'
SEQ ID NO:105	is the determined cDNA sequence for clone	'69996.1'
SEQ ID NO:106	is the determined cDNA sequence for clone	'69997.1'
SEQ ID NO:107	is the determined cDNA sequence for clone	'69999.1'
SEQ ID NO:108	is the determined cDNA sequence for clone	'70000.1'
SEQ ID NO:109	is the determined cDNA sequence for clone	'70001.1'
SEQ ID NO:110	is the determined cDNA sequence for clone	'70002.1'
SEQ ID NO:111	is the determined cDNA sequence for clone	'70003.1'
SEQ ID NO:112	is the determined cDNA sequence for clone	'70004.1'
SEQ ID NO:113	is the determined cDNA sequence for clone	'70006.1'
SEQ ID NO:114	is the determined cDNA sequence for clone	'70007.1'
SEQ ID NO:115	is the determined cDNA sequence for clone	'70009.1'
SEQ ID NO:116	is the determined cDNA sequence for clone	'70010.1'
SEQ ID NO:117	is the determined cDNA sequence for clone	'70011.1'
SEQ ID NO:118	is the determined cDNA sequence for clone	'70012.1'
SEQ ID NO:119	is the determined cDNA sequence for clone	'70013.1'
SEQ ID NO:120	is the determined cDNA sequence for clone	'70015.1'
SEQ ID NO:121	is the determined cDNA sequence for clone	'70016.1'
SEQ ID NO:122	is the determined cDNA sequence for clone	'70017.1'
SEQ ID NO:123	is the determined cDNA sequence for clone	'70018.1'
SEQ ID NO:124	is the determined cDNA sequence for clone	'70020.1'
SEQ ID NO:125	is the determined cDNA sequence for clone	'70021.1'
SEQ ID NO:126	is the determined cDNA sequence for clone	'70022.1'
SEQ ID NO:127	is the determined cDNA sequence for clone	'70024.1'
SEQ ID NO:128	is the determined cDNA sequence for clone	'70025.1'
SEQ ID NO:129	is the determined cDNA sequence for clone	'70026.1'
SEQ ID NO:130	is the determined cDNA sequence for clone	'70028.1'
SEQ ID NO:131	is the determined cDNA sequence for clone	'70029.1'
SEQ ID NO:132	is the determined cDNA sequence for clone	'70030.1'
SEQ ID NO:133	is the determined cDNA sequence for clone	'70032.1'
SEQ ID NO:134	is the determined cDNA sequence for clone	'70033.1'
SEQ ID NO:135	is the determined cDNA sequence for clone	'70034.1'
SEQ ID NO:136	is the determined cDNA sequence for clone	'70036.1'
SEQ ID NO:137	is the determined cDNA sequence for clone	'70037.1'
SEQ ID NO:138	is the determined cDNA sequence for clone	'70038.1'
SEQ ID NO:139	is the determined cDNA sequence for clone	'70040.1'
SEQ ID NO:140	is the determined cDNA sequence for clone	'70041.1'
SEQ ID NO:141	is the determined cDNA sequence for clone	'70044.1'
SEQ ID NO:142	is the determined cDNA sequence for clone	'70045.1'
SEQ ID NO:143	is the determined cDNA sequence for clone	'69489.1'
SEQ ID NO:144	is the determined cDNA sequence for clone	'69490.1'
SEQ ID NO:145	is the determined cDNA sequence for clone	'69491.1'
SEQ ID NO:146	is the determined cDNA sequence for clone	'69492.1'
SEQ ID NO:147	is the determined cDNA sequence for clone	'69493.1'
SEQ ID NO:148	is the determined cDNA sequence for clone	'69494.1'

SEQ ID NO:149	is the determined cDNA sequence for clone	'69496.1'
SEQ ID NO:150	is the determined cDNA sequence for clone	'69497.1'
SEQ ID NO:151	is the determined cDNA sequence for clone	'69498.1'
SEQ ID NO:152	is the determined cDNA sequence for clone	'69499.1'
SEQ ID NO:153	is the determined cDNA sequence for clone	'69500.1'
SEQ ID NO:154	is the determined cDNA sequence for clone	'69501.1'
SEQ ID NO:155	is the determined cDNA sequence for clone	'69503.1'
SEQ ID NO:156	is the determined cDNA sequence for clone	'69505.1'
SEQ ID NO:157	is the determined cDNA sequence for clone	'69506.1'
SEQ ID NO:158	is the determined cDNA sequence for clone	'69507.1'
SEQ ID NO:159	is the determined cDNA sequence for clone	'69508.1'
SEQ ID NO:160	is the determined cDNA sequence for clone	'69509.1'
SEQ ID NO:161	is the determined cDNA sequence for clone	'69511.1'
SEQ ID NO:162	is the determined cDNA sequence for clone	'69512.1'
SEQ ID NO:163	is the determined cDNA sequence for clone	'69513.1'
SEQ ID NO:164	is the determined cDNA sequence for clone	'69514.1'
SEQ ID NO:165	is the determined cDNA sequence for clone	'69516.1'
SEQ ID NO:166	is the determined cDNA sequence for clone	'69517.1'
SEQ ID NO:167	is the determined cDNA sequence for clone	'69518.1'
SEQ ID NO:168	is the determined cDNA sequence for clone	'69520.1'
SEQ ID NO:169	is the determined cDNA sequence for clone	'69521.1'
SEQ ID NO:170	is the determined cDNA sequence for clone	'69523.1'
SEQ ID NO:171	is the determined cDNA sequence for clone	'69524.1'
SEQ ID NO:172	is the determined cDNA sequence for clone	'69525.1'
SEQ ID NO:173	is the determined cDNA sequence for clone	'69526.1'
SEQ ID NO:174	is the determined cDNA sequence for clone	'69527.1'
SEQ ID NO:175	is the determined cDNA sequence for clone	'69528.1'
SEQ ID NO:176	is the determined cDNA sequence for clone	'69529.1'
SEQ ID NO:177	is the determined cDNA sequence for clone	'69530.1'
SEQ ID NO:178	is the determined cDNA sequence for clone	'70019.1'
SEQ ID NO:179	is the determined cDNA sequence for clone	'70023.1'
SEQ ID NO:180	is the determined cDNA sequence for clone	'70035.1'
SEQ ID NO:181	is the determined cDNA sequence for clone	'70039.1'
SEQ ID NO:182	is the determined cDNA sequence for clone	'70046.1'
SEQ ID NO:183	is the determined cDNA sequence for clone	'70047.1'
SEQ ID NO:184	is the determined cDNA sequence for clone	'70048.1'
SEQ ID NO:185	is the determined cDNA sequence for clone	'70049.1'
SEQ ID NO:186	is the determined cDNA sequence for clone	'70050.1'
SEQ ID NO:187	is the determined cDNA sequence for clone	'70051.1'
SEQ ID NO:188	is the determined cDNA sequence for clone	'70052.1'
SEQ ID NO:189	is the determined cDNA sequence for clone	'70053.1'
SEQ ID NO:190	is the determined cDNA sequence for clone	'70054.1'
SEQ ID NO:191	is the determined cDNA sequence for clone	'70055.1'
SEQ ID NO:192	is the determined cDNA sequence for clone	'70058.1'
SEQ ID NO:193	is the determined cDNA sequence for clone	'70059.1'
SEQ ID NO:194	is the determined cDNA sequence for clone	'70060.1'

SEQ ID NO:195	is the determined cDNA sequence for clone	'70061.1'
SEQ ID NO:196	is the determined cDNA sequence for clone	'70064.1'
SEQ ID NO:197	is the determined cDNA sequence for clone	'70065.1'
SEQ ID NO:198	is the determined cDNA sequence for clone	'70066.1'
SEQ ID NO:199	is the determined cDNA sequence for clone	'70067.1'
SEQ ID NO:200	is the determined cDNA sequence for clone	'70068.1'
SEQ ID NO:201	is the determined cDNA sequence for clone	'70069.1'
SEQ ID NO:202	is the determined cDNA sequence for clone	'70070.1'
SEQ ID NO:203	is the determined cDNA sequence for clone	'70071.1'
SEQ ID NO:204	is the determined cDNA sequence for clone	'70072.1'
SEQ ID NO:205	is the determined cDNA sequence for clone	'70073.1'
SEQ ID NO:206	is the determined cDNA sequence for clone	'70074.1'
SEQ ID NO:207	is the determined cDNA sequence for clone	'70075.1'
SEQ ID NO:208	is the determined cDNA sequence for clone	'70077.1'
SEQ ID NO:209	is the determined cDNA sequence for clone	'70078.1'
SEQ ID NO:210	is the determined cDNA sequence for clone	'70079.1'
SEQ ID NO:211	is the determined cDNA sequence for clone	'70144.1'
SEQ ID NO:212	is the determined cDNA sequence for clone	'70145.1'
SEQ ID NO:213	is the determined cDNA sequence for clone	'70146.1'
SEQ ID NO:214	is the determined cDNA sequence for clone	'70147.1'
SEQ ID NO:215	is the determined cDNA sequence for clone	'70148.1'
SEQ ID NO:216	is the determined cDNA sequence for clone	'70149.1'
SEQ ID NO:217	is the determined cDNA sequence for clone	'70150.1'
SEQ ID NO:218	is the determined cDNA sequence for clone	'70151.1'
SEQ ID NO:219	is the determined cDNA sequence for clone	'70152.1'
SEQ ID NO:220	is the determined cDNA sequence for clone	'70153.1'
SEQ ID NO:221	is the determined cDNA sequence for clone	'70154.1'
SEQ ID NO:222	is the determined cDNA sequence for clone	'70155.1'
SEQ ID NO:223	is the determined cDNA sequence for clone	'70158.1'
SEQ ID NO:224	is the determined cDNA sequence for clone	'70159.1'
SEQ ID NO:225	is the determined cDNA sequence for clone	'70160.1'
SEQ ID NO:226	is the determined cDNA sequence for clone	'70161.1'
SEQ ID NO:227	is the determined cDNA sequence for clone	'70162.1'
SEQ ID NO:228	is the determined cDNA sequence for clone	'70163.1'
SEQ ID NO:229	is the determined cDNA sequence for clone	'70165.1'
SEQ ID NO:230	is the determined cDNA sequence for clone	63690041 R0663:A02
SEQ ID NO:231	is the determined cDNA sequence for clone	63690042 R0663:A03
SEQ ID NO:232	is the determined cDNA sequence for clone	63690043 R0663:A05
SEQ ID NO:233	is the determined cDNA sequence for clone	63690045 R0663:A07
SEQ ID NO:234	is the determined cDNA sequence for clone	63690046 R0663:A08
SEQ ID NO:235	is the determined cDNA sequence for clone	63690047 R0663:A09
SEQ ID NO:236	is the determined cDNA sequence for clone	63690048 R0663:A10
SEQ ID NO:237	is the determined cDNA sequence for clone	63690049 R0663:A11
SEQ ID NO:238	is the determined cDNA sequence for clone	63690050 R0663:A12
SEQ ID NO:239	is the determined cDNA sequence for clone	63690051 R0663:B01
SEQ ID NO:240	is the determined cDNA sequence for clone	63690052 R0663:B02

SEQ ID NO:241	is the determined cDNA sequence for clone	63690053 R0663:B03
SEQ ID NO:242	is the determined cDNA sequence for clone	63690054 R0663:B04
SEQ ID NO:243	is the determined cDNA sequence for clone	63690055 R0663:B05
SEQ ID NO:244	is the determined cDNA sequence for clone	63690056 R0663:B06
SEQ ID NO:245	is the determined cDNA sequence for clone	63690057 R0663:B07
SEQ ID NO:246	is the determined cDNA sequence for clone	63690058 R0663:B08
SEQ ID NO:247	is the determined cDNA sequence for clone	63690059 R0663:B09
SEQ ID NO:248	is the determined cDNA sequence for clone	63690061 R0663:B11
SEQ ID NO:249	is the determined cDNA sequence for clone	63690062 R0663:B12
SEQ ID NO:250	is the determined cDNA sequence for clone	63690063 R0663:C01
SEQ ID NO:251	is the determined cDNA sequence for clone	63690065 R0663:C03
SEQ ID NO:252	is the determined cDNA sequence for clone	63690066 R0663:C04
SEQ ID NO:253	is the determined cDNA sequence for clone	63690067 R0663:C05
SEQ ID NO:254	is the determined cDNA sequence for clone	63690068 R0663:C06
SEQ ID NO:255	is the determined cDNA sequence for clone	63690069 R0663:C07
SEQ ID NO:256	is the determined cDNA sequence for clone	63690070 R0663:C08
SEQ ID NO:257	is the determined cDNA sequence for clone	63690071 R0663:C09
SEQ ID NO:258	is the determined cDNA sequence for clone	63690072 R0663:C10
SEQ ID NO:259	is the determined cDNA sequence for clone	63690073 R0663:C11
SEQ ID NO:260	is the determined cDNA sequence for clone	63690074 R0663:C12
SEQ ID NO:261	is the determined cDNA sequence for clone	63690075 R0663:D01
SEQ ID NO:262	is the determined cDNA sequence for clone	63690077 R0663:D03
SEQ ID NO:263	is the determined cDNA sequence for clone	63690078 R0663:D04
SEQ ID NO:264	is the determined cDNA sequence for clone	63690079 R0663:D05
SEQ ID NO:265	is the determined cDNA sequence for clone	63690080 R0663:D06
SEQ ID NO:266	is the determined cDNA sequence for clone	63690081 R0663:D07
SEQ ID NO:267	is the determined cDNA sequence for clone	63690082 R0663:D08
SEQ ID NO:268	is the determined cDNA sequence for clone	63690083 R0663:D09
SEQ ID NO:269	is the determined cDNA sequence for clone	63690084 R0663:D10
SEQ ID NO:270	is the determined cDNA sequence for clone	63690085 R0663:D11
SEQ ID NO:271	is the determined cDNA sequence for clone	63690086 R0663:D12
SEQ ID NO:272	is the determined cDNA sequence for clone	63690087 R0663:E01
SEQ ID NO:273	is the determined cDNA sequence for clone	63690088 R0663:E02
SEQ ID NO:274	is the determined cDNA sequence for clone	63690089 R0663:E03
SEQ ID NO:275	is the determined cDNA sequence for clone	63690090 R0663:E04
SEQ ID NO:276	is the determined cDNA sequence for clone	63690091 R0663:E05
SEQ ID NO:277	is the determined cDNA sequence for clone	63690092 R0663:E06
SEQ ID NO:278	is the determined cDNA sequence for clone	63690094 R0663:E08
SEQ ID NO:279	is the determined cDNA sequence for clone	63690095 R0663:E09
SEQ ID NO:280	is the determined cDNA sequence for clone	63690096 R0663:E10
SEQ ID NO:281	is the determined cDNA sequence for clone	63690097 R0663:E11
SEQ ID NO:282	is the determined cDNA sequence for clone	63690098 R0663:E12
SEQ ID NO:283	is the determined cDNA sequence for clone	63690099 R0663:F01
SEQ ID NO:284	is the determined cDNA sequence for clone	63690100 R0663:F02
SEQ ID NO:285	is the determined cDNA sequence for clone	63690101 R0663:F03
SEQ ID NO:286	is the determined cDNA sequence for clone	63690102 R0663:F04

SEQ ID NO:287	is the determined cDNA sequence for clone	63690104 R0663:F06
SEQ ID NO:288	is the determined cDNA sequence for clone	63690105 R0663:F07
SEQ ID NO:289	is the determined cDNA sequence for clone	63690106 R0663:F08
SEQ ID NO:290	is the determined cDNA sequence for clone	63690107 R0663:F09
SEQ ID NO:291	is the determined cDNA sequence for clone	63690108 R0663:F10
SEQ ID NO:292	is the determined cDNA sequence for clone	63690109 R0663:F11
SEQ ID NO:293	is the determined cDNA sequence for clone	63690110 R0663:F12
SEQ ID NO:294	is the determined cDNA sequence for clone	63690111 R0663:G01
SEQ ID NO:295	is the determined cDNA sequence for clone	63690112 R0663:G02
SEQ ID NO:296	is the determined cDNA sequence for clone	63690114 R0663:G04
SEQ ID NO:297	is the determined cDNA sequence for clone	63690115 R0663:G05
SEQ ID NO:298	is the determined cDNA sequence for clone	63690116 R0663:G06
SEQ ID NO:299	is the determined cDNA sequence for clone	63690117 R0663:G07
SEQ ID NO:300	is the determined cDNA sequence for clone	63690118 R0663:G08
SEQ ID NO:301	is the determined cDNA sequence for clone	63690119 R0663:G09
SEQ ID NO:302	is the determined cDNA sequence for clone	63690121 R0663:G11
SEQ ID NO:303	is the determined cDNA sequence for clone	63690122 R0663:G12
SEQ ID NO:304	is the determined cDNA sequence for clone	63690123 R0663:H01
SEQ ID NO:305	is the determined cDNA sequence for clone	63690124 R0663:H02
SEQ ID NO:306	is the determined cDNA sequence for clone	63690125 R0663:H03
SEQ ID NO:307	is the determined cDNA sequence for clone	63690126 R0663:H04
SEQ ID NO:308	is the determined cDNA sequence for clone	63690127 R0663:H05
SEQ ID NO:309	is the determined cDNA sequence for clone	63690128 R0663:H06
SEQ ID NO:310	is the determined cDNA sequence for clone	63690129 R0663:H07
SEQ ID NO:311	is the determined cDNA sequence for clone	63690130 R0663:H08
SEQ ID NO:312	is the determined cDNA sequence for clone	63690131 R0663:H09
SEQ ID NO:313	is the determined cDNA sequence for clone	63690132 R0663:H10
SEQ ID NO:314	is the determined cDNA sequence for clone	63690133 R0663:H11
SEQ ID NO:315	is the determined cDNA sequence for clone	63689948 R0664:A02
SEQ ID NO:316	is the determined cDNA sequence for clone	63689949 R0664:A03
SEQ ID NO:317	is the determined cDNA sequence for clone	63689950 R0664:A05
SEQ ID NO:318	is the determined cDNA sequence for clone	63689951 R0664:A06
SEQ ID NO:319	is the determined cDNA sequence for clone	63689952 R0664:A07
SEQ ID NO:320	is the determined cDNA sequence for clone	63689953 R0664:A08
SEQ ID NO:321	is the determined cDNA sequence for clone	63689954 R0664:A09
SEQ ID NO:322	is the determined cDNA sequence for clone	63689956 R0664:A11
SEQ ID NO:323	is the determined cDNA sequence for clone	63689957 R0664:A12
SEQ ID NO:324	is the determined cDNA sequence for clone	63689959 R0664:B02
SEQ ID NO:325	is the determined cDNA sequence for clone	63689961 R0664:B04
SEQ ID NO:326	is the determined cDNA sequence for clone	63689962 R0664:B05
SEQ ID NO:327	is the determined cDNA sequence for clone	63689963 R0664:B06
SEQ ID NO:328	is the determined cDNA sequence for clone	63689964 R0664:B07
SEQ ID NO:329	is the determined cDNA sequence for clone	63689965 R0664:B08
SEQ ID NO:330	is the determined cDNA sequence for clone	63689966 R0664:B09
SEQ ID NO:331	is the determined cDNA sequence for clone	63689967 R0664:B10
SEQ ID NO:332	is the determined cDNA sequence for clone	63689968 R0664:B11

SEQ ID NO:333	is the determined cDNA sequence for clone	63689969 R0664:B12
SEQ ID NO:334	is the determined cDNA sequence for clone	63689970 R0664:C01
SEQ ID NO:335	is the determined cDNA sequence for clone	63689972 R0664:C03
SEQ ID NO:336	is the determined cDNA sequence for clone	63689973 R0664:C04
SEQ ID NO:337	is the determined cDNA sequence for clone	63689974 R0664:C05
SEQ ID NO:338	is the determined cDNA sequence for clone	63689975 R0664:C06
SEQ ID NO:339	is the determined cDNA sequence for clone	63689976 R0664:C07
SEQ ID NO:340	is the determined cDNA sequence for clone	63689977 R0664:C08
SEQ ID NO:341	is the determined cDNA sequence for clone	63689978 R0664:C09
SEQ ID NO:342	is the determined cDNA sequence for clone	63689979 R0664:C10
SEQ ID NO:343	is the determined cDNA sequence for clone	63689980 R0664:C11
SEQ ID NO:344	is the determined cDNA sequence for clone	63689981 R0664:C12
SEQ ID NO:345	is the determined cDNA sequence for clone	63689982 R0664:D01
SEQ ID NO:346	is the determined cDNA sequence for clone	63689983 R0664:D02
SEQ ID NO:347	is the determined cDNA sequence for clone	63689984 R0664:D03
SEQ ID NO:348	is the determined cDNA sequence for clone	63689985 R0664:D04
SEQ ID NO:349	is the determined cDNA sequence for clone	63689986 R0664:D05
SEQ ID NO:350	is the determined cDNA sequence for clone	63689987 R0664:D06
SEQ ID NO:351	is the determined cDNA sequence for clone	63689988 R0664:D07
SEQ ID NO:352	is the determined cDNA sequence for clone	63689990 R0664:D09
SEQ ID NO:353	is the determined cDNA sequence for clone	63689992 R0664:D11
SEQ ID NO:354	is the determined cDNA sequence for clone	63689993 R0664:D12
SEQ ID NO:355	is the determined cDNA sequence for clone	63689994 R0664:E01
SEQ ID NO:356	is the determined cDNA sequence for clone	63689995 R0664:E02
SEQ ID NO:357	is the determined cDNA sequence for clone	63689996 R0664:E03
SEQ ID NO:358	is the determined cDNA sequence for clone	63689997 R0664:E04
SEQ ID NO:359	is the determined cDNA sequence for clone	63689998 R0664:E05
SEQ ID NO:360	is the determined cDNA sequence for clone	63689999 R0664:E06
SEQ ID NO:361	is the determined cDNA sequence for clone	63690000 R0664:E07
SEQ ID NO:362	is the determined cDNA sequence for clone	63690001 R0664:E08
SEQ ID NO:363	is the determined cDNA sequence for clone	63690002 R0664:E09
SEQ ID NO:364	is the determined cDNA sequence for clone	63690003 R0664:E10
SEQ ID NO:365	is the determined cDNA sequence for clone	63690004 R0664:E11
SEQ ID NO:366	is the determined cDNA sequence for clone	63690006 R0664:F01
SEQ ID NO:367	is the determined cDNA sequence for clone	63690007 R0664:F02
SEQ ID NO:368	is the determined cDNA sequence for clone	63690008 R0664:F03
SEQ ID NO:369	is the determined cDNA sequence for clone	63690009 R0664:F04
SEQ ID NO:370	is the determined cDNA sequence for clone	63690010 R0664:F05
SEQ ID NO:371	is the determined cDNA sequence for clone	63690011 R0664:F06
SEQ ID NO:372	is the determined cDNA sequence for clone	63690012 R0664:F07
SEQ ID NO:373	is the determined cDNA sequence for clone	63690013 R0664:F08
SEQ ID NO:374	is the determined cDNA sequence for clone	63690014 R0664:F09
SEQ ID NO:375	is the determined cDNA sequence for clone	63690015 R0664:F10
SEQ ID NO:376	is the determined cDNA sequence for clone	63690016 R0664:F11
SEQ ID NO:377	is the determined cDNA sequence for clone	63690017 R0664:F12
SEQ ID NO:378	is the determined cDNA sequence for clone	63690030 R0664:H01

SEQ ID NO:379	is the determined cDNA sequence for clone	63690031 R0664:H02
SEQ ID NO:380	is the determined cDNA sequence for clone	63690032 R0664:H03
SEQ ID NO:381	is the determined cDNA sequence for clone	63690033 R0664:H04
SEQ ID NO:382	is the determined cDNA sequence for clone	63690034 R0664:H05
SEQ ID NO:383	is the determined cDNA sequence for clone	63690035 R0664:H06
SEQ ID NO:384	is the determined cDNA sequence for clone	63690037 R0664:H08
SEQ ID NO:385	is the determined cDNA sequence for clone	63690038 R0664:H09
SEQ ID NO:386	is the determined cDNA sequence for clone	63690040 R0664:H11
SEQ ID NO:387	is the determined cDNA sequence for clone	63689762 R0665:A02
SEQ ID NO:388	is the determined cDNA sequence for clone	63689763 R0665:A03
SEQ ID NO:389	is the determined cDNA sequence for clone	63689764 R0665:A05
SEQ ID NO:390	is the determined cDNA sequence for clone	63689765 R0665:A06
SEQ ID NO:391	is the determined cDNA sequence for clone	63689766 R0665:A07
SEQ ID NO:392	is the determined cDNA sequence for clone	63689767 R0665:A08
SEQ ID NO:393	is the determined cDNA sequence for clone	63689768 R0665:A09
SEQ ID NO:394	is the determined cDNA sequence for clone	63689769 R0665:A10
SEQ ID NO:395	is the determined cDNA sequence for clone	63689770 R0665:A11
SEQ ID NO:396	is the determined cDNA sequence for clone	63689771 R0665:A12
SEQ ID NO:397	is the determined cDNA sequence for clone	63689772 R0665:B01
SEQ ID NO:398	is the determined cDNA sequence for clone	63689773 R0665:B02
SEQ ID NO:399	is the determined cDNA sequence for clone	63689774 R0665:B03
SEQ ID NO:400	is the determined cDNA sequence for clone	63689775 R0665:B04
SEQ ID NO:401	is the determined cDNA sequence for clone	63689777 R0665:B06
SEQ ID NO:402	is the determined cDNA sequence for clone	63689778 R0665:B07
SEQ ID NO:403	is the determined cDNA sequence for clone	63689780 R0665:B09
SEQ ID NO:404	is the determined cDNA sequence for clone	63689781 R0665:B10
SEQ ID NO:405	is the determined cDNA sequence for clone	63689782 R0665:B11
SEQ ID NO:406	is the determined cDNA sequence for clone	63689783 R0665:B12
SEQ ID NO:407	is the determined cDNA sequence for clone	63689784 R0665:C01
SEQ ID NO:408	is the determined cDNA sequence for clone	63689785 R0665:C02
SEQ ID NO:409	is the determined cDNA sequence for clone	63689786 R0665:C03
SEQ ID NO:410	is the determined cDNA sequence for clone	63689788 R0665:C05
SEQ ID NO:411	is the determined cDNA sequence for clone	63689789 R0665:C06
SEQ ID NO:412	is the determined cDNA sequence for clone	63689790 R0665:C07
SEQ ID NO:413	is the determined cDNA sequence for clone	63689791 R0665:C08
SEQ ID NO:414	is the determined cDNA sequence for clone	63689792 R0665:C09
SEQ ID NO:415	is the determined cDNA sequence for clone	63689793 R0665:C10
SEQ ID NO:416	is the determined cDNA sequence for clone	63689794 R0665:C11
SEQ ID NO:417	is the determined cDNA sequence for clone	63689795 R0665:C12
SEQ ID NO:418	is the determined cDNA sequence for clone	63689797 R0665:D02
SEQ ID NO:419	is the determined cDNA sequence for clone	63689798 R0665:D03
SEQ ID NO:420	is the determined cDNA sequence for clone	63689799 R0665:D04
SEQ ID NO:421	is the determined cDNA sequence for clone	63689801 R0665:D06
SEQ ID NO:422	is the determined cDNA sequence for clone	63689802 R0665:D07
SEQ ID NO:423	is the determined cDNA sequence for clone	63689804 R0665:D09
SEQ ID NO:424	is the determined cDNA sequence for clone	63689805 R0665:D10

SEQ ID NO:425	is the determined cDNA sequence for clone	63689806 R0665:D11
SEQ ID NO:426	is the determined cDNA sequence for clone	63689807 R0665:D12
SEQ ID NO:427	is the determined cDNA sequence for clone	63689808 R0665:E01
SEQ ID NO:428	is the determined cDNA sequence for clone	63689809 R0665:E02
SEQ ID NO:429	is the determined cDNA sequence for clone	63689810 R0665:E03
SEQ ID NO:430	is the determined cDNA sequence for clone	63689811 R0665:E04
SEQ ID NO:431	is the determined cDNA sequence for clone	63689812 R0665:E05
SEQ ID NO:432	is the determined cDNA sequence for clone	63689813 R0665:E06
SEQ ID NO:433	is the determined cDNA sequence for clone	63689814 R0665:E07
SEQ ID NO:434	is the determined cDNA sequence for clone	63689815 R0665:E08
SEQ ID NO:435	is the determined cDNA sequence for clone	63689816 R0665:E09
SEQ ID NO:436	is the determined cDNA sequence for clone	63689817 R0665:E10
SEQ ID NO:437	is the determined cDNA sequence for clone	63689818 R0665:E11
SEQ ID NO:438	is the determined cDNA sequence for clone	63689819 R0665:E12
SEQ ID NO:439	is the determined cDNA sequence for clone	63689820 R0665:F01
SEQ ID NO:440	is the determined cDNA sequence for clone	63689821 R0665:F02
SEQ ID NO:441	is the determined cDNA sequence for clone	63689824 R0665:F05
SEQ ID NO:442	is the determined cDNA sequence for clone	63689825 R0665:F06
SEQ ID NO:443	is the determined cDNA sequence for clone	63689826 R0665:F07
SEQ ID NO:444	is the determined cDNA sequence for clone	63689827 R0665:F08
SEQ ID NO:445	is the determined cDNA sequence for clone	63689828 R0665:F09
SEQ ID NO:446	is the determined cDNA sequence for clone	63689829 R0665:F10
SEQ ID NO:447	is the determined cDNA sequence for clone	63689830 R0665:F11
SEQ ID NO:448	is the determined cDNA sequence for clone	63689832 R0665:G01
SEQ ID NO:449	is the determined cDNA sequence for clone	63689833 R0665:G02
SEQ ID NO:450	is the determined cDNA sequence for clone	63689834 R0665:G03
SEQ ID NO:451	is the determined cDNA sequence for clone	63689837 R0665:G06
SEQ ID NO:452	is the determined cDNA sequence for clone	63689838 R0665:G07
SEQ ID NO:453	is the determined cDNA sequence for clone	63689839 R0665:G08
SEQ ID NO:454	is the determined cDNA sequence for clone	63689840 R0665:G09
SEQ ID NO:455	is the determined cDNA sequence for clone	63689842 R0665:G11
SEQ ID NO:456	is the determined cDNA sequence for clone	63689843 R0665:G12
SEQ ID NO:457	is the determined cDNA sequence for clone	63689845 R0665:H02
SEQ ID NO:458	is the determined cDNA sequence for clone	63689846 R0665:H03
SEQ ID NO:459	is the determined cDNA sequence for clone	63689847 R0665:H04
SEQ ID NO:460	is the determined cDNA sequence for clone	63689848 R0665:H05
SEQ ID NO:461	is the determined cDNA sequence for clone	63689849 R0665:H06
SEQ ID NO:462	is the determined cDNA sequence for clone	63689850 R0665:H07
SEQ ID NO:463	is the determined cDNA sequence for clone	63689851 R0665:H08
SEQ ID NO:464	is the determined cDNA sequence for clone	63689852 R0665:H09
SEQ ID NO:465	is the determined cDNA sequence for clone	63689853 R0665:H10
SEQ ID NO:466	is the determined cDNA sequence for clone	63689854 R0665:H11
SEQ ID NO:467	is the determined cDNA sequence for clone	63689577 R0666:A03
SEQ ID NO:468	is the determined cDNA sequence for clone	63689578 R0666:A05
SEQ ID NO:469	is the determined cDNA sequence for clone	63689579 R0666:A06
SEQ ID NO:470	is the determined cDNA sequence for clone	63689580 R0666:A07

SEQ ID NO:471	is the determined cDNA sequence for clone	63689581 R0666:A08
SEQ ID NO:472	is the determined cDNA sequence for clone	63689582 R0666:A09
SEQ ID NO:473	is the determined cDNA sequence for clone	63689583 R0666:A10
SEQ ID NO:474	is the determined cDNA sequence for clone	63689584 R0666:A11
SEQ ID NO:475	is the determined cDNA sequence for clone	63689585 R0666:A12
SEQ ID NO:476	is the determined cDNA sequence for clone	63689586 R0666:B01
SEQ ID NO:477	is the determined cDNA sequence for clone	63689587 R0666:B02
SEQ ID NO:478	is the determined cDNA sequence for clone	63689590 R0666:B05
SEQ ID NO:479	is the determined cDNA sequence for clone	63689591 R0666:B06
SEQ ID NO:480	is the determined cDNA sequence for clone	63689592 R0666:B07
SEQ ID NO:481	is the determined cDNA sequence for clone	63689593 R0666:B08
SEQ ID NO:482	is the determined cDNA sequence for clone	63689594 R0666:B09
SEQ ID NO:483	is the determined cDNA sequence for clone	63689595 R0666:B10
SEQ ID NO:484	is the determined cDNA sequence for clone	63689596 R0666:B11
SEQ ID NO:485	is the determined cDNA sequence for clone	63689598 R0666:C01
SEQ ID NO:486	is the determined cDNA sequence for clone	63689600 R0666:C03
SEQ ID NO:487	is the determined cDNA sequence for clone	63689601 R0666:C04
SEQ ID NO:488	is the determined cDNA sequence for clone	63689602 R0666:C05
SEQ ID NO:489	is the determined cDNA sequence for clone	63689603 R0666:C06
SEQ ID NO:490	is the determined cDNA sequence for clone	63689606 R0666:C09
SEQ ID NO:491	is the determined cDNA sequence for clone	63689607 R0666:C10
SEQ ID NO:492	is the determined cDNA sequence for clone	63689608 R0666:C11
SEQ ID NO:493	is the determined cDNA sequence for clone	63689609 R0666:C12
SEQ ID NO:494	is the determined cDNA sequence for clone	63689610 R0666:D01
SEQ ID NO:495	is the determined cDNA sequence for clone	63689611 R0666:D02
SEQ ID NO:496	is the determined cDNA sequence for clone	63689612 R0666:D03
SEQ ID NO:497	is the determined cDNA sequence for clone	63689613 R0666:D04
SEQ ID NO:498	is the determined cDNA sequence for clone	63689614 R0666:D05
SEQ ID NO:499	is the determined cDNA sequence for clone	63689615 R0666:D06
SEQ ID NO:500	is the determined cDNA sequence for clone	63689616 R0666:D07
SEQ ID NO:501	is the determined cDNA sequence for clone	63689617 R0666:D08
SEQ ID NO:502	is the determined cDNA sequence for clone	63689618 R0666:D09
SEQ ID NO:503	is the determined cDNA sequence for clone	63689619 R0666:D10
SEQ ID NO:504	is the determined cDNA sequence for clone	63689620 R0666:D11
SEQ ID NO:505	is the determined cDNA sequence for clone	63689622 R0666:E01
SEQ ID NO:506	is the determined cDNA sequence for clone	63689624 R0666:E03
SEQ ID NO:507	is the determined cDNA sequence for clone	63689625 R0666:E04
SEQ ID NO:508	is the determined cDNA sequence for clone	63689626 R0666:E05
SEQ ID NO:509	is the determined cDNA sequence for clone	63689627 R0666:E06
SEQ ID NO:510	is the determined cDNA sequence for clone	63689628 R0666:E07
SEQ ID NO:511	is the determined cDNA sequence for clone	63689630 R0666:E09
SEQ ID NO:512	is the determined cDNA sequence for clone	63689631 R0666:E10
SEQ ID NO:513	is the determined cDNA sequence for clone	63689632 R0666:E11
SEQ ID NO:514	is the determined cDNA sequence for clone	63689633 R0666:E12
SEQ ID NO:515	is the determined cDNA sequence for clone	63689634 R0666:F01
SEQ ID NO:516	is the determined cDNA sequence for clone	63689635 R0666:F02

SEQ ID NO:517	is the determined cDNA sequence for clone	63689636 R0666:F03
SEQ ID NO:518	is the determined cDNA sequence for clone	63689637 R0666:F04
SEQ ID NO:519	is the determined cDNA sequence for clone	63689638 R0666:F05
SEQ ID NO:520	is the determined cDNA sequence for clone	63689639 R0666:F06
SEQ ID NO:521	is the determined cDNA sequence for clone	63689641 R0666:F08
SEQ ID NO:522	is the determined cDNA sequence for clone	63689642 R0666:F09
SEQ ID NO:523	is the determined cDNA sequence for clone	63689643 R0666:F10
SEQ ID NO:524	is the determined cDNA sequence for clone	63689644 R0666:F11
SEQ ID NO:525	is the determined cDNA sequence for clone	63689645 R0666:F12
SEQ ID NO:526	is the determined cDNA sequence for clone	63689648 R0666:G03
SEQ ID NO:527	is the determined cDNA sequence for clone	63689649 R0666:G04
SEQ ID NO:528	is the determined cDNA sequence for clone	63689650 R0666:G05
SEQ ID NO:529	is the determined cDNA sequence for clone	63689652 R0666:G07
SEQ ID NO:530	is the determined cDNA sequence for clone	63689653 R0666:G08
SEQ ID NO:531	is the determined cDNA sequence for clone	63689654 R0666:G09
SEQ ID NO:532	is the determined cDNA sequence for clone	63689655 R0666:G10
SEQ ID NO:533	is the determined cDNA sequence for clone	63689656 R0666:G11
SEQ ID NO:534	is the determined cDNA sequence for clone	63689658 R0666:H01
SEQ ID NO:535	is the determined cDNA sequence for clone	63689659 R0666:H02
SEQ ID NO:536	is the determined cDNA sequence for clone	63689660 R0666:H03
SEQ ID NO:537	is the determined cDNA sequence for clone	63689661 R0666:H04
SEQ ID NO:538	is the determined cDNA sequence for clone	63689662 R0666:H05
SEQ ID NO:539	is the determined cDNA sequence for clone	63689663 R0666:H06
SEQ ID NO:540	is the determined cDNA sequence for clone	63689664 R0666:H07
SEQ ID NO:541	is the determined cDNA sequence for clone	63689665 R0666:H08
SEQ ID NO:542	is the determined cDNA sequence for clone	63689666 R0666:H09
SEQ ID NO:543	is the determined cDNA sequence for clone	63689667 R0666:H10
SEQ ID NO:544	is the determined cDNA sequence for clone	63689668 R0666:H11
SEQ ID NO:545	is the determined cDNA sequence for clone	63689484 R0667:A03
SEQ ID NO:546	is the determined cDNA sequence for clone	63689485 R0667:A05
SEQ ID NO:547	is the determined cDNA sequence for clone	63689486 R0667:A06
SEQ ID NO:548	is the determined cDNA sequence for clone	63689487 R0667:A07
SEQ ID NO:549	is the determined cDNA sequence for clone	63689488 R0667:A08
SEQ ID NO:550	is the determined cDNA sequence for clone	63689489 R0667:A09
SEQ ID NO:551	is the determined cDNA sequence for clone	63689491 R0667:A11
SEQ ID NO:552	is the determined cDNA sequence for clone	63689492 R0667:A12
SEQ ID NO:553	is the determined cDNA sequence for clone	63689493 R0667:B01
SEQ ID NO:554	is the determined cDNA sequence for clone	63689494 R0667:B02
SEQ ID NO:555	is the determined cDNA sequence for clone	63689495 R0667:B03
SEQ ID NO:556	is the determined cDNA sequence for clone	63689496 R0667:B04
SEQ ID NO:557	is the determined cDNA sequence for clone	63689497 R0667:B05
SEQ ID NO:558	is the determined cDNA sequence for clone	63689498 R0667:B06
SEQ ID NO:559	is the determined cDNA sequence for clone	63689499 R0667:B07
SEQ ID NO:560	is the determined cDNA sequence for clone	63689500 R0667:B08
SEQ ID NO:561	is the determined cDNA sequence for clone	63689501 R0667:B09
SEQ ID NO:562	is the determined cDNA sequence for clone	63689502 R0667:B10

SEQ ID NO:563	is the determined cDNA sequence for clone	63689503 R0667:B11
SEQ ID NO:564	is the determined cDNA sequence for clone	63689504 R0667:B12
SEQ ID NO:565	is the determined cDNA sequence for clone	63689505 R0667:C01
SEQ ID NO:566	is the determined cDNA sequence for clone	63689506 R0667:C02
SEQ ID NO:567	is the determined cDNA sequence for clone	63689507 R0667:C03
SEQ ID NO:568	is the determined cDNA sequence for clone	63689508 R0667:C04
SEQ ID NO:569	is the determined cDNA sequence for clone	63689509 R0667:C05
SEQ ID NO:570	is the determined cDNA sequence for clone	63689511 R0667:C07
SEQ ID NO:571	is the determined cDNA sequence for clone	63689512 R0667:C08
SEQ ID NO:572	is the determined cDNA sequence for clone	63689514 R0667:C10
SEQ ID NO:573	is the determined cDNA sequence for clone	63689515 R0667:C11
SEQ ID NO:574	is the determined cDNA sequence for clone	63689516 R0667:C12
SEQ ID NO:575	is the determined cDNA sequence for clone	63689517 R0667:D01
SEQ ID NO:576	is the determined cDNA sequence for clone	63689518 R0667:D02
SEQ ID NO:577	is the determined cDNA sequence for clone	63689519 R0667:D03
SEQ ID NO:578	is the determined cDNA sequence for clone	63689520 R0667:D04
SEQ ID NO:579	is the determined cDNA sequence for clone	63689521 R0667:D05
SEQ ID NO:580	is the determined cDNA sequence for clone	63689522 R0667:D06
SEQ ID NO:581	is the determined cDNA sequence for clone	63689523 R0667:D07
SEQ ID NO:582	is the determined cDNA sequence for clone	63689524 R0667:D08
SEQ ID NO:583	is the determined cDNA sequence for clone	63689526 R0667:D10
SEQ ID NO:584	is the determined cDNA sequence for clone	63689527 R0667:D11
SEQ ID NO:585	is the determined cDNA sequence for clone	63689528 R0667:D12
SEQ ID NO:586	is the determined cDNA sequence for clone	63689529 R0667:E01
SEQ ID NO:587	is the determined cDNA sequence for clone	63689532 R0667:E04
SEQ ID NO:588	is the determined cDNA sequence for clone	63689533 R0667:E05
SEQ ID NO:589	is the determined cDNA sequence for clone	63689534 R0667:E06
SEQ ID NO:590	is the determined cDNA sequence for clone	63689535 R0667:E07
SEQ ID NO:591	is the determined cDNA sequence for clone	63689536 R0667:E08
SEQ ID NO:592	is the determined cDNA sequence for clone	63689537 R0667:E09
SEQ ID NO:593	is the determined cDNA sequence for clone	63689538 R0667:E10
SEQ ID NO:594	is the determined cDNA sequence for clone	63689539 R0667:E11
SEQ ID NO:595	is the determined cDNA sequence for clone	63689540 R0667:E12
SEQ ID NO:596	is the determined cDNA sequence for clone	63689541 R0667:F01
SEQ ID NO:597	is the determined cDNA sequence for clone	63689542 R0667:F02
SEQ ID NO:598	is the determined cDNA sequence for clone	63689544 R0667:F04
SEQ ID NO:599	is the determined cDNA sequence for clone	63689546 R0667:F06
SEQ ID NO:600	is the determined cDNA sequence for clone	63689547 R0667:F07
SEQ ID NO:601	is the determined cDNA sequence for clone	63689548 R0667:F08
SEQ ID NO:602	is the determined cDNA sequence for clone	63689549 R0667:F09
SEQ ID NO:603	is the determined cDNA sequence for clone	63689550 R0667:F10
SEQ ID NO:604	is the determined cDNA sequence for clone	63689551 R0667:F11
SEQ ID NO:605	is the determined cDNA sequence for clone	63689552 R0667:F12
SEQ ID NO:606	is the determined cDNA sequence for clone	63689553 R0667:G01
SEQ ID NO:607	is the determined cDNA sequence for clone	63689554 R0667:G02
SEQ ID NO:608	is the determined cDNA sequence for clone	63689555 R0667:G03

SEQ ID NO:609	is the determined cDNA sequence for clone	63689557 R0667:G05
SEQ ID NO:610	is the determined cDNA sequence for clone	63689558 R0667:G06
SEQ ID NO:611	is the determined cDNA sequence for clone	63689559 R0667:G07
SEQ ID NO:612	is the determined cDNA sequence for clone	63689560 R0667:G08
SEQ ID NO:613	is the determined cDNA sequence for clone	63689561 R0667:G09
SEQ ID NO:614	is the determined cDNA sequence for clone	63689562 R0667:G10
SEQ ID NO:615	is the determined cDNA sequence for clone	63689563 R0667:G11
SEQ ID NO:616	is the determined cDNA sequence for clone	63689564 R0667:G12
SEQ ID NO:617	is the determined cDNA sequence for clone	63689565 R0667:H01
SEQ ID NO:618	is the determined cDNA sequence for clone	63689566 R0667:H02
SEQ ID NO:619	is the determined cDNA sequence for clone	63689569 R0667:H05
SEQ ID NO:620	is the determined cDNA sequence for clone	63689570 R0667:H06
SEQ ID NO:621	is the determined cDNA sequence for clone	63689571 R0667:H07
SEQ ID NO:622	is the determined cDNA sequence for clone	63689572 R0667:H08
SEQ ID NO:623	is the determined cDNA sequence for clone	63689573 R0667:H09
SEQ ID NO:624	is the determined cDNA sequence for clone	63689574 R0667:H10
SEQ ID NO:625	is the determined cDNA sequence for clone	63689575 R0667:H11
SEQ ID NO:626	is the determined cDNA sequence for clone	63689390 R0668:A02
SEQ ID NO:627	is the determined cDNA sequence for clone	63689391 R0668:A03
SEQ ID NO:628	is the determined cDNA sequence for clone	63689392 R0668:A05
SEQ ID NO:629	is the determined cDNA sequence for clone	63689393 R0668:A06
SEQ ID NO:630	is the determined cDNA sequence for clone	63689394 R0668:A07
SEQ ID NO:631	is the determined cDNA sequence for clone	63689395 R0668:A08
SEQ ID NO:632	is the determined cDNA sequence for clone	63689396 R0668:A09
SEQ ID NO:633	is the determined cDNA sequence for clone	63689397 R0668:A10
SEQ ID NO:634	is the determined cDNA sequence for clone	63689398 R0668:A11
SEQ ID NO:635	is the determined cDNA sequence for clone	63689399 R0668:A12
SEQ ID NO:636	is the determined cDNA sequence for clone	63689401 R0668:B02
SEQ ID NO:637	is the determined cDNA sequence for clone	63689402 R0668:B03
SEQ ID NO:638	is the determined cDNA sequence for clone	63689403 R0668:B04
SEQ ID NO:639	is the determined cDNA sequence for clone	63689404 R0668:B05
SEQ ID NO:640	is the determined cDNA sequence for clone	63689405 R0668:B06
SEQ ID NO:641	is the determined cDNA sequence for clone	63689406 R0668:B07
SEQ ID NO:642	is the determined cDNA sequence for clone	63689407 R0668:B08
SEQ ID NO:643	is the determined cDNA sequence for clone	63689408 R0668:B09
SEQ ID NO:644	is the determined cDNA sequence for clone	63689409 R0668:B10
SEQ ID NO:645	is the determined cDNA sequence for clone	63689410 R0668:B11
SEQ ID NO:646	is the determined cDNA sequence for clone	63689411 R0668:B12
SEQ ID NO:647	is the determined cDNA sequence for clone	63689412 R0668:C01
SEQ ID NO:648	is the determined cDNA sequence for clone	63689413 R0668:C02
SEQ ID NO:649	is the determined cDNA sequence for clone	63689414 R0668:C03
SEQ ID NO:650	is the determined cDNA sequence for clone	63689415 R0668:C04
SEQ ID NO:651	is the determined cDNA sequence for clone	63689416 R0668:C05
SEQ ID NO:652	is the determined cDNA sequence for clone	63689417 R0668:C06
SEQ ID NO:653	is the determined cDNA sequence for clone	63689418 R0668:C07
SEQ ID NO:654	is the determined cDNA sequence for clone	63689419 R0668:C08

SEQ ID NO:655	is the determined cDNA sequence for clone	63689420 R0668:C09
SEQ ID NO:656	is the determined cDNA sequence for clone	63689421 R0668:C10
SEQ ID NO:657	is the determined cDNA sequence for clone	63689422 R0668:C11
SEQ ID NO:658	is the determined cDNA sequence for clone	63689423 R0668:C12
SEQ ID NO:659	is the determined cDNA sequence for clone	63689424 R0668:D01
SEQ ID NO:660	is the determined cDNA sequence for clone	63689425 R0668:D02
SEQ ID NO:661	is the determined cDNA sequence for clone	63689426 R0668:D03
SEQ ID NO:662	is the determined cDNA sequence for clone	63689427 R0668:D04
SEQ ID NO:663	is the determined cDNA sequence for clone	63689428 R0668:D05
SEQ ID NO:664	is the determined cDNA sequence for clone	63689429 R0668:D06
SEQ ID NO:665	is the determined cDNA sequence for clone	63689430 R0668:D07
SEQ ID NO:666	is the determined cDNA sequence for clone	63689431 R0668:D08
SEQ ID NO:667	is the determined cDNA sequence for clone	63689432 R0668:D09
SEQ ID NO:668	is the determined cDNA sequence for clone	63689433 R0668:D10
SEQ ID NO:669	is the determined cDNA sequence for clone	63689434 R0668:D11
SEQ ID NO:670	is the determined cDNA sequence for clone	63689435 R0668:D12
SEQ ID NO:671	is the determined cDNA sequence for clone	63689436 R0668:E01
SEQ ID NO:672	is the determined cDNA sequence for clone	63689437 R0668:E02
SEQ ID NO:673	is the determined cDNA sequence for clone	63689438 R0668:E03
SEQ ID NO:674	is the determined cDNA sequence for clone	63689439 R0668:E04
SEQ ID NO:675	is the determined cDNA sequence for clone	63689440 R0668:E05
SEQ ID NO:676	is the determined cDNA sequence for clone	63689441 R0668:E06
SEQ ID NO:677	is the determined cDNA sequence for clone	63689442 R0668:E07
SEQ ID NO:678	is the determined cDNA sequence for clone	63689443 R0668:E08
SEQ ID NO:679	is the determined cDNA sequence for clone	63689444 R0668:E09
SEQ ID NO:680	is the determined cDNA sequence for clone	63689446 R0668:E11
SEQ ID NO:681	is the determined cDNA sequence for clone	63689447 R0668:E12
SEQ ID NO:682	is the determined cDNA sequence for clone	63689450 R0668:F03
SEQ ID NO:683	is the determined cDNA sequence for clone	63689451 R0668:F04
SEQ ID NO:684	is the determined cDNA sequence for clone	63689452 R0668:F05
SEQ ID NO:685	is the determined cDNA sequence for clone	63689453 R0668:F06
SEQ ID NO:686	is the determined cDNA sequence for clone	63689454 R0668:F07
SEQ ID NO:687	is the determined cDNA sequence for clone	63689455 R0668:F08
SEQ ID NO:688	is the determined cDNA sequence for clone	63689456 R0668:F09
SEQ ID NO:689	is the determined cDNA sequence for clone	63689457 R0668:F10
SEQ ID NO:690	is the determined cDNA sequence for clone	63689458 R0668:F11
SEQ ID NO:691	is the determined cDNA sequence for clone	63689459 R0668:F12
SEQ ID NO:692	is the determined cDNA sequence for clone	63689460 R0668:G01
SEQ ID NO:693	is the determined cDNA sequence for clone	63689461 R0668:G02
SEQ ID NO:694	is the determined cDNA sequence for clone	63689462 R0668:G03
SEQ ID NO:695	is the determined cDNA sequence for clone	63689463 R0668:G04
SEQ ID NO:696	is the determined cDNA sequence for clone	63689464 R0668:G05
SEQ ID NO:697	is the determined cDNA sequence for clone	63689465 R0668:G06
SEQ ID NO:698	is the determined cDNA sequence for clone	63689466 R0668:G07
SEQ ID NO:699	is the determined cDNA sequence for clone	63689467 R0668:G08
SEQ ID NO:700	is the determined cDNA sequence for clone	63689468 R0668:G09

SEQ ID NO:701	is the determined cDNA sequence for clone	63689469 R0668:G10
SEQ ID NO:702	is the determined cDNA sequence for clone	63689470 R0668:G11
SEQ ID NO:703	is the determined cDNA sequence for clone	63689471 R0668:G12
SEQ ID NO:704	is the determined cDNA sequence for clone	63689474 R0668:H03
SEQ ID NO:705	is the determined cDNA sequence for clone	63689476 R0668:H05
SEQ ID NO:706	is the determined cDNA sequence for clone	63689477 R0668:H06
SEQ ID NO:707	is the determined cDNA sequence for clone	63689478 R0668:H07
SEQ ID NO:708	is the determined cDNA sequence for clone	63689479 R0668:H08
SEQ ID NO:709	is the determined cDNA sequence for clone	63689480 R0668:H09
SEQ ID NO:710	is the determined cDNA sequence for clone	63689481 R0668:H10
SEQ ID NO:711	is the determined cDNA sequence for clone	63689482 R0668:H11
SEQ ID NO:712	is the determined cDNA sequence for clone	63690135 R0669:A03
SEQ ID NO:713	is the determined cDNA sequence for clone	63690137 R0669:A06
SEQ ID NO:714	is the determined cDNA sequence for clone	63690139 R0669:A08
SEQ ID NO:715	is the determined cDNA sequence for clone	63690140 R0669:A09
SEQ ID NO:716	is the determined cDNA sequence for clone	63690141 R0669:A10
SEQ ID NO:717	is the determined cDNA sequence for clone	63690142 R0669:A11
SEQ ID NO:718	is the determined cDNA sequence for clone	63690143 R0669:A12
SEQ ID NO:719	is the determined cDNA sequence for clone	63690146 R0669:B03
SEQ ID NO:720	is the determined cDNA sequence for clone	63690147 R0669:B04
SEQ ID NO:721	is the determined cDNA sequence for clone	63690148 R0669:B05
SEQ ID NO:722	is the determined cDNA sequence for clone	63690149 R0669:B06
SEQ ID NO:723	is the determined cDNA sequence for clone	63690150 R0669:B07
SEQ ID NO:724	is the determined cDNA sequence for clone	63690151 R0669:B08
SEQ ID NO:725	is the determined cDNA sequence for clone	63690152 R0669:B09
SEQ ID NO:726	is the determined cDNA sequence for clone	63690153 R0669:B10
SEQ ID NO:727	is the determined cDNA sequence for clone	63690154 R0669:B11
SEQ ID NO:728	is the determined cDNA sequence for clone	63690155 R0669:B12
SEQ ID NO:729	is the determined cDNA sequence for clone	63690156 R0669:C01
SEQ ID NO:730	is the determined cDNA sequence for clone	63690157 R0669:C02
SEQ ID NO:731	is the determined cDNA sequence for clone	63690158 R0669:C03
SEQ ID NO:732	is the determined cDNA sequence for clone	63690159 R0669:C04
SEQ ID NO:733	is the determined cDNA sequence for clone	63690160 R0669:C05
SEQ ID NO:734	is the determined cDNA sequence for clone	63690161 R0669:C06
SEQ ID NO:735	is the determined cDNA sequence for clone	63690162 R0669:C07
SEQ ID NO:736	is the determined cDNA sequence for clone	63690163 R0669:C08
SEQ ID NO:737	is the determined cDNA sequence for clone	63690164 R0669:C09
SEQ ID NO:738	is the determined cDNA sequence for clone	63690165 R0669:C10
SEQ ID NO:739	is the determined cDNA sequence for clone	63690166 R0669:C11
SEQ ID NO:740	is the determined cDNA sequence for clone	63690167 R0669:C12
SEQ ID NO:741	is the determined cDNA sequence for clone	63690168 R0669:D01
SEQ ID NO:742	is the determined cDNA sequence for clone	63690169 R0669:D02
SEQ ID NO:743	is the determined cDNA sequence for clone	63690170 R0669:D03
SEQ ID NO:744	is the determined cDNA sequence for clone	63690171 R0669:D04
SEQ ID NO:745	is the determined cDNA sequence for clone	63690172 R0669:D05
SEQ ID NO:746	is the determined cDNA sequence for clone	63690173 R0669:D06

SEQ ID NO:747	is the determined cDNA sequence for clone	63690174 R0669:D07
SEQ ID NO:748	is the determined cDNA sequence for clone	63690175 R0669:D08
SEQ ID NO:749	is the determined cDNA sequence for clone	63690176 R0669:D09
SEQ ID NO:750	is the determined cDNA sequence for clone	63690177 R0669:D10
SEQ ID NO:751	is the determined cDNA sequence for clone	63690178 R0669:D11
SEQ ID NO:752	is the determined cDNA sequence for clone	63690179 R0669:D12
SEQ ID NO:753	is the determined cDNA sequence for clone	63690180 R0669:E01
SEQ ID NO:754	is the determined cDNA sequence for clone	63690181 R0669:E02
SEQ ID NO:755	is the determined cDNA sequence for clone	63690182 R0669:E03
SEQ ID NO:756	is the determined cDNA sequence for clone	63690183 R0669:E04
SEQ ID NO:757	is the determined cDNA sequence for clone	63690184 R0669:E05
SEQ ID NO:758	is the determined cDNA sequence for clone	63690185 R0669:E06
SEQ ID NO:759	is the determined cDNA sequence for clone	63690186 R0669:E07
SEQ ID NO:760	is the determined cDNA sequence for clone	63690187 R0669:E08
SEQ ID NO:761	is the determined cDNA sequence for clone	63690188 R0669:E09
SEQ ID NO:762	is the determined cDNA sequence for clone	63690189 R0669:E10
SEQ ID NO:763	is the determined cDNA sequence for clone	63690190 R0669:E11
SEQ ID NO:764	is the determined cDNA sequence for clone	63690191 R0669:E12
SEQ ID NO:765	is the determined cDNA sequence for clone	63690192 R0669:F01
SEQ ID NO:766	is the determined cDNA sequence for clone	63690193 R0669:F02
SEQ ID NO:767	is the determined cDNA sequence for clone	63690194 R0669:F03
SEQ ID NO:768	is the determined cDNA sequence for clone	63690195 R0669:F04
SEQ ID NO:769	is the determined cDNA sequence for clone	63690196 R0669:F05
SEQ ID NO:770	is the determined cDNA sequence for clone	63690197 R0669:F06
SEQ ID NO:771	is the determined cDNA sequence for clone	63690198 R0669:F07
SEQ ID NO:772	is the determined cDNA sequence for clone	63690199 R0669:F08
SEQ ID NO:773	is the determined cDNA sequence for clone	63690200 R0669:F09
SEQ ID NO:774	is the determined cDNA sequence for clone	63690201 R0669:F10
SEQ ID NO:775	is the determined cDNA sequence for clone	63690202 R0669:F11
SEQ ID NO:776	is the determined cDNA sequence for clone	63690203 R0669:F12
SEQ ID NO:777	is the determined cDNA sequence for clone	63690204 R0669:G01
SEQ ID NO:778	is the determined cDNA sequence for clone	63690205 R0669:G02
SEQ ID NO:779	is the determined cDNA sequence for clone	63690206 R0669:G03
SEQ ID NO:780	is the determined cDNA sequence for clone	63690208 R0669:G05
SEQ ID NO:781	is the determined cDNA sequence for clone	63690210 R0669:G07
SEQ ID NO:782	is the determined cDNA sequence for clone	63690211 R0669:G08
SEQ ID NO:783	is the determined cDNA sequence for clone	63690212 R0669:G09
SEQ ID NO:784	is the determined cDNA sequence for clone	63690213 R0669:G10
SEQ ID NO:785	is the determined cDNA sequence for clone	63690214 R0669:G11
SEQ ID NO:786	is the determined cDNA sequence for clone	63690215 R0669:G12
SEQ ID NO:787	is the determined cDNA sequence for clone	63690216 R0669:H01
SEQ ID NO:788	is the determined cDNA sequence for clone	63690217 R0669:H02
SEQ ID NO:789	is the determined cDNA sequence for clone	63690218 R0669:H03
SEQ ID NO:790	is the determined cDNA sequence for clone	63690219 R0669:H04
SEQ ID NO:791	is the determined cDNA sequence for clone	63690220 R0669:H05
SEQ ID NO:792	is the determined cDNA sequence for clone	63690222 R0669:H07

SEQ ID NO:793	is the determined cDNA sequence for clone	63690223 R0669:H08
SEQ ID NO:794	is the determined cDNA sequence for clone	63690224 R0669:H09
SEQ ID NO:795	is the determined cDNA sequence for clone	63690225 R0669:H10
SEQ ID NO:796	is the determined cDNA sequence for clone	63690226 R0669:H11
SEQ ID NO:797	is the determined cDNA sequence for clone	63695095 R0670:A02
SEQ ID NO:798	is the determined cDNA sequence for clone	63695097 R0670:A05
SEQ ID NO:799	is the determined cDNA sequence for clone	63695098 R0670:A06
SEQ ID NO:800	is the determined cDNA sequence for clone	63695099 R0670:A07
SEQ ID NO:801	is the determined cDNA sequence for clone	63695100 R0670:A08
SEQ ID NO:802	is the determined cDNA sequence for clone	63695101 R0670:A09
SEQ ID NO:803	is the determined cDNA sequence for clone	63695102 R0670:A10
SEQ ID NO:804	is the determined cDNA sequence for clone	63695103 R0670:A11
SEQ ID NO:805	is the determined cDNA sequence for clone	63695105 R0670:B01
SEQ ID NO:806	is the determined cDNA sequence for clone	63695107 R0670:B03
SEQ ID NO:807	is the determined cDNA sequence for clone	63695108 R0670:B04
SEQ ID NO:808	is the determined cDNA sequence for clone	63695109 R0670:B05
SEQ ID NO:809	is the determined cDNA sequence for clone	63695110 R0670:B06
SEQ ID NO:810	is the determined cDNA sequence for clone	63695111 R0670:B07
SEQ ID NO:811	is the determined cDNA sequence for clone	63695112 R0670:B08
SEQ ID NO:812	is the determined cDNA sequence for clone	63695113 R0670:B09
SEQ ID NO:813	is the determined cDNA sequence for clone	63695115 R0670:B11
SEQ ID NO:814	is the determined cDNA sequence for clone	63695116 R0670:B12
SEQ ID NO:815	is the determined cDNA sequence for clone	63695117 R0670:C01
SEQ ID NO:816	is the determined cDNA sequence for clone	63695118 R0670:C02
SEQ ID NO:817	is the determined cDNA sequence for clone	63695119 R0670:C03
SEQ ID NO:818	is the determined cDNA sequence for clone	63695120 R0670:C04
SEQ ID NO:819	is the determined cDNA sequence for clone	63695121 R0670:C05
SEQ ID NO:820	is the determined cDNA sequence for clone	63695122 R0670:C06
SEQ ID NO:821	is the determined cDNA sequence for clone	63695123 R0670:C07
SEQ ID NO:822	is the determined cDNA sequence for clone	63695124 R0670:C08
SEQ ID NO:823	is the determined cDNA sequence for clone	63695125 R0670:C09
SEQ ID NO:824	is the determined cDNA sequence for clone	63695126 R0670:C10
SEQ ID NO:825	is the determined cDNA sequence for clone	63695127 R0670:C11
SEQ ID NO:826	is the determined cDNA sequence for clone	63695128 R0670:C12
SEQ ID NO:827	is the determined cDNA sequence for clone	63695129 R0670:D01
SEQ ID NO:828	is the determined cDNA sequence for clone	63695130 R0670:D02
SEQ ID NO:829	is the determined cDNA sequence for clone	63695131 R0670:D03
SEQ ID NO:830	is the determined cDNA sequence for clone	63695132 R0670:D04
SEQ ID NO:831	is the determined cDNA sequence for clone	63695133 R0670:D05
SEQ ID NO:832	is the determined cDNA sequence for clone	63695134 R0670:D06
SEQ ID NO:833	is the determined cDNA sequence for clone	63695135 R0670:D07
SEQ ID NO:834	is the determined cDNA sequence for clone	63695136 R0670:D08
SEQ ID NO:835	is the determined cDNA sequence for clone	63695137 R0670:D09
SEQ ID NO:836	is the determined cDNA sequence for clone	63695138 R0670:D10
SEQ ID NO:837	is the determined cDNA sequence for clone	63695139 R0670:D11
SEQ ID NO:838	is the determined cDNA sequence for clone	63695140 R0670:D12

SEQ ID NO:839	is the determined cDNA sequence for clone	63695142 R0670:E02
SEQ ID NO:840	is the determined cDNA sequence for clone	63695143 R0670:E03
SEQ ID NO:841	is the determined cDNA sequence for clone	63695144 R0670:E04
SEQ ID NO:842	is the determined cDNA sequence for clone	63695145 R0670:E05
SEQ ID NO:843	is the determined cDNA sequence for clone	63695147 R0670:E07
SEQ ID NO:844	is the determined cDNA sequence for clone	63695148 R0670:E08
SEQ ID NO:845	is the determined cDNA sequence for clone	63695149 R0670:E09
SEQ ID NO:846	is the determined cDNA sequence for clone	63695150 R0670:E10
SEQ ID NO:847	is the determined cDNA sequence for clone	63695151 R0670:E11
SEQ ID NO:848	is the determined cDNA sequence for clone	63695152 R0670:E12
SEQ ID NO:849	is the determined cDNA sequence for clone	63695153 R0670:F01
SEQ ID NO:850	is the determined cDNA sequence for clone	63695154 R0670:F02
SEQ ID NO:851	is the determined cDNA sequence for clone	63695155 R0670:F03
SEQ ID NO:852	is the determined cDNA sequence for clone	63695156 R0670:F04
SEQ ID NO:853	is the determined cDNA sequence for clone	63695157 R0670:F05
SEQ ID NO:854	is the determined cDNA sequence for clone	63695158 R0670:F06
SEQ ID NO:855	is the determined cDNA sequence for clone	63695159 R0670:F07
SEQ ID NO:856	is the determined cDNA sequence for clone	63695160 R0670:F08
SEQ ID NO:857	is the determined cDNA sequence for clone	63695161 R0670:F09
SEQ ID NO:858	is the determined cDNA sequence for clone	63695162 R0670:F10
SEQ ID NO:859	is the determined cDNA sequence for clone	63695163 R0670:F11
SEQ ID NO:860	is the determined cDNA sequence for clone	63695164 R0670:F12
SEQ ID NO:861	is the determined cDNA sequence for clone	63695165 R0670:G01
SEQ ID NO:862	is the determined cDNA sequence for clone	63695166 R0670:G02
SEQ ID NO:863	is the determined cDNA sequence for clone	63695167 R0670:G03
SEQ ID NO:864	is the determined cDNA sequence for clone	63695168 R0670:G04
SEQ ID NO:865	is the determined cDNA sequence for clone	63695169 R0670:G05
SEQ ID NO:866	is the determined cDNA sequence for clone	63695170 R0670:G06
SEQ ID NO:867	is the determined cDNA sequence for clone	63695171 R0670:G07
SEQ ID NO:868	is the determined cDNA sequence for clone	63695172 R0670:G08
SEQ ID NO:869	is the determined cDNA sequence for clone	63695173 R0670:G09
SEQ ID NO:870	is the determined cDNA sequence for clone	63695174 R0670:G10
SEQ ID NO:871	is the determined cDNA sequence for clone	63695175 R0670:G11
SEQ ID NO:872	is the determined cDNA sequence for clone	63695176 R0670:G12
SEQ ID NO:873	is the determined cDNA sequence for clone	63695177 R0670:H01
SEQ ID NO:874	is the determined cDNA sequence for clone	63695178 R0670:H02
SEQ ID NO:875	is the determined cDNA sequence for clone	63695179 R0670:H03
SEQ ID NO:876	is the determined cDNA sequence for clone	63695180 R0670:H04
SEQ ID NO:877	is the determined cDNA sequence for clone	63695181 R0670:H05
SEQ ID NO:878	is the determined cDNA sequence for clone	63695182 R0670:H06
SEQ ID NO:879	is the determined cDNA sequence for clone	63695183 R0670:H07
SEQ ID NO:880	is the determined cDNA sequence for clone	63695184 R0670:H08
SEQ ID NO:881	is the determined cDNA sequence for clone	63695185 R0670:H09
SEQ ID NO:882	is the determined cDNA sequence for clone	63695186 R0670:H10
SEQ ID NO:883	is the determined cDNA sequence for clone	63695187 R0670:H11
SEQ ID NO:884	is the determined cDNA sequence for clone	63695653 R0671:A02

SEQ ID NO:885	is the determined cDNA sequence for clone	63695654 R0671:A03
SEQ ID NO:886	is the determined cDNA sequence for clone	63695655 R0671:A05
SEQ ID NO:887	is the determined cDNA sequence for clone	63695657 R0671:A07
SEQ ID NO:888	is the determined cDNA sequence for clone	63695659 R0671:A09
SEQ ID NO:889	is the determined cDNA sequence for clone	63695660 R0671:A10
SEQ ID NO:890	is the determined cDNA sequence for clone	63695661 R0671:A11
SEQ ID NO:891	is the determined cDNA sequence for clone	63695663 R0671:B01
SEQ ID NO:892	is the determined cDNA sequence for clone	63695664 R0671:B02
SEQ ID NO:893	is the determined cDNA sequence for clone	63695665 R0671:B03
SEQ ID NO:894	is the determined cDNA sequence for clone	63695666 R0671:B04
SEQ ID NO:895	is the determined cDNA sequence for clone	63695667 R0671:B05
SEQ ID NO:896	is the determined cDNA sequence for clone	63695668 R0671:B06
SEQ ID NO:897	is the determined cDNA sequence for clone	63695669 R0671:B07
SEQ ID NO:898	is the determined cDNA sequence for clone	63695670 R0671:B08
SEQ ID NO:899	is the determined cDNA sequence for clone	63695671 R0671:B09
SEQ ID NO:900	is the determined cDNA sequence for clone	63695672 R0671:B10
SEQ ID NO:901	is the determined cDNA sequence for clone	63695673 R0671:B11
SEQ ID NO:902	is the determined cDNA sequence for clone	63695675 R0671:C01
SEQ ID NO:903	is the determined cDNA sequence for clone	63695676 R0671:C02
SEQ ID NO:904	is the determined cDNA sequence for clone	63695678 R0671:C04
SEQ ID NO:905	is the determined cDNA sequence for clone	63695679 R0671:C05
SEQ ID NO:906	is the determined cDNA sequence for clone	63695680 R0671:C06
SEQ ID NO:907	is the determined cDNA sequence for clone	63695682 R0671:C08
SEQ ID NO:908	is the determined cDNA sequence for clone	63695683 R0671:C09
SEQ ID NO:909	is the determined cDNA sequence for clone	63695685 R0671:C11
SEQ ID NO:910	is the determined cDNA sequence for clone	63695686 R0671:C12
SEQ ID NO:911	is the determined cDNA sequence for clone	63695687 R0671:D01
SEQ ID NO:912	is the determined cDNA sequence for clone	63695688 R0671:D02
SEQ ID NO:913	is the determined cDNA sequence for clone	63695689 R0671:D03
SEQ ID NO:914	is the determined cDNA sequence for clone	63695690 R0671:D04
SEQ ID NO:915	is the determined cDNA sequence for clone	63695691 R0671:D05
SEQ ID NO:916	is the determined cDNA sequence for clone	63695692 R0671:D06
SEQ ID NO:917	is the determined cDNA sequence for clone	63695693 R0671:D07
SEQ ID NO:918	is the determined cDNA sequence for clone	63695694 R0671:D08
SEQ ID NO:919	is the determined cDNA sequence for clone	63695695 R0671:D09
SEQ ID NO:920	is the determined cDNA sequence for clone	63695696 R0671:D10
SEQ ID NO:921	is the determined cDNA sequence for clone	63695697 R0671:D11
SEQ ID NO:922	is the determined cDNA sequence for clone	63695698 R0671:D12
SEQ ID NO:923	is the determined cDNA sequence for clone	63695699 R0671:E01
SEQ ID NO:924	is the determined cDNA sequence for clone	63695700 R0671:E02
SEQ ID NO:925	is the determined cDNA sequence for clone	63695701 R0671:E03
SEQ ID NO:926	is the determined cDNA sequence for clone	63695702 R0671:E04
SEQ ID NO:927	is the determined cDNA sequence for clone	63695703 R0671:E05
SEQ ID NO:928	is the determined cDNA sequence for clone	63695704 R0671:E06
SEQ ID NO:929	is the determined cDNA sequence for clone	63695705 R0671:E07
SEQ ID NO:930	is the determined cDNA sequence for clone	63695706 R0671:E08

SEQ ID NO:931	is the determined cDNA sequence for clone	63695708 R0671:E10
SEQ ID NO:932	is the determined cDNA sequence for clone	63695710 R0671:E12
SEQ ID NO:933	is the determined cDNA sequence for clone	63695711 R0671:F01
SEQ ID NO:934	is the determined cDNA sequence for clone	63695712 R0671:F02
SEQ ID NO:935	is the determined cDNA sequence for clone	63695713 R0671:F03
SEQ ID NO:936	is the determined cDNA sequence for clone	63695715 R0671:F05
SEQ ID NO:937	is the determined cDNA sequence for clone	63695716 R0671:F06
SEQ ID NO:938	is the determined cDNA sequence for clone	63695717 R0671:F07
SEQ ID NO:939	is the determined cDNA sequence for clone	63695718 R0671:F08
SEQ ID NO:940	is the determined cDNA sequence for clone	63695719 R0671:F09
SEQ ID NO:941	is the determined cDNA sequence for clone	63695720 R0671:F10
SEQ ID NO:942	is the determined cDNA sequence for clone	63695721 R0671:F11
SEQ ID NO:943	is the determined cDNA sequence for clone	63695722 R0671:F12
SEQ ID NO:944	is the determined cDNA sequence for clone	63695723 R0671:G01
SEQ ID NO:945	is the determined cDNA sequence for clone	63695724 R0671:G02
SEQ ID NO:946	is the determined cDNA sequence for clone	63695725 R0671:G03
SEQ ID NO:947	is the determined cDNA sequence for clone	63695727 R0671:G05
SEQ ID NO:948	is the determined cDNA sequence for clone	63695728 R0671:G06
SEQ ID NO:949	is the determined cDNA sequence for clone	63695729 R0671:G07
SEQ ID NO:950	is the determined cDNA sequence for clone	63695730 R0671:G08
SEQ ID NO:951	is the determined cDNA sequence for clone	63695733 R0671:G11
SEQ ID NO:952	is the determined cDNA sequence for clone	63695734 R0671:G12
SEQ ID NO:953	is the determined cDNA sequence for clone	63695735 R0671:H01
SEQ ID NO:954	is the determined cDNA sequence for clone	63695736 R0671:H02
SEQ ID NO:955	is the determined cDNA sequence for clone	63695737 R0671:H03
SEQ ID NO:956	is the determined cDNA sequence for clone	63695738 R0671:H04
SEQ ID NO:957	is the determined cDNA sequence for clone	63695739 R0671:H05
SEQ ID NO:958	is the determined cDNA sequence for clone	63695740 R0671:H06
SEQ ID NO:959	is the determined cDNA sequence for clone	63695741 R0671:H07
SEQ ID NO:960	is the determined cDNA sequence for clone	63695742 R0671:H08
SEQ ID NO:961	is the determined cDNA sequence for clone	63695743 R0671:H09
SEQ ID NO:962	is the determined cDNA sequence for clone	63695744 R0671:H10
SEQ ID NO:963	is the determined cDNA sequence for clone	63695745 R0671:H11
SEQ ID NO:964	is the determined cDNA sequence for clone	63695002 R0672:A02
SEQ ID NO:965	is the determined cDNA sequence for clone	63695003 R0672:A03
SEQ ID NO:966	is the determined cDNA sequence for clone	63695004 R0672:A05
SEQ ID NO:967	is the determined cDNA sequence for clone	63695005 R0672:A06
SEQ ID NO:968	is the determined cDNA sequence for clone	63695007 R0672:A08
SEQ ID NO:969	is the determined cDNA sequence for clone	63695008 R0672:A09
SEQ ID NO:970	is the determined cDNA sequence for clone	63695009 R0672:A10
SEQ ID NO:971	is the determined cDNA sequence for clone	63695010 R0672:A11
SEQ ID NO:972	is the determined cDNA sequence for clone	63695011 R0672:A12
SEQ ID NO:973	is the determined cDNA sequence for clone	63695012 R0672:B01
SEQ ID NO:974	is the determined cDNA sequence for clone	63695013 R0672:B02
SEQ ID NO:975	is the determined cDNA sequence for clone	63695015 R0672:B04
SEQ ID NO:976	is the determined cDNA sequence for clone	63695016 R0672:B05

SEQ ID NO:977	is the determined cDNA sequence for clone	63695017 R0672:B06
SEQ ID NO:978	is the determined cDNA sequence for clone	63695018 R0672:B07
SEQ ID NO:979	is the determined cDNA sequence for clone	63695019 R0672:B08
SEQ ID NO:980	is the determined cDNA sequence for clone	63695020 R0672:B09
SEQ ID NO:981	is the determined cDNA sequence for clone	63695021 R0672:B10
SEQ ID NO:982	is the determined cDNA sequence for clone	63695022 R0672:B11
SEQ ID NO:983	is the determined cDNA sequence for clone	63695023 R0672:B12
SEQ ID NO:984	is the determined cDNA sequence for clone	63695024 R0672:C01
SEQ ID NO:985	is the determined cDNA sequence for clone	63695025 R0672:C02
SEQ ID NO:986	is the determined cDNA sequence for clone	63695026 R0672:C03
SEQ ID NO:987	is the determined cDNA sequence for clone	63695027 R0672:C04
SEQ ID NO:988	is the determined cDNA sequence for clone	63695028 R0672:C05
SEQ ID NO:989	is the determined cDNA sequence for clone	63695029 R0672:C06
SEQ ID NO:990	is the determined cDNA sequence for clone	63695030 R0672:C07
SEQ ID NO:991	is the determined cDNA sequence for clone	63695031 R0672:C08
SEQ ID NO:992	is the determined cDNA sequence for clone	63695032 R0672:C09
SEQ ID NO:993	is the determined cDNA sequence for clone	63695033 R0672:C10
SEQ ID NO:994	is the determined cDNA sequence for clone	63695034 R0672:C11
SEQ ID NO:995	is the determined cDNA sequence for clone	63695035 R0672:C12
SEQ ID NO:996	is the determined cDNA sequence for clone	63695036 R0672:D01
SEQ ID NO:997	is the determined cDNA sequence for clone	63695037 R0672:D02
SEQ ID NO:998	is the determined cDNA sequence for clone	63695038 R0672:D03
SEQ ID NO:999	is the determined cDNA sequence for clone	63695039 R0672:D04
SEQ ID NO:1000	is the determined cDNA sequence for clone	63695040 R0672:D05
SEQ ID NO:1001	is the determined cDNA sequence for clone	63695043 R0672:D08
SEQ ID NO:1002	is the determined cDNA sequence for clone	63695044 R0672:D09
SEQ ID NO:1003	is the determined cDNA sequence for clone	63695045 R0672:D10
SEQ ID NO:1004	is the determined cDNA sequence for clone	63695046 R0672:D11
SEQ ID NO:1005	is the determined cDNA sequence for clone	63695047 R0672:D12
SEQ ID NO:1006	is the determined cDNA sequence for clone	63695048 R0672:E01
SEQ ID NO:1007	is the determined cDNA sequence for clone	63695049 R0672:E02
SEQ ID NO:1008	is the determined cDNA sequence for clone	63695050 R0672:E03
SEQ ID NO:1009	is the determined cDNA sequence for clone	63695051 R0672:E04
SEQ ID NO:1010	is the determined cDNA sequence for clone	63695052 R0672:E05
SEQ ID NO:1011	is the determined cDNA sequence for clone	63695053 R0672:E06
SEQ ID NO:1012	is the determined cDNA sequence for clone	63695054 R0672:E07
SEQ ID NO:1013	is the determined cDNA sequence for clone	63695055 R0672:E08
SEQ ID NO:1014	is the determined cDNA sequence for clone	63695056 R0672:E09
SEQ ID NO:1015	is the determined cDNA sequence for clone	63695057 R0672:E10
SEQ ID NO:1016	is the determined cDNA sequence for clone	63695058 R0672:E11
SEQ ID NO:1017	is the determined cDNA sequence for clone	63695059 R0672:E12
SEQ ID NO:1018	is the determined cDNA sequence for clone	63695060 R0672:F01
SEQ ID NO:1019	is the determined cDNA sequence for clone	63695061 R0672:F02
SEQ ID NO:1020	is the determined cDNA sequence for clone	63695062 R0672:F03
SEQ ID NO:1021	is the determined cDNA sequence for clone	63695063 R0672:F04
SEQ ID NO:1022	is the determined cDNA sequence for clone	63695064 R0672:F05

SEQ ID NO:1023	is the determined cDNA sequence for clone	63695065 R0672:F06
SEQ ID NO:1024	is the determined cDNA sequence for clone	63695066 R0672:F07
SEQ ID NO:1025	is the determined cDNA sequence for clone	63695068 R0672:F09
SEQ ID NO:1026	is the determined cDNA sequence for clone	63695069 R0672:F10
SEQ ID NO:1027	is the determined cDNA sequence for clone	63695070 R0672:F11
SEQ ID NO:1028	is the determined cDNA sequence for clone	63695071 R0672:F12
SEQ ID NO:1029	is the determined cDNA sequence for clone	63695072 R0672:G01
SEQ ID NO:1030	is the determined cDNA sequence for clone	63695073 R0672:G02
SEQ ID NO:1031	is the determined cDNA sequence for clone	63695074 R0672:G03
SEQ ID NO:1032	is the determined cDNA sequence for clone	63695075 R0672:G04
SEQ ID NO:1033	is the determined cDNA sequence for clone	63695076 R0672:G05
SEQ ID NO:1034	is the determined cDNA sequence for clone	63695077 R0672:G06
SEQ ID NO:1035	is the determined cDNA sequence for clone	63695078 R0672:G07
SEQ ID NO:1036	is the determined cDNA sequence for clone	63695079 R0672:G08
SEQ ID NO:1037	is the determined cDNA sequence for clone	63695080 R0672:G09
SEQ ID NO:1038	is the determined cDNA sequence for clone	63695081 R0672:G10
SEQ ID NO:1039	is the determined cDNA sequence for clone	63695082 R0672:G11
SEQ ID NO:1040	is the determined cDNA sequence for clone	63695083 R0672:G12
SEQ ID NO:1041	is the determined cDNA sequence for clone	63695085 R0672:H02
SEQ ID NO:1042	is the determined cDNA sequence for clone	63695086 R0672:H03
SEQ ID NO:1043	is the determined cDNA sequence for clone	63695087 R0672:H04
SEQ ID NO:1044	is the determined cDNA sequence for clone	63695088 R0672:H05
SEQ ID NO:1045	is the determined cDNA sequence for clone	63695089 R0672:H06
SEQ ID NO:1046	is the determined cDNA sequence for clone	63695090 R0672:H07
SEQ ID NO:1047	is the determined cDNA sequence for clone	63695091 R0672:H08
SEQ ID NO:1048	is the determined cDNA sequence for clone	63695092 R0672:H09
SEQ ID NO:1049	is the determined cDNA sequence for clone	63695093 R0672:H10
SEQ ID NO:1050	is the determined cDNA sequence for clone	63695094 R0672:H11
SEQ ID NO:1051	is the determined cDNA sequence for clone	63695282 R0673:A03
SEQ ID NO:1052	is the determined cDNA sequence for clone	63695284 R0673:A06
SEQ ID NO:1053	is the determined cDNA sequence for clone	63695285 R0673:A07
SEQ ID NO:1054	is the determined cDNA sequence for clone	63695286 R0673:A08
SEQ ID NO:1055	is the determined cDNA sequence for clone	63695287 R0673:A09
SEQ ID NO:1056	is the determined cDNA sequence for clone	63695289 R0673:A11
SEQ ID NO:1057	is the determined cDNA sequence for clone	63695290 R0673:A12
SEQ ID NO:1058	is the determined cDNA sequence for clone	63695291 R0673:B01
SEQ ID NO:1059	is the determined cDNA sequence for clone	63695292 R0673:B02
SEQ ID NO:1060	is the determined cDNA sequence for clone	63695294 R0673:B04
SEQ ID NO:1061	is the determined cDNA sequence for clone	63695295 R0673:B05
SEQ ID NO:1062	is the determined cDNA sequence for clone	63695296 R0673:B06
SEQ ID NO:1063	is the determined cDNA sequence for clone	63695297 R0673:B07
SEQ ID NO:1064	is the determined cDNA sequence for clone	63695298 R0673:B08
SEQ ID NO:1065	is the determined cDNA sequence for clone	63695301 R0673:B11
SEQ ID NO:1066	is the determined cDNA sequence for clone	63695303 R0673:C01
SEQ ID NO:1067	is the determined cDNA sequence for clone	63695304 R0673:C02
SEQ ID NO:1068	is the determined cDNA sequence for clone	63695305 R0673:C03

SEQ ID NO:1069	is the determined cDNA sequence for clone	63695306 R0673:C04
SEQ ID NO:1070	is the determined cDNA sequence for clone	63695307 R0673:C05
SEQ ID NO:1071	is the determined cDNA sequence for clone	63695308 R0673:C06
SEQ ID NO:1072	is the determined cDNA sequence for clone	63695310 R0673:C08
SEQ ID NO:1073	is the determined cDNA sequence for clone	63695311 R0673:C09
SEQ ID NO:1074	is the determined cDNA sequence for clone	63695312 R0673:C10
SEQ ID NO:1075	is the determined cDNA sequence for clone	63695313 R0673:C11
SEQ ID NO:1076	is the determined cDNA sequence for clone	63695314 R0673:C12
SEQ ID NO:1077	is the determined cDNA sequence for clone	63695315 R0673:D01
SEQ ID NO:1078	is the determined cDNA sequence for clone	63695316 R0673:D02
SEQ ID NO:1079	is the determined cDNA sequence for clone	63695317 R0673:D03
SEQ ID NO:1080	is the determined cDNA sequence for clone	63695318 R0673:D04
SEQ ID NO:1081	is the determined cDNA sequence for clone	63695319 R0673:D05
SEQ ID NO:1082	is the determined cDNA sequence for clone	63695320 R0673:D06
SEQ ID NO:1083	is the determined cDNA sequence for clone	63695321 R0673:D07
SEQ ID NO:1084	is the determined cDNA sequence for clone	63695323 R0673:D09
SEQ ID NO:1085	is the determined cDNA sequence for clone	63695324 R0673:D10
SEQ ID NO:1086	is the determined cDNA sequence for clone	63695325 R0673:D11
SEQ ID NO:1087	is the determined cDNA sequence for clone	63695326 R0673:D12
SEQ ID NO:1088	is the determined cDNA sequence for clone	63695327 R0673:E01
SEQ ID NO:1089	is the determined cDNA sequence for clone	63695328 R0673:E02
SEQ ID NO:1090	is the determined cDNA sequence for clone	63695329 R0673:E03
SEQ ID NO:1091	is the determined cDNA sequence for clone	63695330 R0673:E04
SEQ ID NO:1092	is the determined cDNA sequence for clone	63695331 R0673:E05
SEQ ID NO:1093	is the determined cDNA sequence for clone	63695333 R0673:E07
SEQ ID NO:1094	is the determined cDNA sequence for clone	63695334 R0673:E08
SEQ ID NO:1095	is the determined cDNA sequence for clone	63695335 R0673:E09
SEQ ID NO:1096	is the determined cDNA sequence for clone	63695337 R0673:E11
SEQ ID NO:1097	is the determined cDNA sequence for clone	63695338 R0673:E12
SEQ ID NO:1098	is the determined cDNA sequence for clone	63695339 R0673:F01
SEQ ID NO:1099	is the determined cDNA sequence for clone	63695341 R0673:F03
SEQ ID NO:1100	is the determined cDNA sequence for clone	63695342 R0673:F04
SEQ ID NO:1101	is the determined cDNA sequence for clone	63695344 R0673:F06
SEQ ID NO:1102	is the determined cDNA sequence for clone	63695346 R0673:F08
SEQ ID NO:1103	is the determined cDNA sequence for clone	63695347 R0673:F09
SEQ ID NO:1104	is the determined cDNA sequence for clone	63695348 R0673:F10
SEQ ID NO:1105	is the determined cDNA sequence for clone	63695349 R0673:F11
SEQ ID NO:1106	is the determined cDNA sequence for clone	63695350 R0673:F12
SEQ ID NO:1107	is the determined cDNA sequence for clone	63695351 R0673:G01
SEQ ID NO:1108	is the determined cDNA sequence for clone	63695352 R0673:G02
SEQ ID NO:1109	is the determined cDNA sequence for clone	63695353 R0673:G03
SEQ ID NO:1110	is the determined cDNA sequence for clone	63695354 R0673:G04
SEQ ID NO:1111	is the determined cDNA sequence for clone	63695356 R0673:G06
SEQ ID NO:1112	is the determined cDNA sequence for clone	63695357 R0673:G07
SEQ ID NO:1113	is the determined cDNA sequence for clone	63695358 R0673:G08
SEQ ID NO:1114	is the determined cDNA sequence for clone	63695359 R0673:G09

SEQ ID NO:1115	is the determined cDNA sequence for clone	63695361 R0673:G11
SEQ ID NO:1116	is the determined cDNA sequence for clone	63695363 R0673:H01
SEQ ID NO:1117	is the determined cDNA sequence for clone	63695364 R0673:H02
SEQ ID NO:1118	is the determined cDNA sequence for clone	63695366 R0673:H04
SEQ ID NO:1119	is the determined cDNA sequence for clone	63695367 R0673:H05
SEQ ID NO:1120	is the determined cDNA sequence for clone	63695368 R0673:H06
SEQ ID NO:1121	is the determined cDNA sequence for clone	63695369 R0673:H07
SEQ ID NO:1122	is the determined cDNA sequence for clone	63695370 R0673:H08
SEQ ID NO:1123	is the determined cDNA sequence for clone	63695371 R0673:H09
SEQ ID NO:1124	is the determined cDNA sequence for clone	63695372 R0673:H10
SEQ ID NO:1125	is the determined cDNA sequence for clone	63695373 R0673:H11
SEQ ID NO:1126	is the determined cDNA sequence for clone	63695188 R0674:A02
SEQ ID NO:1127	is the determined cDNA sequence for clone	63695189 R0674:A03
SEQ ID NO:1128	is the determined cDNA sequence for clone	63695190 R0674:A05
SEQ ID NO:1129	is the determined cDNA sequence for clone	63695191 R0674:A06
SEQ ID NO:1130	is the determined cDNA sequence for clone	63695192 R0674:A07
SEQ ID NO:1131	is the determined cDNA sequence for clone	63695194 R0674:A09
SEQ ID NO:1132	is the determined cDNA sequence for clone	63695196 R0674:A11
SEQ ID NO:1133	is the determined cDNA sequence for clone	63695197 R0674:A12
SEQ ID NO:1134	is the determined cDNA sequence for clone	63695198 R0674:B01
SEQ ID NO:1135	is the determined cDNA sequence for clone	63695199 R0674:B02
SEQ ID NO:1136	is the determined cDNA sequence for clone	63695200 R0674:B03
SEQ ID NO:1137	is the determined cDNA sequence for clone	63695202 R0674:B05
SEQ ID NO:1138	is the determined cDNA sequence for clone	63695203 R0674:B06
SEQ ID NO:1139	is the determined cDNA sequence for clone	63695205 R0674:B08
SEQ ID NO:1140	is the determined cDNA sequence for clone	63695206 R0674:B09
SEQ ID NO:1141	is the determined cDNA sequence for clone	63695207 R0674:B10
SEQ ID NO:1142	is the determined cDNA sequence for clone	63695208 R0674:B11
SEQ ID NO:1143	is the determined cDNA sequence for clone	63695209 R0674:B12
SEQ ID NO:1144	is the determined cDNA sequence for clone	63695210 R0674:C01
SEQ ID NO:1145	is the determined cDNA sequence for clone	63695212 R0674:C03
SEQ ID NO:1146	is the determined cDNA sequence for clone	63695213 R0674:C04
SEQ ID NO:1147	is the determined cDNA sequence for clone	63695214 R0674:C05
SEQ ID NO:1148	is the determined cDNA sequence for clone	63695216 R0674:C07
SEQ ID NO:1149	is the determined cDNA sequence for clone	63695218 R0674:C09
SEQ ID NO:1150	is the determined cDNA sequence for clone	63695220 R0674:C11
SEQ ID NO:1151	is the determined cDNA sequence for clone	63695221 R0674:C12
SEQ ID NO:1152	is the determined cDNA sequence for clone	63695223 R0674:D02
SEQ ID NO:1153	is the determined cDNA sequence for clone	63695224 R0674:D03
SEQ ID NO:1154	is the determined cDNA sequence for clone	63695225 R0674:D04
SEQ ID NO:1155	is the determined cDNA sequence for clone	63695226 R0674:D05
SEQ ID NO:1156	is the determined cDNA sequence for clone	63695227 R0674:D06
SEQ ID NO:1157	is the determined cDNA sequence for clone	63695228 R0674:D07
SEQ ID NO:1158	is the determined cDNA sequence for clone	63695234 R0674:E01
SEQ ID NO:1159	is the determined cDNA sequence for clone	63695236 R0674:E03
SEQ ID NO:1160	is the determined cDNA sequence for clone	63695237 R0674:E04

SEQ ID NO:1161	is the determined cDNA sequence for clone	63695238 R0674:E05
SEQ ID NO:1162	is the determined cDNA sequence for clone	63695241 R0674:E08
SEQ ID NO:1163	is the determined cDNA sequence for clone	63695244 R0674:E11
SEQ ID NO:1164	is the determined cDNA sequence for clone	63695247 R0674:F02
SEQ ID NO:1165	is the determined cDNA sequence for clone	63695248 R0674:F03
SEQ ID NO:1166	is the determined cDNA sequence for clone	63695249 R0674:F04
SEQ ID NO:1167	is the determined cDNA sequence for clone	63695250 R0674:F05
SEQ ID NO:1168	is the determined cDNA sequence for clone	63695251 R0674:F06
SEQ ID NO:1169	is the determined cDNA sequence for clone	63695252 R0674:F07
SEQ ID NO:1170	is the determined cDNA sequence for clone	63695255 R0674:F10
SEQ ID NO:1171	is the determined cDNA sequence for clone	63695256 R0674:F11
SEQ ID NO:1172	is the determined cDNA sequence for clone	63695257 R0674:F12
SEQ ID NO:1173	is the determined cDNA sequence for clone	63695261 R0674:G04
SEQ ID NO:1174	is the determined cDNA sequence for clone	63695262 R0674:G05
SEQ ID NO:1175	is the determined cDNA sequence for clone	63695263 R0674:G06
SEQ ID NO:1176	is the determined cDNA sequence for clone	63695264 R0674:G07
SEQ ID NO:1177	is the determined cDNA sequence for clone	63695265 R0674:G08
SEQ ID NO:1178	is the determined cDNA sequence for clone	63695266 R0674:G09
SEQ ID NO:1179	is the determined cDNA sequence for clone	63695267 R0674:G10
SEQ ID NO:1180	is the determined cDNA sequence for clone	63695268 R0674:G11
SEQ ID NO:1181	is the determined cDNA sequence for clone	63695270 R0674:H01
SEQ ID NO:1182	is the determined cDNA sequence for clone	63695271 R0674:H02
SEQ ID NO:1183	is the determined cDNA sequence for clone	63695272 R0674:H03
SEQ ID NO:1184	is the determined cDNA sequence for clone	63695273 R0674:H04
SEQ ID NO:1185	is the determined cDNA sequence for clone	63695274 R0674:H05
SEQ ID NO:1186	is the determined cDNA sequence for clone	63695275 R0674:H06
SEQ ID NO:1187	is the determined cDNA sequence for clone	63695276 R0674:H07
SEQ ID NO:1188	is the determined cDNA sequence for clone	63695278 R0674:H09
SEQ ID NO:1189	is the determined cDNA sequence for clone	63695279 R0674:H10
SEQ ID NO:1190	is the determined cDNA sequence for clone	63695280 R0674:H11
SEQ ID NO:1191	is the determined cDNA sequence for clone	63694910 R0675:A03
SEQ ID NO:1192	is the determined cDNA sequence for clone	63694911 R0675:A05
SEQ ID NO:1193	is the determined cDNA sequence for clone	63694912 R0675:A06
SEQ ID NO:1194	is the determined cDNA sequence for clone	63694913 R0675:A07
SEQ ID NO:1195	is the determined cDNA sequence for clone	63694914 R0675:A08
SEQ ID NO:1196	is the determined cDNA sequence for clone	63694915 R0675:A09
SEQ ID NO:1197	is the determined cDNA sequence for clone	63694916 R0675:A10
SEQ ID NO:1198	is the determined cDNA sequence for clone	63694917 R0675:A11
SEQ ID NO:1199	is the determined cDNA sequence for clone	63694918 R0675:A12
SEQ ID NO:1200	is the determined cDNA sequence for clone	63694919 R0675:B01
SEQ ID NO:1201	is the determined cDNA sequence for clone	63694920 R0675:B02
SEQ ID NO:1202	is the determined cDNA sequence for clone	63694921 R0675:B03
SEQ ID NO:1203	is the determined cDNA sequence for clone	63694922 R0675:B04
SEQ ID NO:1204	is the determined cDNA sequence for clone	63694923 R0675:B05
SEQ ID NO:1205	is the determined cDNA sequence for clone	63694924 R0675:B06
SEQ ID NO:1206	is the determined cDNA sequence for clone	63694925 R0675:B07

SEQ ID NO:1207	is the determined cDNA sequence for clone	63694926 R0675:B08
SEQ ID NO:1208	is the determined cDNA sequence for clone	63694927 R0675:B09
SEQ ID NO:1209	is the determined cDNA sequence for clone	63694928 R0675:B10
SEQ ID NO:1210	is the determined cDNA sequence for clone	63694929 R0675:B11
SEQ ID NO:1211	is the determined cDNA sequence for clone	63694930 R0675:B12
SEQ ID NO:1212	is the determined cDNA sequence for clone	63694931 R0675:C01
SEQ ID NO:1213	is the determined cDNA sequence for clone	63694932 R0675:C02
SEQ ID NO:1214	is the determined cDNA sequence for clone	63694934 R0675:C04
SEQ ID NO:1215	is the determined cDNA sequence for clone	63694935 R0675:C05
SEQ ID NO:1216	is the determined cDNA sequence for clone	63694936 R0675:C06
SEQ ID NO:1217	is the determined cDNA sequence for clone	63694937 R0675:C07
SEQ ID NO:1218	is the determined cDNA sequence for clone	63694938 R0675:C08
SEQ ID NO:1219	is the determined cDNA sequence for clone	63694939 R0675:C09
SEQ ID NO:1220	is the determined cDNA sequence for clone	63694940 R0675:C10
SEQ ID NO:1221	is the determined cDNA sequence for clone	63694941 R0675:C11
SEQ ID NO:1222	is the determined cDNA sequence for clone	63694943 R0675:D01
SEQ ID NO:1223	is the determined cDNA sequence for clone	63694944 R0675:D02
SEQ ID NO:1224	is the determined cDNA sequence for clone	63694946 R0675:D04
SEQ ID NO:1225	is the determined cDNA sequence for clone	63694947 R0675:D05
SEQ ID NO:1226	is the determined cDNA sequence for clone	63694948 R0675:D06
SEQ ID NO:1227	is the determined cDNA sequence for clone	63694949 R0675:D07
SEQ ID NO:1228	is the determined cDNA sequence for clone	63694950 R0675:D08
SEQ ID NO:1229	is the determined cDNA sequence for clone	63694952 R0675:D10
SEQ ID NO:1230	is the determined cDNA sequence for clone	63694953 R0675:D11
SEQ ID NO:1231	is the determined cDNA sequence for clone	63694954 R0675:D12
SEQ ID NO:1232	is the determined cDNA sequence for clone	63694955 R0675:E01
SEQ ID NO:1233	is the determined cDNA sequence for clone	63694958 R0675:E04
SEQ ID NO:1234	is the determined cDNA sequence for clone	63694959 R0675:E05
SEQ ID NO:1235	is the determined cDNA sequence for clone	63694960 R0675:E06
SEQ ID NO:1236	is the determined cDNA sequence for clone	63694961 R0675:E07
SEQ ID NO:1237	is the determined cDNA sequence for clone	63694962 R0675:E08
SEQ ID NO:1238	is the determined cDNA sequence for clone	63694963 R0675:E09
SEQ ID NO:1239	is the determined cDNA sequence for clone	63694964 R0675:E10
SEQ ID NO:1240	is the determined cDNA sequence for clone	63694966 R0675:E12
SEQ ID NO:1241	is the determined cDNA sequence for clone	63694967 R0675:F01
SEQ ID NO:1242	is the determined cDNA sequence for clone	63694968 R0675:F02
SEQ ID NO:1243	is the determined cDNA sequence for clone	63694969 R0675:F03
SEQ ID NO:1244	is the determined cDNA sequence for clone	63694970 R0675:F04
SEQ ID NO:1245	is the determined cDNA sequence for clone	63694971 R0675:F05
SEQ ID NO:1246	is the determined cDNA sequence for clone	63694972 R0675:F06
SEQ ID NO:1247	is the determined cDNA sequence for clone	63694973 R0675:F07
SEQ ID NO:1248	is the determined cDNA sequence for clone	63694974 R0675:F08
SEQ ID NO:1249	is the determined cDNA sequence for clone	63694975 R0675:F09
SEQ ID NO:1250	is the determined cDNA sequence for clone	63694976 R0675:F10
SEQ ID NO:1251	is the determined cDNA sequence for clone	63694977 R0675:F11
SEQ ID NO:1252	is the determined cDNA sequence for clone	63694978 R0675:F12

SEQ ID NO:1253	is the determined cDNA sequence for clone	63694979 R0675:G01
SEQ ID NO:1254	is the determined cDNA sequence for clone	63694980 R0675:G02
SEQ ID NO:1255	is the determined cDNA sequence for clone	63694981 R0675:G03
SEQ ID NO:1256	is the determined cDNA sequence for clone	63694982 R0675:G04
SEQ ID NO:1257	is the determined cDNA sequence for clone	63694983 R0675:G05
SEQ ID NO:1258	is the determined cDNA sequence for clone	63694984 R0675:G06
SEQ ID NO:1259	is the determined cDNA sequence for clone	63694985 R0675:G07
SEQ ID NO:1260	is the determined cDNA sequence for clone	63694986 R0675:G08
SEQ ID NO:1261	is the determined cDNA sequence for clone	63694987 R0675:G09
SEQ ID NO:1262	is the determined cDNA sequence for clone	63694988 R0675:G10
SEQ ID NO:1263	is the determined cDNA sequence for clone	63694990 R0675:G12
SEQ ID NO:1264	is the determined cDNA sequence for clone	63694991 R0675:H01
SEQ ID NO:1265	is the determined cDNA sequence for clone	63694992 R0675:H02
SEQ ID NO:1266	is the determined cDNA sequence for clone	63694993 R0675:H03
SEQ ID NO:1267	is the determined cDNA sequence for clone	63694995 R0675:H05
SEQ ID NO:1268	is the determined cDNA sequence for clone	63694996 R0675:H06
SEQ ID NO:1269	is the determined cDNA sequence for clone	63694997 R0675:H07
SEQ ID NO:1270	is the determined cDNA sequence for clone	63694999 R0675:H09
SEQ ID NO:1271	is the determined cDNA sequence for clone	63695000 R0675:H10
SEQ ID NO:1272	is the determined cDNA sequence for clone	63695746 R0676:A02
SEQ ID NO:1273	is the determined cDNA sequence for clone	63695747 R0676:A03
SEQ ID NO:1274	is the determined cDNA sequence for clone	63695748 R0676:A05
SEQ ID NO:1275	is the determined cDNA sequence for clone	63695749 R0676:A06
SEQ ID NO:1276	is the determined cDNA sequence for clone	63695750 R0676:A07
SEQ ID NO:1277	is the determined cDNA sequence for clone	63695751 R0676:A08
SEQ ID NO:1278	is the determined cDNA sequence for clone	63695752 R0676:A09
SEQ ID NO:1279	is the determined cDNA sequence for clone	63695754 R0676:A11
SEQ ID NO:1280	is the determined cDNA sequence for clone	63695755 R0676:A12
SEQ ID NO:1281	is the determined cDNA sequence for clone	63695756 R0676:B01
SEQ ID NO:1282	is the determined cDNA sequence for clone	63695758 R0676:B03
SEQ ID NO:1283	is the determined cDNA sequence for clone	63695759 R0676:B04
SEQ ID NO:1284	is the determined cDNA sequence for clone	63695760 R0676:B05
SEQ ID NO:1285	is the determined cDNA sequence for clone	63695762 R0676:B07
SEQ ID NO:1286	is the determined cDNA sequence for clone	63695764 R0676:B09
SEQ ID NO:1287	is the determined cDNA sequence for clone	63695766 R0676:B11
SEQ ID NO:1288	is the determined cDNA sequence for clone	63695769 R0676:C02
SEQ ID NO:1289	is the determined cDNA sequence for clone	63695770 R0676:C03
SEQ ID NO:1290	is the determined cDNA sequence for clone	63695771 R0676:C04
SEQ ID NO:1291	is the determined cDNA sequence for clone	63695772 R0676:C05
SEQ ID NO:1292	is the determined cDNA sequence for clone	63695773 R0676:C06
SEQ ID NO:1293	is the determined cDNA sequence for clone	63695774 R0676:C07
SEQ ID NO:1294	is the determined cDNA sequence for clone	63695775 R0676:C08
SEQ ID NO:1295	is the determined cDNA sequence for clone	63695777 R0676:C10
SEQ ID NO:1296	is the determined cDNA sequence for clone	63695778 R0676:C11
SEQ ID NO:1297	is the determined cDNA sequence for clone	63695779 R0676:C12
SEQ ID NO:1298	is the determined cDNA sequence for clone	63695780 R0676:D01

SEQ ID NO:1299	is the determined cDNA sequence for clone	63695782 R0676:D03
SEQ ID NO:1300	is the determined cDNA sequence for clone	63695784 R0676:D05
SEQ ID NO:1301	is the determined cDNA sequence for clone	63695786 R0676:D07
SEQ ID NO:1302	is the determined cDNA sequence for clone	63695787 R0676:D08
SEQ ID NO:1303	is the determined cDNA sequence for clone	63695788 R0676:D09
SEQ ID NO:1304	is the determined cDNA sequence for clone	63695790 R0676:D11
SEQ ID NO:1305	is the determined cDNA sequence for clone	63695791 R0676:D12
SEQ ID NO:1306	is the determined cDNA sequence for clone	63695792 R0676:E01
SEQ ID NO:1307	is the determined cDNA sequence for clone	63695793 R0676:E02
SEQ ID NO:1308	is the determined cDNA sequence for clone	63695794 R0676:E03
SEQ ID NO:1309	is the determined cDNA sequence for clone	63695796 R0676:E05
SEQ ID NO:1310	is the determined cDNA sequence for clone	63695797 R0676:E06
SEQ ID NO:1311	is the determined cDNA sequence for clone	63695798 R0676:E07
SEQ ID NO:1312	is the determined cDNA sequence for clone	63695803 R0676:E12
SEQ ID NO:1313	is the determined cDNA sequence for clone	63695804 R0676:F01
SEQ ID NO:1314	is the determined cDNA sequence for clone	63695806 R0676:F03
SEQ ID NO:1315	is the determined cDNA sequence for clone	63695807 R0676:F04
SEQ ID NO:1316	is the determined cDNA sequence for clone	63695808 R0676:F05
SEQ ID NO:1317	is the determined cDNA sequence for clone	63695809 R0676:F06
SEQ ID NO:1318	is the determined cDNA sequence for clone	63695810 R0676:F07
SEQ ID NO:1319	is the determined cDNA sequence for clone	63695811 R0676:F08
SEQ ID NO:1320	is the determined cDNA sequence for clone	63695812 R0676:F09
SEQ ID NO:1321	is the determined cDNA sequence for clone	63695813 R0676:F10
SEQ ID NO:1322	is the determined cDNA sequence for clone	63695814 R0676:F11
SEQ ID NO:1323	is the determined cDNA sequence for clone	63695815 R0676:F12
SEQ ID NO:1324	is the determined cDNA sequence for clone	63695816 R0676:G01
SEQ ID NO:1325	is the determined cDNA sequence for clone	63695817 R0676:G02
SEQ ID NO:1326	is the determined cDNA sequence for clone	63695818 R0676:G03
SEQ ID NO:1327	is the determined cDNA sequence for clone	63695820 R0676:G05
SEQ ID NO:1328	is the determined cDNA sequence for clone	63695822 R0676:G07
SEQ ID NO:1329	is the determined cDNA sequence for clone	63695823 R0676:G08
SEQ ID NO:1330	is the determined cDNA sequence for clone	63695824 R0676:G09
SEQ ID NO:1331	is the determined cDNA sequence for clone	63695825 R0676:G10
SEQ ID NO:1332	is the determined cDNA sequence for clone	63695826 R0676:G11
SEQ ID NO:1333	is the determined cDNA sequence for clone	63695827 R0676:G12
SEQ ID NO:1334	is the determined cDNA sequence for clone	63695828 R0676:H01
SEQ ID NO:1335	is the determined cDNA sequence for clone	63695829 R0676:H02
SEQ ID NO:1336	is the determined cDNA sequence for clone	63695830 R0676:H03
SEQ ID NO:1337	is the determined cDNA sequence for clone	63695831 R0676:H04
SEQ ID NO:1338	is the determined cDNA sequence for clone	63695832 R0676:H05
SEQ ID NO:1339	is the determined cDNA sequence for clone	63695833 R0676:H06
SEQ ID NO:1340	is the determined cDNA sequence for clone	63695834 R0676:H07
SEQ ID NO:1341	is the determined cDNA sequence for clone	63695835 R0676:H08
SEQ ID NO:1342	is the determined cDNA sequence for clone	63695836 R0676:H09
SEQ ID NO:1343	is the determined cDNA sequence for clone	63695837 R0676:H10
SEQ ID NO:1344	is the determined cDNA sequence for clone	63695838 R0676:H11

SEQ ID NO:1345	is the determined cDNA sequence for clone	63695374 R0677:A02
SEQ ID NO:1346	is the determined cDNA sequence for clone	63695375 R0677:A03
SEQ ID NO:1347	is the determined cDNA sequence for clone	63695376 R0677:A05
SEQ ID NO:1348	is the determined cDNA sequence for clone	63695378 R0677:A07
SEQ ID NO:1349	is the determined cDNA sequence for clone	63695379 R0677:A08
SEQ ID NO:1350	is the determined cDNA sequence for clone	63695380 R0677:A09
SEQ ID NO:1351	is the determined cDNA sequence for clone	63695381 R0677:A10
SEQ ID NO:1352	is the determined cDNA sequence for clone	63695382 R0677:A11
SEQ ID NO:1353	is the determined cDNA sequence for clone	63695383 R0677:A12
SEQ ID NO:1354	is the determined cDNA sequence for clone	63695384 R0677:B01
SEQ ID NO:1355	is the determined cDNA sequence for clone	63695386 R0677:B03
SEQ ID NO:1356	is the determined cDNA sequence for clone	63695387 R0677:B04
SEQ ID NO:1357	is the determined cDNA sequence for clone	63695388 R0677:B05
SEQ ID NO:1358	is the determined cDNA sequence for clone	63695389 R0677:B06
SEQ ID NO:1359	is the determined cDNA sequence for clone	63695390 R0677:B07
SEQ ID NO:1360	is the determined cDNA sequence for clone	63695391 R0677:B08
SEQ ID NO:1361	is the determined cDNA sequence for clone	63695392 R0677:B09
SEQ ID NO:1362	is the determined cDNA sequence for clone	63695393 R0677:B10
SEQ ID NO:1363	is the determined cDNA sequence for clone	63695394 R0677:B11
SEQ ID NO:1364	is the determined cDNA sequence for clone	63695395 R0677:B12
SEQ ID NO:1365	is the determined cDNA sequence for clone	63695397 R0677:C02
SEQ ID NO:1366	is the determined cDNA sequence for clone	63695398 R0677:C03
SEQ ID NO:1367	is the determined cDNA sequence for clone	63695399 R0677:C04
SEQ ID NO:1368	is the determined cDNA sequence for clone	63695400 R0677:C05
SEQ ID NO:1369	is the determined cDNA sequence for clone	63695401 R0677:C06
SEQ ID NO:1370	is the determined cDNA sequence for clone	63695402 R0677:C07
SEQ ID NO:1371	is the determined cDNA sequence for clone	63695403 R0677:C08
SEQ ID NO:1372	is the determined cDNA sequence for clone	63695404 R0677:C09
SEQ ID NO:1373	is the determined cDNA sequence for clone	63695405 R0677:C10
SEQ ID NO:1374	is the determined cDNA sequence for clone	63695406 R0677:C11
SEQ ID NO:1375	is the determined cDNA sequence for clone	63695408 R0677:D01
SEQ ID NO:1376	is the determined cDNA sequence for clone	63695409 R0677:D02
SEQ ID NO:1377	is the determined cDNA sequence for clone	63695411 R0677:D04
SEQ ID NO:1378	is the determined cDNA sequence for clone	63695412 R0677:D05
SEQ ID NO:1379	is the determined cDNA sequence for clone	63695413 R0677:D06
SEQ ID NO:1380	is the determined cDNA sequence for clone	63695414 R0677:D07
SEQ ID NO:1381	is the determined cDNA sequence for clone	63695415 R0677:D08
SEQ ID NO:1382	is the determined cDNA sequence for clone	63695416 R0677:D09
SEQ ID NO:1383	is the determined cDNA sequence for clone	63695418 R0677:D11
SEQ ID NO:1384	is the determined cDNA sequence for clone	63695419 R0677:D12
SEQ ID NO:1385	is the determined cDNA sequence for clone	63695420 R0677:E01
SEQ ID NO:1386	is the determined cDNA sequence for clone	63695421 R0677:E02
SEQ ID NO:1387	is the determined cDNA sequence for clone	63695422 R0677:E03
SEQ ID NO:1388	is the determined cDNA sequence for clone	63695423 R0677:E04
SEQ ID NO:1389	is the determined cDNA sequence for clone	63695424 R0677:E05
SEQ ID NO:1390	is the determined cDNA sequence for clone	63695425 R0677:E06

SEQ ID NO:1391	is the determined cDNA sequence for clone	63695426 R0677:E07
SEQ ID NO:1392	is the determined cDNA sequence for clone	63695427 R0677:E08
SEQ ID NO:1393	is the determined cDNA sequence for clone	63695428 R0677:E09
SEQ ID NO:1394	is the determined cDNA sequence for clone	63695429 R0677:E10
SEQ ID NO:1395	is the determined cDNA sequence for clone	63695430 R0677:E11
SEQ ID NO:1396	is the determined cDNA sequence for clone	63695431 R0677:E12
SEQ ID NO:1397	is the determined cDNA sequence for clone	63695432 R0677:F01
SEQ ID NO:1398	is the determined cDNA sequence for clone	63695433 R0677:F02
SEQ ID NO:1399	is the determined cDNA sequence for clone	63695434 R0677:F03
SEQ ID NO:1400	is the determined cDNA sequence for clone	63695435 R0677:F04
SEQ ID NO:1401	is the determined cDNA sequence for clone	63695436 R0677:F05
SEQ ID NO:1402	is the determined cDNA sequence for clone	63695437 R0677:F06
SEQ ID NO:1403	is the determined cDNA sequence for clone	63695439 R0677:F08
SEQ ID NO:1404	is the determined cDNA sequence for clone	63695440 R0677:F09
SEQ ID NO:1405	is the determined cDNA sequence for clone	63695442 R0677:F11
SEQ ID NO:1406	is the determined cDNA sequence for clone	63695443 R0677:F12
SEQ ID NO:1407	is the determined cDNA sequence for clone	63695444 R0677:G01
SEQ ID NO:1408	is the determined cDNA sequence for clone	63695445 R0677:G02
SEQ ID NO:1409	is the determined cDNA sequence for clone	63695446 R0677:G03
SEQ ID NO:1410	is the determined cDNA sequence for clone	63695447 R0677:G04
SEQ ID NO:1411	is the determined cDNA sequence for clone	63695448 R0677:G05
SEQ ID NO:1412	is the determined cDNA sequence for clone	63695449 R0677:G06
SEQ ID NO:1413	is the determined cDNA sequence for clone	63695450 R0677:G07
SEQ ID NO:1414	is the determined cDNA sequence for clone	63695451 R0677:G08
SEQ ID NO:1415	is the determined cDNA sequence for clone	63695452 R0677:G09
SEQ ID NO:1416	is the determined cDNA sequence for clone	63695453 R0677:G10
SEQ ID NO:1417	is the determined cDNA sequence for clone	63695454 R0677:G11
SEQ ID NO:1418	is the determined cDNA sequence for clone	63695455 R0677:G12
SEQ ID NO:1419	is the determined cDNA sequence for clone	63695456 R0677:H01
SEQ ID NO:1420	is the determined cDNA sequence for clone	63695457 R0677:H02
SEQ ID NO:1421	is the determined cDNA sequence for clone	63695458 R0677:H03
SEQ ID NO:1422	is the determined cDNA sequence for clone	63695459 R0677:H04
SEQ ID NO:1423	is the determined cDNA sequence for clone	63695460 R0677:H05
SEQ ID NO:1424	is the determined cDNA sequence for clone	63695461 R0677:H06
SEQ ID NO:1425	is the determined cDNA sequence for clone	63695462 R0677:H07
SEQ ID NO:1426	is the determined cDNA sequence for clone	63695463 R0677:H08
SEQ ID NO:1427	is the determined cDNA sequence for clone	63695464 R0677:H09
SEQ ID NO:1428	is the determined cDNA sequence for clone	63695465 R0677:H10
SEQ ID NO:1429	is the determined cDNA sequence for clone	63695466 R0677:H11
SEQ ID NO:1430	is the determined cDNA sequence for clone	63708283 R0678:A02
SEQ ID NO:1431	is the determined cDNA sequence for clone	63708284 R0678:A03
SEQ ID NO:1432	is the determined cDNA sequence for clone	63708285 R0678:A05
SEQ ID NO:1433	is the determined cDNA sequence for clone	63708286 R0678:A06
SEQ ID NO:1434	is the determined cDNA sequence for clone	63708287 R0678:A07
SEQ ID NO:1435	is the determined cDNA sequence for clone	63708289 R0678:A09
SEQ ID NO:1436	is the determined cDNA sequence for clone	63708290 R0678:A10

SEQ ID NO:1437	is the determined cDNA sequence for clone	63708291 R0678:A11
SEQ ID NO:1438	is the determined cDNA sequence for clone	63708292 R0678:A12
SEQ ID NO:1439	is the determined cDNA sequence for clone	63708293 R0678:B01
SEQ ID NO:1440	is the determined cDNA sequence for clone	63708294 R0678:B02
SEQ ID NO:1441	is the determined cDNA sequence for clone	63708295 R0678:B03
SEQ ID NO:1442	is the determined cDNA sequence for clone	63708296 R0678:B04
SEQ ID NO:1443	is the determined cDNA sequence for clone	63708297 R0678:B05
SEQ ID NO:1444	is the determined cDNA sequence for clone	63708298 R0678:B06
SEQ ID NO:1445	is the determined cDNA sequence for clone	63708299 R0678:B07
SEQ ID NO:1446	is the determined cDNA sequence for clone	63708300 R0678:B08
SEQ ID NO:1447	is the determined cDNA sequence for clone	63708302 R0678:B10
SEQ ID NO:1448	is the determined cDNA sequence for clone	63708304 R0678:B12
SEQ ID NO:1449	is the determined cDNA sequence for clone	63708305 R0678:C01
SEQ ID NO:1450	is the determined cDNA sequence for clone	63708306 R0678:C02
SEQ ID NO:1451	is the determined cDNA sequence for clone	63708307 R0678:C03
SEQ ID NO:1452	is the determined cDNA sequence for clone	63708308 R0678:C04
SEQ ID NO:1453	is the determined cDNA sequence for clone	63708309 R0678:C05
SEQ ID NO:1454	is the determined cDNA sequence for clone	63708311 R0678:C07
SEQ ID NO:1455	is the determined cDNA sequence for clone	63708313 R0678:C09
SEQ ID NO:1456	is the determined cDNA sequence for clone	63708314 R0678:C10
SEQ ID NO:1457	is the determined cDNA sequence for clone	63708315 R0678:C11
SEQ ID NO:1458	is the determined cDNA sequence for clone	63708316 R0678:C12
SEQ ID NO:1459	is the determined cDNA sequence for clone	63708317 R0678:D01
SEQ ID NO:1460	is the determined cDNA sequence for clone	63708318 R0678:D02
SEQ ID NO:1461	is the determined cDNA sequence for clone	63708319 R0678:D03
SEQ ID NO:1462	is the determined cDNA sequence for clone	63708321 R0678:D05
SEQ ID NO:1463	is the determined cDNA sequence for clone	63708322 R0678:D06
SEQ ID NO:1464	is the determined cDNA sequence for clone	63708323 R0678:D07
SEQ ID NO:1465	is the determined cDNA sequence for clone	63708324 R0678:D08
SEQ ID NO:1466	is the determined cDNA sequence for clone	63708325 R0678:D09
SEQ ID NO:1467	is the determined cDNA sequence for clone	63708326 R0678:D10
SEQ ID NO:1468	is the determined cDNA sequence for clone	63708327 R0678:D11
SEQ ID NO:1469	is the determined cDNA sequence for clone	63708328 R0678:D12
SEQ ID NO:1470	is the determined cDNA sequence for clone	63708330 R0678:E02
SEQ ID NO:1471	is the determined cDNA sequence for clone	63708331 R0678:E03
SEQ ID NO:1472	is the determined cDNA sequence for clone	63708332 R0678:E04
SEQ ID NO:1473	is the determined cDNA sequence for clone	63708333 R0678:E05
SEQ ID NO:1474	is the determined cDNA sequence for clone	63708334 R0678:E06
SEQ ID NO:1475	is the determined cDNA sequence for clone	63708335 R0678:E07
SEQ ID NO:1476	is the determined cDNA sequence for clone	63708336 R0678:E08
SEQ ID NO:1477	is the determined cDNA sequence for clone	63708337 R0678:E09
SEQ ID NO:1478	is the determined cDNA sequence for clone	63708338 R0678:E10
SEQ ID NO:1479	is the determined cDNA sequence for clone	63708339 R0678:E11
SEQ ID NO:1480	is the determined cDNA sequence for clone	63708340 R0678:E12
SEQ ID NO:1481	is the determined cDNA sequence for clone	63708341 R0678:F01
SEQ ID NO:1482	is the determined cDNA sequence for clone	63708342 R0678:F02

SEQ ID NO:1483	is the determined cDNA sequence for clone	63708343 R0678:F03
SEQ ID NO:1484	is the determined cDNA sequence for clone	63708344 R0678:F04
SEQ ID NO:1485	is the determined cDNA sequence for clone	63708345 R0678:F05
SEQ ID NO:1486	is the determined cDNA sequence for clone	63708346 R0678:F06
SEQ ID NO:1487	is the determined cDNA sequence for clone	63708347 R0678:F07
SEQ ID NO:1488	is the determined cDNA sequence for clone	63708348 R0678:F08
SEQ ID NO:1489	is the determined cDNA sequence for clone	63708349 R0678:F09
SEQ ID NO:1490	is the determined cDNA sequence for clone	63708350 R0678:F10
SEQ ID NO:1491	is the determined cDNA sequence for clone	63708352 R0678:F12
SEQ ID NO:1492	is the determined cDNA sequence for clone	63708354 R0678:G02
SEQ ID NO:1493	is the determined cDNA sequence for clone	63708355 R0678:G03
SEQ ID NO:1494	is the determined cDNA sequence for clone	63708356 R0678:G04
SEQ ID NO:1495	is the determined cDNA sequence for clone	63708357 R0678:G05
SEQ ID NO:1496	is the determined cDNA sequence for clone	63708358 R0678:G06
SEQ ID NO:1497	is the determined cDNA sequence for clone	63708359 R0678:G07
SEQ ID NO:1498	is the determined cDNA sequence for clone	63708361 R0678:G09
SEQ ID NO:1499	is the determined cDNA sequence for clone	63708362 R0678:G10
SEQ ID NO:1500	is the determined cDNA sequence for clone	63708363 R0678:G11
SEQ ID NO:1501	is the determined cDNA sequence for clone	63708365 R0678:H01
SEQ ID NO:1502	is the determined cDNA sequence for clone	63708366 R0678:H02
SEQ ID NO:1503	is the determined cDNA sequence for clone	63708367 R0678:H03
SEQ ID NO:1504	is the determined cDNA sequence for clone	63708370 R0678:H06
SEQ ID NO:1505	is the determined cDNA sequence for clone	63708371 R0678:H07
SEQ ID NO:1506	is the determined cDNA sequence for clone	63708372 R0678:H08
SEQ ID NO:1507	is the determined cDNA sequence for clone	63708373 R0678:H09
SEQ ID NO:1508	is the determined cDNA sequence for clone	63708374 R0678:H10
SEQ ID NO:1509	is the determined cDNA sequence for clone	63708375 R0678:H11
SEQ ID NO:1510	is the determined cDNA sequence for clone	63695560 R0679:A02
SEQ ID NO:1511	is the determined cDNA sequence for clone	63695561 R0679:A03
SEQ ID NO:1512	is the determined cDNA sequence for clone	63695562 R0679:A05
SEQ ID NO:1513	is the determined cDNA sequence for clone	63695563 R0679:A06
SEQ ID NO:1514	is the determined cDNA sequence for clone	63695564 R0679:A07
SEQ ID NO:1515	is the determined cDNA sequence for clone	63695565 R0679:A08
SEQ ID NO:1516	is the determined cDNA sequence for clone	63695566 R0679:A09
SEQ ID NO:1517	is the determined cDNA sequence for clone	63695567 R0679:A10
SEQ ID NO:1518	is the determined cDNA sequence for clone	63695568 R0679:A11
SEQ ID NO:1519	is the determined cDNA sequence for clone	63695569 R0679:A12
SEQ ID NO:1520	is the determined cDNA sequence for clone	63695570 R0679:B01
SEQ ID NO:1521	is the determined cDNA sequence for clone	63695571 R0679:B02
SEQ ID NO:1522	is the determined cDNA sequence for clone	63695572 R0679:B03
SEQ ID NO:1523	is the determined cDNA sequence for clone	63695573 R0679:B04
SEQ ID NO:1524	is the determined cDNA sequence for clone	63695574 R0679:B05
SEQ ID NO:1525	is the determined cDNA sequence for clone	63695575 R0679:B06
SEQ ID NO:1526	is the determined cDNA sequence for clone	63695576 R0679:B07
SEQ ID NO:1527	is the determined cDNA sequence for clone	63695577 R0679:B08
SEQ ID NO:1528	is the determined cDNA sequence for clone	63695578 R0679:B09

SEQ ID NO:1529	is the determined cDNA sequence for clone	63695579 R0679:B10
SEQ ID NO:1530	is the determined cDNA sequence for clone	63695580 R0679:B11
SEQ ID NO:1531	is the determined cDNA sequence for clone	63695581 R0679:B12
SEQ ID NO:1532	is the determined cDNA sequence for clone	63695582 R0679:C01
SEQ ID NO:1533	is the determined cDNA sequence for clone	63695583 R0679:C02
SEQ ID NO:1534	is the determined cDNA sequence for clone	63695586 R0679:C05
SEQ ID NO:1535	is the determined cDNA sequence for clone	63695587 R0679:C06
SEQ ID NO:1536	is the determined cDNA sequence for clone	63695589 R0679:C08
SEQ ID NO:1537	is the determined cDNA sequence for clone	63695590 R0679:C09
SEQ ID NO:1538	is the determined cDNA sequence for clone	63695591 R0679:C10
SEQ ID NO:1539	is the determined cDNA sequence for clone	63695592 R0679:C11
SEQ ID NO:1540	is the determined cDNA sequence for clone	63695593 R0679:C12
SEQ ID NO:1541	is the determined cDNA sequence for clone	63695594 R0679:D01
SEQ ID NO:1542	is the determined cDNA sequence for clone	63695595 R0679:D02
SEQ ID NO:1543	is the determined cDNA sequence for clone	63695596 R0679:D03
SEQ ID NO:1544	is the determined cDNA sequence for clone	63695597 R0679:D04
SEQ ID NO:1545	is the determined cDNA sequence for clone	63695598 R0679:D05
SEQ ID NO:1546	is the determined cDNA sequence for clone	63695599 R0679:D06
SEQ ID NO:1547	is the determined cDNA sequence for clone	63695600 R0679:D07
SEQ ID NO:1548	is the determined cDNA sequence for clone	63695602 R0679:D09
SEQ ID NO:1549	is the determined cDNA sequence for clone	63695603 R0679:D10
SEQ ID NO:1550	is the determined cDNA sequence for clone	63695604 R0679:D11
SEQ ID NO:1551	is the determined cDNA sequence for clone	63695605 R0679:D12
SEQ ID NO:1552	is the determined cDNA sequence for clone	63695606 R0679:E01
SEQ ID NO:1553	is the determined cDNA sequence for clone	63695608 R0679:E03
SEQ ID NO:1554	is the determined cDNA sequence for clone	63695609 R0679:E04
SEQ ID NO:1555	is the determined cDNA sequence for clone	63695610 R0679:E05
SEQ ID NO:1556	is the determined cDNA sequence for clone	63695611 R0679:E06
SEQ ID NO:1557	is the determined cDNA sequence for clone	63695612 R0679:E07
SEQ ID NO:1558	is the determined cDNA sequence for clone	63695613 R0679:E08
SEQ ID NO:1559	is the determined cDNA sequence for clone	63695614 R0679:E09
SEQ ID NO:1560	is the determined cDNA sequence for clone	63695615 R0679:E10
SEQ ID NO:1561	is the determined cDNA sequence for clone	63695616 R0679:E11
SEQ ID NO:1562	is the determined cDNA sequence for clone	63695617 R0679:E12
SEQ ID NO:1563	is the determined cDNA sequence for clone	63695618 R0679:F01
SEQ ID NO:1564	is the determined cDNA sequence for clone	63695619 R0679:F02
SEQ ID NO:1565	is the determined cDNA sequence for clone	63695620 R0679:F03
SEQ ID NO:1566	is the determined cDNA sequence for clone	63695622 R0679:F05
SEQ ID NO:1567	is the determined cDNA sequence for clone	63695623 R0679:F06
SEQ ID NO:1568	is the determined cDNA sequence for clone	63695624 R0679:F07
SEQ ID NO:1569	is the determined cDNA sequence for clone	63695625 R0679:F08
SEQ ID NO:1570	is the determined cDNA sequence for clone	63695626 R0679:F09
SEQ ID NO:1571	is the determined cDNA sequence for clone	63695627 R0679:F10
SEQ ID NO:1572	is the determined cDNA sequence for clone	63695629 R0679:F12
SEQ ID NO:1573	is the determined cDNA sequence for clone	63695630 R0679:G01
SEQ ID NO:1574	is the determined cDNA sequence for clone	63695631 R0679:G02

SEQ ID NO:1575	is the determined cDNA sequence for clone	63695633 R0679:G04
SEQ ID NO:1576	is the determined cDNA sequence for clone	63695635 R0679:G06
SEQ ID NO:1577	is the determined cDNA sequence for clone	63695636 R0679:G07
SEQ ID NO:1578	is the determined cDNA sequence for clone	63695637 R0679:G08
SEQ ID NO:1579	is the determined cDNA sequence for clone	63695640 R0679:G11
SEQ ID NO:1580	is the determined cDNA sequence for clone	63695641 R0679:G12
SEQ ID NO:1581	is the determined cDNA sequence for clone	63695642 R0679:H01
SEQ ID NO:1582	is the determined cDNA sequence for clone	63695643 R0679:H02
SEQ ID NO:1583	is the determined cDNA sequence for clone	63695644 R0679:H03
SEQ ID NO:1584	is the determined cDNA sequence for clone	63695645 R0679:H04
SEQ ID NO:1585	is the determined cDNA sequence for clone	63695646 R0679:H05
SEQ ID NO:1586	is the determined cDNA sequence for clone	63695647 R0679:H06
SEQ ID NO:1587	is the determined cDNA sequence for clone	63695649 R0679:H08
SEQ ID NO:1588	is the determined cDNA sequence for clone	63695650 R0679:H09
SEQ ID NO:1589	is the determined cDNA sequence for clone	63695652 R0679:H11
SEQ ID NO:1590	is the determined cDNA sequence for clone	63695468 R0680:A03
SEQ ID NO:1591	is the determined cDNA sequence for clone	63695469 R0680:A05
SEQ ID NO:1592	is the determined cDNA sequence for clone	63695470 R0680:A06
SEQ ID NO:1593	is the determined cDNA sequence for clone	63695471 R0680:A07
SEQ ID NO:1594	is the determined cDNA sequence for clone	63695472 R0680:A08
SEQ ID NO:1595	is the determined cDNA sequence for clone	63695473 R0680:A09
SEQ ID NO:1596	is the determined cDNA sequence for clone	63695474 R0680:A10
SEQ ID NO:1597	is the determined cDNA sequence for clone	63695475 R0680:A11
SEQ ID NO:1598	is the determined cDNA sequence for clone	63695476 R0680:A12
SEQ ID NO:1599	is the determined cDNA sequence for clone	63695477 R0680:B01
SEQ ID NO:1600	is the determined cDNA sequence for clone	63695478 R0680:B02
SEQ ID NO:1601	is the determined cDNA sequence for clone	63695480 R0680:B04
SEQ ID NO:1602	is the determined cDNA sequence for clone	63695482 R0680:B06
SEQ ID NO:1603	is the determined cDNA sequence for clone	63695483 R0680:B07
SEQ ID NO:1604	is the determined cDNA sequence for clone	63695484 R0680:B08
SEQ ID NO:1605	is the determined cDNA sequence for clone	63695485 R0680:B09
SEQ ID NO:1606	is the determined cDNA sequence for clone	63695486 R0680:B10
SEQ ID NO:1607	is the determined cDNA sequence for clone	63695487 R0680:B11
SEQ ID NO:1608	is the determined cDNA sequence for clone	63695488 R0680:B12
SEQ ID NO:1609	is the determined cDNA sequence for clone	63695489 R0680:C01
SEQ ID NO:1610	is the determined cDNA sequence for clone	63695490 R0680:C02
SEQ ID NO:1611	is the determined cDNA sequence for clone	63695491 R0680:C03
SEQ ID NO:1612	is the determined cDNA sequence for clone	63695492 R0680:C04
SEQ ID NO:1613	is the determined cDNA sequence for clone	63695495 R0680:C07
SEQ ID NO:1614	is the determined cDNA sequence for clone	63695496 R0680:C08
SEQ ID NO:1615	is the determined cDNA sequence for clone	63695497 R0680:C09
SEQ ID NO:1616	is the determined cDNA sequence for clone	63695498 R0680:C10
SEQ ID NO:1617	is the determined cDNA sequence for clone	63695499 R0680:C11
SEQ ID NO:1618	is the determined cDNA sequence for clone	63695501 R0680:D01
SEQ ID NO:1619	is the determined cDNA sequence for clone	63695502 R0680:D02
SEQ ID NO:1620	is the determined cDNA sequence for clone	63695503 R0680:D03

SEQ ID NO:1621	is the determined cDNA sequence for clone	63695504 R0680:D04
SEQ ID NO:1622	is the determined cDNA sequence for clone	63695507 R0680:D07
SEQ ID NO:1623	is the determined cDNA sequence for clone	63695509 R0680:D09
SEQ ID NO:1624	is the determined cDNA sequence for clone	63695510 R0680:D10
SEQ ID NO:1625	is the determined cDNA sequence for clone	63695511 R0680:D11
SEQ ID NO:1626	is the determined cDNA sequence for clone	63695512 R0680:D12
SEQ ID NO:1627	is the determined cDNA sequence for clone	63695513 R0680:E01
SEQ ID NO:1628	is the determined cDNA sequence for clone	63695515 R0680:E03
SEQ ID NO:1629	is the determined cDNA sequence for clone	63695516 R0680:E04
SEQ ID NO:1630	is the determined cDNA sequence for clone	63695518 R0680:E06
SEQ ID NO:1631	is the determined cDNA sequence for clone	63695519 R0680:E07
SEQ ID NO:1632	is the determined cDNA sequence for clone	63695520 R0680:E08
SEQ ID NO:1633	is the determined cDNA sequence for clone	63695521 R0680:E09
SEQ ID NO:1634	is the determined cDNA sequence for clone	63695522 R0680:E10
SEQ ID NO:1635	is the determined cDNA sequence for clone	63695523 R0680:E11
SEQ ID NO:1636	is the determined cDNA sequence for clone	63695524 R0680:E12
SEQ ID NO:1637	is the determined cDNA sequence for clone	63695525 R0680:F01
SEQ ID NO:1638	is the determined cDNA sequence for clone	63695526 R0680:F02
SEQ ID NO:1639	is the determined cDNA sequence for clone	63695527 R0680:F03
SEQ ID NO:1640	is the determined cDNA sequence for clone	63695528 R0680:F04
SEQ ID NO:1641	is the determined cDNA sequence for clone	63695530 R0680:F06
SEQ ID NO:1642	is the determined cDNA sequence for clone	63695532 R0680:F08
SEQ ID NO:1643	is the determined cDNA sequence for clone	63695534 R0680:F10
SEQ ID NO:1644	is the determined cDNA sequence for clone	63695535 R0680:F11
SEQ ID NO:1645	is the determined cDNA sequence for clone	63695536 R0680:F12
SEQ ID NO:1646	is the determined cDNA sequence for clone	63695537 R0680:G01
SEQ ID NO:1647	is the determined cDNA sequence for clone	63695538 R0680:G02
SEQ ID NO:1648	is the determined cDNA sequence for clone	63695539 R0680:G03
SEQ ID NO:1649	is the determined cDNA sequence for clone	63695540 R0680:G04
SEQ ID NO:1650	is the determined cDNA sequence for clone	63695542 R0680:G06
SEQ ID NO:1651	is the determined cDNA sequence for clone	63695544 R0680:G08
SEQ ID NO:1652	is the determined cDNA sequence for clone	63695545 R0680:G09
SEQ ID NO:1653	is the determined cDNA sequence for clone	63695546 R0680:G10
SEQ ID NO:1654	is the determined cDNA sequence for clone	63695547 R0680:G11
SEQ ID NO:1655	is the determined cDNA sequence for clone	63695549 R0680:H01
SEQ ID NO:1656	is the determined cDNA sequence for clone	63695551 R0680:H03
SEQ ID NO:1657	is the determined cDNA sequence for clone	63695552 R0680:H04
SEQ ID NO:1658	is the determined cDNA sequence for clone	63695554 R0680:H06
SEQ ID NO:1659	is the determined cDNA sequence for clone	63695556 R0680:H08
SEQ ID NO:1660	is the determined cDNA sequence for clone	63695559 R0680:H11
SEQ ID NO:1661	is the determined cDNA sequence for clone	673.A9
SEQ ID NO:1662	is the determined cDNA sequence for clone	673.H12
SEQ ID NO:1663	is the determined cDNA sequence for clone	674.A7.GI:12728304
SEQ ID NO:1664	is the determined cDNA sequence for clone	674.A7
SEQ ID NO:1665	is the determined cDNA sequence for clone	675.G9.GI:12736649
SEQ ID NO:1666	is the determined cDNA sequence for clone	675.G9

SEQ ID NO:1667	is the determined cDNA sequence for clone	675.A11.GI:10435821
SEQ ID NO:1668	is the determined cDNA sequence for clone	675.A11
SEQ ID NO:1669	is the determined cDNA sequence for clone	676.F9
SEQ ID NO:1670	is the determined cDNA sequence for clone	677.F11
SEQ ID NO:1671	is the determined cDNA sequence for clone	680.F1.GI:3088574
SEQ ID NO:1672	is the determined cDNA sequence for clone	680.F1
SEQ ID NO:1673	is the determined cDNA sequence for clone	680.H3.GI:12652924
SEQ ID NO:1674	is the determined cDNA sequence for clone	680.H3
SEQ ID NO:1675	is the determined cDNA sequence for clone	680.B11
SEQ ID NO:1676	is the determined cDNA sequence for clone	685.F11
SEQ ID NO:1677	is the determined cDNA sequence for clone	687.B3.72249
SEQ ID NO:1678	is the determined cDNA sequence for clone	678.D2.GI:12734542
SEQ ID NO:1679	is the determined cDNA sequence for clone	678.D2.72899
SEQ ID NO:1680	is the determined cDNA sequence for clone	683.G3.GI:4185790
SEQ ID NO:1681	is the determined cDNA sequence for clone	683.G3.70426
SEQ ID NO:1682	is the determined cDNA sequence for clone	673.E12.GI:10436905
SEQ ID NO:1683	is the determined cDNA sequence for clone	673.E12.72901
SEQ ID NO:1684	is the determined cDNA sequence for clone	672.E3
SEQ ID NO:1685	is the determined cDNA sequence for clone	672.E3.72233
SEQ ID NO:1686	is the determined cDNA sequence for clone	677.C7.GI:10434626
SEQ ID NO:1687	is the determined cDNA sequence for clone	677.C7.72240
SEQ ID NO:1688	is the determined cDNA sequence for clone	678.E10.GI:12733361
SEQ ID NO:1689	is the determined cDNA sequence for clone	678.E10.72242
SEQ ID NO:1690	is the determined cDNA sequence for clone	679.C11.GI:13111934
SEQ ID NO:1691	is the determined cDNA sequence for clone	679.C11.72243
SEQ ID NO:1692	is the determined cDNA sequence for clone	674.D10.71575
SEQ ID NO:1693	is the determined cDNA sequence for clone	664.B3.GI:11526264
SEQ ID NO:1694	is the determined cDNA sequence for clone	664.B3.71569
SEQ ID NO:1695	is the determined cDNA sequence for clone	670.A3.71571
SEQ ID NO:1696	is the determined cDNA sequence for clone	665.B9.GI:12737771.
SEQ ID NO:1697	is the determined cDNA sequence for clone	665.B9.70580
SEQ ID NO:1698	is the determined cDNA sequence for clone	676G4(70581). 678H12(70582). 681B5(70586). 682E4(70589)
SEQ ID NO:1699	is the determined cDNA sequence for clone	681.F7.GI:12737278.
SEQ ID NO:1700	is the determined cDNA sequence for clone	681.F7.70587
SEQ ID NO:1701	is the determined cDNA sequence for clone	681.H11.GI:12655152
SEQ ID NO:1702	is the determined cDNA sequence for clone	681.H11.70584
SEQ ID NO:1703	is the determined cDNA sequence for clone	681.H3.GI:11427606
SEQ ID NO:1704	is the determined cDNA sequence for clone	681.H3.70588
SEQ ID NO:1705	is the determined cDNA sequence for clone	'70984.1'
SEQ ID NO:1706	is the determined cDNA sequence for clone	'70985.1'
SEQ ID NO:1707	is the determined cDNA sequence for clone	'70990.1'
SEQ ID NO:1708	is the determined cDNA sequence for clone	'70991.1'
SEQ ID NO:1709	is the determined cDNA sequence for clone	4.contig.GI:11427276

SEQ ID NO:1710	is the determined cDNA sequence for clone	'71023.1'
SEQ ID NO:1711	is the determined cDNA sequence for clone	5.contig.GI:11422221
SEQ ID NO:1712	is the determined cDNA sequence for clone	'71016.1'
SEQ ID NO:1713	is the determined cDNA sequence for clone	'71003.1'
SEQ ID NO:1714	is the determined cDNA sequence for clone	7.contig.GI:6330128
SEQ ID NO:1715	is the determined cDNA sequence for clone	'71043.1'
SEQ ID NO:1716	is the determined cDNA sequence for clone	8.contig.GI:11526264
SEQ ID NO:1717	is the determined cDNA sequence for clone	'71000.1'
SEQ ID NO:1718	is the determined cDNA sequence for clone	'71033.1'
SEQ ID NO:1719	is the determined cDNA sequence for clone	9.contig.GI:7657545
SEQ ID NO:1720	is the determined cDNA sequence for clone	'70989.1'
SEQ ID NO:1721	is the determined cDNA sequence for clone	10.contig.GI:482908
SEQ ID NO:1722	is the determined cDNA sequence for clone	'71040.1'
SEQ ID NO:1723	is the determined cDNA sequence for clone	'71035.1'
SEQ ID NO:1724	is the determined cDNA sequence for clone	'71038.1'
SEQ ID NO:1725	is the determined cDNA sequence for clone	'71007.1'
SEQ ID NO:1726	is the determined cDNA sequence for clone	'71047.1'
SEQ ID NO:1727	is the determined cDNA sequence for clone	14.contig.GI:4096861
SEQ ID NO:1728	is the determined cDNA sequence for clone	'71013.1'
SEQ ID NO:1729	is the determined cDNA sequence for clone	'70983.1'
SEQ ID NO:1730	is the determined cDNA sequence for clone	'71027.1'
SEQ ID NO:1731	is the determined cDNA sequence for clone	16.Contig.GI:11419857
SEQ ID NO:1732	is the determined cDNA sequence for clone	'71054.1'
SEQ ID NO:1733	is the determined cDNA sequence for clone	'71041.1'
SEQ ID NO:1734	is the determined cDNA sequence for clone	'71031.1'
SEQ ID NO:1735	is the determined cDNA sequence for clone	'71034.1'
SEQ ID NO:1736	is the determined cDNA sequence for clone	'71019.1'
SEQ ID NO:1737	is the determined cDNA sequence for clone	'71050.1'
SEQ ID NO:1738	is the determined cDNA sequence for clone	23.contig.GI:4502778
SEQ ID NO:1739	is the determined cDNA sequence for clone	'71010.1'
SEQ ID NO:1740	is the determined cDNA sequence for clone	24.Contig.GI:6005991
SEQ ID NO:1741	is the determined cDNA sequence for clone	'71044.1'
SEQ ID NO:1742	is the determined cDNA sequence for clone	'70996.1'
SEQ ID NO:1743	is the determined cDNA sequence for clone	26.Contig.GI:177801
SEQ ID NO:1744	is the determined cDNA sequence for clone	'71060.1'
SEQ ID NO:1745	is the determined cDNA sequence for clone	27.Contig.GI:10439726
SEQ ID NO:1746	is the determined cDNA sequence for clone	'71057.1'
SEQ ID NO:1747	is the determined cDNA sequence for clone	'71001.1'
SEQ ID NO:1748	is the determined cDNA sequence for clone	29.contig.gbID.11429588
SEQ ID NO:1749	is the determined cDNA sequence for clone	'70971.1'
SEQ ID NO:1750	is the determined cDNA sequence for clone	'70973.1'
SEQ ID NO:1751	is the determined cDNA sequence for clone	'70974.1'
SEQ ID NO:1752	is the determined cDNA sequence for clone	'70975.1'
SEQ ID NO:1753	is the determined cDNA sequence for clone	'70977.1'
SEQ ID NO:1754	is the determined cDNA sequence for clone	'70980.1'

SEQ ID NO:1755	is the determined cDNA sequence for clone	'70981.1'
SEQ ID NO:1756	is the determined cDNA sequence for clone	'70982.1'
SEQ ID NO:1757	is the determined cDNA sequence for clone	'70986.1'
SEQ ID NO:1758	is the determined cDNA sequence for clone	'70987.1'
SEQ ID NO:1759	is the determined cDNA sequence for clone	'70988.1'
SEQ ID NO:1760	is the determined cDNA sequence for clone	'70997.1'
SEQ ID NO:1761	is the determined cDNA sequence for clone	'70998.1'
SEQ ID NO:1762	is the determined cDNA sequence for clone	'70999.1'
SEQ ID NO:1763	is the determined cDNA sequence for clone	'71006.1'
SEQ ID NO:1764	is the determined cDNA sequence for clone	'71008.1'
SEQ ID NO:1765	is the determined cDNA sequence for clone	'71009.1'
SEQ ID NO:1766	is the determined cDNA sequence for clone	'71011.1'
SEQ ID NO:1767	is the determined cDNA sequence for clone	'71012.1'
SEQ ID NO:1768	is the determined cDNA sequence for clone	'71018.1'
SEQ ID NO:1769	is the determined cDNA sequence for clone	'71021.1'
SEQ ID NO:1770	is the determined cDNA sequence for clone	'71022.1'
SEQ ID NO:1771	is the determined cDNA sequence for clone	'71024.1'
SEQ ID NO:1772	is the determined cDNA sequence for clone	'71028.1'
SEQ ID NO:1773	is the determined cDNA sequence for clone	'71029.1'
SEQ ID NO:1774	is the determined cDNA sequence for clone	'71032.1'
SEQ ID NO:1775	is the determined cDNA sequence for clone	'71036.1'
SEQ ID NO:1776	is the determined cDNA sequence for clone	'71037.1'
SEQ ID NO:1777	is the determined cDNA sequence for clone	'71039.1'
SEQ ID NO:1778	is the determined cDNA sequence for clone	'71045.1'
SEQ ID NO:1779	is the determined cDNA sequence for clone	'71049.1'
SEQ ID NO:1780	is the determined cDNA sequence for clone	'71051.1'
SEQ ID NO:1781	is the determined cDNA sequence for clone	'71055.1'
SEQ ID NO:1782	is the determined cDNA sequence for clone	'71058.1'
SEQ ID NO:1783	is the determined cDNA sequence for clone	'71059.1'
SEQ ID NO:1784	is the determined cDNA sequence for clone	'71062.1'
SEQ ID NO:1785	is the determined cDNA sequence for clone	'71063.1'
SEQ ID NO:1786	is the determined cDNA sequence for clone	'71065.1'
SEQ ID NO:1787	is the determined cDNA sequence for clone	'71066.1'
SEQ ID NO:1788	is the determined cDNA sequence for clone	602287 Human E1A enhancer binding protein (E1A-F)
SEQ ID NO:1789	is the predicted amino acid sequence for	SEQ ID NO:1788, Human E1A enhancer binding protein (E1A-F)

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed generally to compositions and their use in the therapy and diagnosis of cancer, particularly colon cancer. As described further below, illustrative compositions of the present invention include, but are not restricted to, polypeptides, particularly immunogenic polypeptides, polynucleotides encoding such polypeptides, antibodies and other binding agents, antigen presenting cells (APCs) and immune system cells (*e.g.*, T cells).

The practice of the present invention will employ, unless indicated specifically to the contrary, conventional methods of virology, immunology, microbiology, molecular biology and recombinant DNA techniques within the skill of the art, many of which are described below for the purpose of illustration. Such techniques are explained fully in the literature. See, *e.g.*, Sambrook, et al. *Molecular Cloning: A Laboratory Manual* (2nd Edition, 1989); Maniatis et al. *Molecular Cloning: A Laboratory Manual* (1982); *DNA Cloning: A Practical Approach*, vol. I & II (D. Glover, ed.); *Oligonucleotide Synthesis* (N. Gait, ed., 1984); *Nucleic Acid Hybridization* (B. Hames & S. Higgins, eds., 1985); *Transcription and Translation* (B. Hames & S. Higgins, eds., 1984); *Animal Cell Culture* (R. Freshney, ed., 1986); Perbal, *A Practical Guide to Molecular Cloning* (1984).

All publications, patents and patent applications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety.

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.

Polypeptide Compositions

As used herein, the term "polypeptide" is used in its conventional meaning, *i.e.*, as a sequence of amino acids. The polypeptides are not limited to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide, and such terms may be used interchangeably herein unless specifically indicated otherwise. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations,

phosphorylations and the like, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. A polypeptide may be an entire protein, or a subsequence thereof. Particular polypeptides of interest in the context of this invention are amino acid subsequences comprising epitopes, *i.e.*, antigenic determinants substantially responsible for the immunogenic properties of a polypeptide and being capable of evoking an immune response.

Particularly illustrative polypeptides of the present invention comprise those encoded by a polynucleotide sequence set forth in any one of SEQ ID NO:1-1788, or a sequence that hybridizes under moderately stringent conditions, or, alternatively, under highly stringent conditions, to a polynucleotide sequence set forth in any one of SEQ ID NO:1-1788. Certain other illustrative polypeptides of the invention comprise amino acid sequences as set forth in any one of SEQ ID NO:1789.

The polypeptides of the present invention are sometimes herein referred to as colon tumor proteins or colon tumor polypeptides, as an indication that their identification has been based at least in part upon their increased levels of expression in colon tumor samples. Thus, a "colon tumor polypeptide" or "colon tumor protein," refers generally to a polypeptide sequence of the present invention, or a polynucleotide sequence encoding such a polypeptide, that is expressed in a substantial proportion of colon tumor samples, for example preferably greater than about 20%, more preferably greater than about 30%, and most preferably greater than about 50% or more of colon tumor samples tested, at a level that is at least two fold, and preferably at least five fold, greater than the level of expression in normal tissues, as determined using a representative assay provided herein. A colon tumor polypeptide sequence of the invention, based upon its increased level of expression in tumor cells, has particular utility both as a diagnostic marker as well as a therapeutic target, as further described below.

In certain preferred embodiments, the polypeptides of the invention are immunogenic, *i.e.*, they react detectably within an immunoassay (such as an ELISA or T-cell stimulation assay) with antisera and/or T-cells from a patient with colon cancer. Screening for immunogenic activity can be performed using techniques well known to the skilled artisan. For example, such screens can be performed using methods such as

those described in Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In one illustrative example, a polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A.

As would be recognized by the skilled artisan, immunogenic portions of the polypeptides disclosed herein are also encompassed by the present invention. An "immunogenic portion," as used herein, is a fragment of an immunogenic polypeptide of the invention that itself is immunologically reactive (*i.e.*, specifically binds) with the B-cells and/or T-cell surface antigen receptors that recognize the polypeptide. Immunogenic portions may generally be identified using well known techniques, such as those summarized in Paul, *Fundamental Immunology*, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are "antigen-specific" if they specifically bind to an antigen (*i.e.*, they react with the protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well-known techniques.

In one preferred embodiment, an immunogenic portion of a polypeptide of the present invention is a portion that reacts with antisera and/or T-cells at a level that is not substantially less than the reactivity of the full-length polypeptide (*e.g.*, in an ELISA and/or T-cell reactivity assay). Preferably, the level of immunogenic activity of the immunogenic portion is at least about 50%, preferably at least about 70% and most preferably greater than about 90% of the immunogenicity for the full-length polypeptide. In some instances, preferred immunogenic portions will be identified that have a level of immunogenic activity greater than that of the corresponding full-length polypeptide, *e.g.*, having greater than about 100% or 150% or more immunogenic activity.

In certain other embodiments, illustrative immunogenic portions may include peptides in which an N-terminal leader sequence and/or transmembrane domain have been deleted. Other illustrative immunogenic portions will contain a small N-

and/or C-terminal deletion (*e.g.*, 1-30 amino acids, preferably 5-15 amino acids), relative to the mature protein.

In another embodiment, a polypeptide composition of the invention may also comprise one or more polypeptides that are immunologically reactive with T cells
5 and/or antibodies generated against a polypeptide of the invention, particularly a polypeptide having an amino acid sequence disclosed herein, or to an immunogenic fragment or variant thereof.

In another embodiment of the invention, polypeptides are provided that comprise one or more polypeptides that are capable of eliciting T cells and/or antibodies
10 that are immunologically reactive with one or more polypeptides described herein, or one or more polypeptides encoded by contiguous nucleic acid sequences contained in the polynucleotide sequences disclosed herein, or immunogenic fragments or variants thereof, or to one or more nucleic acid sequences which hybridize to one or more of these sequences under conditions of moderate to high stringency.

15 The present invention, in another aspect, provides polypeptide fragments comprising at least about 5, 10, 15, 20, 25, 50, or 100 contiguous amino acids, or more, including all intermediate lengths, of a polypeptide compositions set forth herein, such as those set forth in SEQ ID NO:1789, or those encoded by a polynucleotide sequence set forth in a sequence of SEQ ID NO:1-1788.

20 In another aspect, the present invention provides variants of the polypeptide compositions described herein. Polypeptide variants generally encompassed by the present invention will typically exhibit at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity (determined as described below), along its length, to a polypeptide sequences set forth
25 herein.

In one preferred embodiment, the polypeptide fragments and variants provided by the present invention are immunologically reactive with an antibody and/or T-cell that reacts with a full-length polypeptide specifically set forth herein.

In another preferred embodiment, the polypeptide fragments and variants
30 provided by the present invention exhibit a level of immunogenic activity of at least about 50%, preferably at least about 70%, and most preferably at least about 90% or

more of that exhibited by a full-length polypeptide sequence specifically set forth herein.

A polypeptide "variant," as the term is used herein, is a polypeptide that typically differs from a polypeptide specifically disclosed herein in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of the above polypeptide sequences of the invention and evaluating their immunogenic activity as described herein and/or using any of a number of techniques well known in the art.

For example, certain illustrative variants of the polypeptides of the invention include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed. Other illustrative variants include variants in which a small portion (*e.g.*, 1-30 amino acids, preferably 5-15 amino acids) has been removed from the N- and/or C-terminal of the mature protein.

In many instances, a variant will contain conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. As described above, modifications may be made in the structure of the polynucleotides and polypeptides of the present invention and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics, *e.g.*, with immunogenic characteristics. When it is desired to alter the amino acid sequence of a polypeptide to create an equivalent, or even an improved, immunogenic variant or portion of a polypeptide of the invention, one skilled in the art will typically change one or more of the codons of the encoding DNA sequence according to Table 1.

For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence

substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides

5 without appreciable loss of their biological utility or activity.

TABLE 1

Amino Acids			Codons						
Alanine	Ala	A	GCA	GCC	GCG	GCU			
Cysteine	Cys	C	UGC	UGU					
Aspartic acid	Asp	D	GAC	GAU					
Glutamic acid	Glu	E	GAA	GAG					
Phenylalanine	Phe	F	UUC	UUU					
Glycine	Gly	G	GGA	GGC	GGG	GGU			
Histidine	His	H	CAC	CAU					
Isoleucine	Ile	I	AUA	AUC	AUU				
Lysine	Lys	K	AAA	AAG					
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU	
Methionine	Met	M	AUG						
Asparagine	Asn	N	AAC	AAU					
Proline	Pro	P	CCA	CCC	CCG	CCU			
Glutamine	Gln	Q	CAA	CAG					
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU	
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU	
Threonine	Thr	T	ACA	ACC	ACG	ACU			
Valine	Val	V	GUA	GUC	GUG	GUU			
Tryptophan	Trp	W	UGG						
Tyrosine	Tyr	Y	UAC	UAU					

10 In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and

Doolittle, 1982, incorporated herein by reference). It is accepted that the relative hydrophobic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydrophobic index on the basis of its hydrophobicity and charge characteristics (Kyte and Doolittle, 1982). These values are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (−4.5).

It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydrophobic index or score and still result in a protein with similar biological activity, *i.e.* still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydrophobic indices are within ± 2 is preferred, those within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U. S. Patent 4,554,101 (specifically incorporated herein by reference in its entirety), states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.

As detailed in U. S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 \pm 1); glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5 \pm 1); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5); tryptophan (−3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

In addition, any polynucleotide may be further modified to increase stability *in vivo*. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl-methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

Amino acid substitutions may further be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. In a preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydrophobic nature of the polypeptide.

As noted above, polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein, which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or

other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

When comparing polypeptide sequences, two sequences are said to be
5 “identical” if the sequence of amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions,
10 usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR,
15 Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990)
20 Unified Approach to Alignment and Phylogenies pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor* 11:105; Saitou, N. Nei, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and*
25 *Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad. Sci. USA* 80:726-730.

Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J.*
30 *Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these

algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) *Nucl. Acids Res.* 25:3389-3402 and Altschul et al. (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.

In one preferred approach, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polypeptide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

Within other illustrative embodiments, a polypeptide may be a xenogeneic polypeptide that comprises an polypeptide having substantial sequence identity, as described above, to the human polypeptide (also termed autologous antigen)

which served as a reference polypeptide, but which xenogeneic polypeptide is derived from a different, non-human species. One skilled in the art will recognize that "self" antigens are often poor stimulators of CD8+ and CD4+ T-lymphocyte responses, and therefore efficient immunotherapeutic strategies directed against tumor polypeptides require the development of methods to overcome immune tolerance to particular self tumor polypeptides. For example, humans immunized with prostate protein from a xenogeneic (non human) origin are capable of mounting an immune response against the counterpart human protein, *e.g.* the human prostate tumor protein present on human tumor cells. Accordingly, the present invention provides methods for purifying the xenogeneic form of the tumor proteins set forth herein, such as the polypeptide set forth in SEQ ID NO:1789, or those encoded by polynucleotide sequences set forth in SEQ ID NO:1-1788.

Therefore, one aspect of the present invention provides xenogeneic variants of the polypeptide compositions described herein. Such xenogeneic variants generally encompassed by the present invention will typically exhibit at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity along their lengths, to a polypeptide sequences set forth herein.

More particularly, the invention is directed to mouse, rat, monkey, porcine and other non-human polypeptides which can be used as xenogeneic forms of human polypeptides set forth herein, to induce immune responses directed against tumor polypeptides of the invention.

Within other illustrative embodiments, a polypeptide may be a fusion polypeptide that comprises multiple polypeptides as described herein, or that comprises at least one polypeptide as described herein and an unrelated sequence, such as a known tumor protein. A fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the polypeptide or to enable the polypeptide to be targeted to

desired intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the polypeptide.

Fusion polypeptides may generally be prepared using standard techniques, including chemical conjugation. Preferably, a fusion polypeptide is expressed as a recombinant polypeptide, allowing the production of increased levels, relative to a non-fused polypeptide, in an expression system. Briefly, DNA sequences encoding the polypeptide components may be assembled separately, and ligated into an appropriate expression vector. The 3' end of the DNA sequence encoding one polypeptide component is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in phase. This permits translation into a single fusion polypeptide that retains the biological activity of both component polypeptides.

A peptide linker sequence may be employed to separate the first and second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion polypeptide using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., *Gene* 40:39-46, 1985; Murphy et al., *Proc. Natl. Acad. Sci. USA* 83:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements

responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

- 5 The fusion polypeptide can comprise a polypeptide as described herein together with an unrelated immunogenic protein, such as an immunogenic protein capable of eliciting a recall response. Examples of such proteins include tetanus, tuberculosis and hepatitis proteins (*see*, for example, Stoute et al. *New Engl. J. Med.*, 336:86-91, 1997).
- 10 In one preferred embodiment, the immunological fusion partner is derived from a *Mycobacterium* sp., such as a *Mycobacterium tuberculosis*-derived Ra12 fragment. Ra12 compositions and methods for their use in enhancing the expression and/or immunogenicity of heterologous polynucleotide/polypeptide sequences is described in U.S. Patent Application 60/158,585, the disclosure of which is
- 15 incorporated herein by reference in its entirety. Briefly, Ra12 refers to a polynucleotide region that is a subsequence of a *Mycobacterium tuberculosis* MTB32A nucleic acid. MTB32A is a serine protease of 32 KD molecular weight encoded by a gene in virulent and avirulent strains of *M. tuberculosis*. The nucleotide sequence and amino acid sequence of MTB32A have been described (for example, U.S. Patent Application
- 20 60/158,585; *see also*, Skeiky et al., *Infection and Immun.* (1999) 67:3998-4007, incorporated herein by reference). C-terminal fragments of the MTB32A coding sequence express at high levels and remain as a soluble polypeptides throughout the purification process. Moreover, Ra12 may enhance the immunogenicity of heterologous immunogenic polypeptides with which it is fused. One preferred Ra12 fusion
- 25 polypeptide comprises a 14 KD C-terminal fragment corresponding to amino acid residues 192 to 323 of MTB32A. Other preferred Ra12 polynucleotides generally comprise at least about 15 consecutive nucleotides, at least about 30 nucleotides, at least about 60 nucleotides, at least about 100 nucleotides, at least about 200 nucleotides, or at least about 300 nucleotides that encode a portion of a Ra12 polypeptide. Ra12
- 30 polynucleotides may comprise a native sequence (*i.e.*, an endogenous sequence that encodes a Ra12 polypeptide or a portion thereof) or may comprise a variant of such a

sequence. Ra12 polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions such that the biological activity of the encoded fusion polypeptide is not substantially diminished, relative to a fusion polypeptide comprising a native Ra12 polypeptide. Variants preferably exhibit at least about 70% identity, more preferably at least about 80% identity and most preferably at least about 90% identity to a polynucleotide sequence that encodes a native Ra12 polypeptide or a portion thereof.

Within other preferred embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium *Haemophilus influenza B* (WO 91/18926). Preferably, a protein D derivative comprises approximately the first third of the protein (e.g., the first N-terminal 100-110 amino acids), and a protein D derivative may be lipidated. Within certain preferred embodiments, the first 109 residues of a Lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes and to increase the expression level in *E. coli* (thus functioning as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells. Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from *Streptococcus pneumoniae*, which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the *LytA* gene; *Gene* 43:265-292, 1986). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of *E. coli* C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see *Biotechnology* 10:795-798, 1992). Within a preferred embodiment, a repeat portion of LYTA may be incorporated

into a fusion polypeptide. A repeat portion is found in the C-terminal region starting at residue 178. A particularly preferred repeat portion incorporates residues 188-305.

Yet another illustrative embodiment involves fusion polypeptides, and the polynucleotides encoding them, wherein the fusion partner comprises a targeting
5 signal capable of directing a polypeptide to the endosomal/lysosomal compartment, as described in U.S. Patent No. 5,633,234. An immunogenic polypeptide of the invention, when fused with this targeting signal, will associate more efficiently with MHC class II molecules and thereby provide enhanced in vivo stimulation of CD4⁺ T-cells specific for the polypeptide.

10 Polypeptides of the invention are prepared using any of a variety of well known synthetic and/or recombinant techniques, the latter of which are further described below. Polypeptides, portions and other variants generally less than about 150 amino acids can be generated by synthetic means, using techniques well known to those of ordinary skill in the art. In one illustrative example, such polypeptides are
15 synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, *J. Am. Chem. Soc.* 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, CA), and
20 may be operated according to the manufacturer's instructions.

In general, polypeptide compositions (including fusion polypeptides) of the invention are isolated. An "isolated" polypeptide is one that is removed from its original environment. For example, a naturally-occurring protein or polypeptide is isolated if it is separated from some or all of the coexisting materials in the natural
25 system. Preferably, such polypeptides are also purified, *e.g.*, are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure.

Polynucleotide Compositions

The present invention, in other aspects, provides polynucleotide
30 compositions. The terms "DNA" and "polynucleotide" are used essentially

interchangeably herein to refer to a DNA molecule that has been isolated free of total genomic DNA of a particular species. "Isolated," as used herein, means that a polynucleotide is substantially away from other coding sequences, and that the DNA molecule does not contain large portions of unrelated coding DNA, such as large
5 chromosomal fragments or other functional genes or polypeptide coding regions. Of course, this refers to the DNA molecule as originally isolated, and does not exclude genes or coding regions later added to the segment by the hand of man.

As will be understood by those skilled in the art, the polynucleotide compositions of this invention can include genomic sequences, extra-genomic and
10 plasmid-encoded sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides, peptides and the like. Such segments may be naturally isolated, or modified synthetically by the hand of man.

As will be also recognized by the skilled artisan, polynucleotides of the invention may be single-stranded (coding or antisense) or double-stranded, and may be
15 DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules may include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one manner, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules
20 and/or support materials.

Polynucleotides may comprise a native sequence (*i.e.*, an endogenous sequence that encodes a polypeptide/protein of the invention or a portion thereof) or may comprise a sequence that encodes a variant or derivative, preferably and immunogenic variant or derivative, of such a sequence.

25 Therefore, according to another aspect of the present invention, polynucleotide compositions are provided that comprise some or all of a polynucleotide sequence set forth in any one of SEQ ID NO:1-1788, complements of a polynucleotide sequence set forth in any one of SEQ ID NO:1-1788, and degenerate variants of a polynucleotide sequence set forth in any one of SEQ ID NO:1-1788. In certain
30 preferred embodiments, the polynucleotide sequences set forth herein encode immunogenic polypeptides, as described above.

In other related embodiments, the present invention provides polynucleotide variants having substantial identity to the sequences disclosed herein in SEQ ID NO:1-1788, for example those comprising at least 70% sequence identity, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, 5 sequence identity compared to a polynucleotide sequence of this invention using the methods described herein, (*e.g.*, BLAST analysis using standard parameters, as described below). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, 10 reading frame positioning and the like.

Typically, polynucleotide variants will contain one or more substitutions, additions, deletions and/or insertions, preferably such that the immunogenicity of the polypeptide encoded by the variant polynucleotide is not substantially diminished relative to a polypeptide encoded by a polynucleotide sequence specifically set forth 15 herein). The term "variants" should also be understood to encompass homologous genes of xenogenic origin.

In additional embodiments, the present invention provides polynucleotide fragments comprising or consisting of various lengths of contiguous stretches of sequence identical to or complementary to one or more of the sequences 20 disclosed herein. For example, polynucleotides are provided by this invention that comprise or consist of at least about 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of one or more of the sequences disclosed herein as well as all intermediate lengths there between. It will be readily understood that "intermediate lengths", in this context, means any length between the quoted 25 values, such as 16, 17, 18, 19, *etc.*; 21, 22, 23, *etc.*; 30, 31, 32, *etc.*; 50, 51, 52, 53, *etc.*; 100, 101, 102, 103, *etc.*; 150, 151, 152, 153, *etc.*; including all integers through 200-500; 500-1,000, and the like. A polynucleotide sequence as described here may be extended at one or both ends by additional nucleotides not found in the native sequence. This additional sequence may consist of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 30 16, 17, 18, 19, or 20 nucleotides at either end of the disclosed sequence or at both ends of the disclosed sequence.

In another embodiment of the invention, polynucleotide compositions are provided that are capable of hybridizing under moderate to high stringency conditions to a polynucleotide sequence provided herein, or a fragment thereof, or a complementary sequence thereof. Hybridization techniques are well known in the art of molecular biology. For purposes of illustration, suitable moderately stringent conditions for testing the hybridization of a polynucleotide of this invention with other polynucleotides include prewashing in a solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-60°C, 5 X SSC, overnight; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS. One skilled in the art will understand that the stringency of hybridization can be readily manipulated, such as by altering the salt content of the hybridization solution and/or the temperature at which the hybridization is performed. For example, in another embodiment, suitable highly stringent hybridization conditions include those described above, with the exception that the temperature of hybridization is increased, *e.g.*, to 60-65°C or 65-70°C.

In certain preferred embodiments, the polynucleotides described above, *e.g.*, polynucleotide variants, fragments and hybridizing sequences, encode polypeptides that are immunologically cross-reactive with a polypeptide sequence specifically set forth herein. In other preferred embodiments, such polynucleotides encode polypeptides that have a level of immunogenic activity of at least about 50%, preferably at least about 70%, and more preferably at least about 90% of that for a polypeptide sequence specifically set forth herein.

The polynucleotides of the present invention, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, illustrative polynucleotide segments with total lengths of about 10,000, about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50

base pairs in length, and the like, (including all intermediate lengths) are contemplated to be useful in many implementations of this invention.

When comparing polynucleotide sequences, two sequences are said to be “identical” if the sequence of nucleotides in the two sequences is the same when aligned
5 for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a
10 reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several
15 alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenies pp. 626-645 *Methods in Enzymology*
20 vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and
25 Lipman, D.J. (1983) *Proc. Natl. Acad., Sci. USA* 80:726-730.

Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988)
30 *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics

Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) *Nucl. Acids Res.* 25:3389-3402 and Altschul et al. (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and a comparison of both strands.

Preferably, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the

reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal
5 homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous
10 genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).

Therefore, in another embodiment of the invention, a mutagenesis
15 approach, such as site-specific mutagenesis, is employed for the preparation of immunogenic variants and/or derivatives of the polypeptides described herein. By this approach, specific modifications in a polypeptide sequence can be made through mutagenesis of the underlying polynucleotides that encode them. These techniques provides a straightforward approach to prepare and test sequence variants, for example,
20 incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the polynucleotide.

Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a
25 primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Mutations may be employed in a selected polynucleotide sequence to improve, alter, decrease, modify, or otherwise change the properties of the polynucleotide itself, and/or alter the properties, activity, composition, stability, or primary sequence of the encoded polypeptide.

30 In certain embodiments of the present invention, the inventors contemplate the mutagenesis of the disclosed polynucleotide sequences to alter one or

more properties of the encoded polypeptide, such as the immunogenicity of a polypeptide vaccine. The techniques of site-specific mutagenesis are well-known in the art, and are widely used to create variants of both polypeptides and polynucleotides. For example, site-specific mutagenesis is often used to alter a specific portion of a DNA molecule. In such embodiments, a primer comprising typically about 14 to about 25 nucleotides or so in length is employed, with about 5 to about 10 residues on both sides of the junction of the sequence being altered.

As will be appreciated by those of skill in the art, site-specific mutagenesis techniques have often employed a phage vector that exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage are readily commercially-available and their use is generally well-known to those skilled in the art. Double-stranded plasmids are also routinely employed in site directed mutagenesis that eliminates the step of transferring the gene of interest from a plasmid to a phage.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart of two strands of a double-stranded vector that includes within its sequence a DNA sequence that encodes the desired peptide. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

The preparation of sequence variants of the selected peptide-encoding DNA segments using site-directed mutagenesis provides a means of producing potentially useful species and is not meant to be limiting as there are other ways in which sequence variants of peptides and the DNA sequences encoding them may be obtained. For example, recombinant vectors encoding the desired peptide sequence may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence

variants. Specific details regarding these methods and protocols are found in the teachings of Maloy *et al.*, 1994; Segal, 1976; Prokop and Bajpai, 1991; Kuby, 1994; and Maniatis *et al.*, 1982, each incorporated herein by reference, for that purpose.

As used herein, the term "oligonucleotide directed mutagenesis
5 procedure" refers to template-dependent processes and vector-mediated propagation which result in an increase in the concentration of a specific nucleic acid molecule relative to its initial concentration, or in an increase in the concentration of a detectable signal, such as amplification. As used herein, the term "oligonucleotide directed
10 template-dependent extension of a primer molecule. The term template dependent process refers to nucleic acid synthesis of an RNA or a DNA molecule wherein the sequence of the newly synthesized strand of nucleic acid is dictated by the well-known rules of complementary base pairing (see, for example, Watson, 1987). Typically, vector mediated methodologies involve the introduction of the nucleic acid fragment
15 into a DNA or RNA vector, the clonal amplification of the vector, and the recovery of the amplified nucleic acid fragment. Examples of such methodologies are provided by U. S. Patent No. 4,237,224, specifically incorporated herein by reference in its entirety.

In another approach for the production of polypeptide variants of the present invention, recursive sequence recombination, as described in U.S. Patent No.
20 5,837,458, may be employed. In this approach, iterative cycles of recombination and screening or selection are performed to "evolve" individual polynucleotide variants of the invention having, for example, enhanced immunogenic activity.

In other embodiments of the present invention, the polynucleotide sequences provided herein can be advantageously used as probes or primers for nucleic
25 acid hybridization. As such, it is contemplated that nucleic acid segments that comprise or consist of a sequence region of at least about a 15 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 15 nucleotide long contiguous sequence disclosed herein will find particular utility. Longer contiguous identical or complementary sequences, *e.g.*, those of about 20, 30, 40, 50, 100, 200, 500,
30 1000 (including all intermediate lengths) and even up to full length sequences will also be of use in certain embodiments.

The ability of such nucleic acid probes to specifically hybridize to a sequence of interest will enable them to be of use in detecting the presence of complementary sequences in a given sample. However, other uses are also envisioned, such as the use of the sequence information for the preparation of mutant species
5 primers, or primers for use in preparing other genetic constructions.

Polynucleotide molecules having sequence regions consisting of contiguous nucleotide stretches of 10-14, 15-20, 30, 50, or even of 100-200 nucleotides or so (including intermediate lengths as well), identical or complementary to a polynucleotide sequence disclosed herein, are particularly contemplated as hybridization
10 probes for use in, *e.g.*, Southern and Northern blotting. This would allow a gene product, or fragment thereof, to be analyzed, both in diverse cell types and also in various bacterial cells. The total size of fragment, as well as the size of the complementary stretch(es), will ultimately depend on the intended use or application of the particular nucleic acid segment. Smaller fragments will generally find use in
15 hybridization embodiments, wherein the length of the contiguous complementary region may be varied, such as between about 15 and about 100 nucleotides, but larger contiguous complementarity stretches may be used, according to the length complementary sequences one wishes to detect.

The use of a hybridization probe of about 15-25 nucleotides in length
20 allows the formation of a duplex molecule that is both stable and selective. Molecules having contiguous complementary sequences over stretches greater than 15 bases in length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having gene-
25 complementary stretches of 15 to 25 contiguous nucleotides, or even longer where desired.

Hybridization probes may be selected from any portion of any of the sequences disclosed herein. All that is required is to review the sequences set forth herein, or to any continuous portion of the sequences, from about 15-25 nucleotides in
30 length up to and including the full length sequence, that one wishes to utilize as a probe or primer. The choice of probe and primer sequences may be governed by various

factors. For example, one may wish to employ primers from towards the termini of the total sequence.

Small polynucleotide segments or fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer. Also, fragments may be obtained by application of nucleic acid reproduction technology, such as the PCRTM technology of U. S. Patent 4,683,202 (incorporated herein by reference), by introducing selected sequences into recombinant vectors for recombinant production, and by other recombinant DNA techniques generally known to those of skill in the art of molecular biology.

The nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of the entire gene or gene fragments of interest. Depending on the application envisioned, one will typically desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, *e.g.*, one will select relatively low salt and/or high temperature conditions, such as provided by a salt concentration of from about 0.02 M to about 0.15 M salt at temperatures of from about 50°C to about 70°C. Such selective conditions tolerate little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating related sequences.

Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template, less stringent (reduced stringency) hybridization conditions will typically be needed in order to allow formation of the heteroduplex. In these circumstances, one may desire to employ salt conditions such as those of from about 0.15 M to about 0.9 M salt, at temperatures ranging from about 20°C to about 55°C. Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide, which serves to destabilize the hybrid duplex in the same manner as increased temperature. Thus,

hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results.

According to another embodiment of the present invention, polynucleotide compositions comprising antisense oligonucleotides are provided.

5 Antisense oligonucleotides have been demonstrated to be effective and targeted inhibitors of protein synthesis, and, consequently, provide a therapeutic approach by which a disease can be treated by inhibiting the synthesis of proteins that contribute to the disease. The efficacy of antisense oligonucleotides for inhibiting protein synthesis is well established. For example, the synthesis of polygalacturonase and the muscarine

10 type 2 acetylcholine receptor are inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U. S. Patent 5,739,119 and U. S. Patent 5,759,829). Further, examples of antisense inhibition have been demonstrated with the nuclear protein cyclin, the multiple drug resistance gene (MDG1), ICAM-1, E-selectin, STK-1, striatal GABA_A receptor and human EGF (Jaskulski *et al.*, Science. 1988 Jun

15 10;240(4858):1544-6; Vasanthakumar and Ahmed, Cancer Commun. 1989;1(4):225-32; Peris *et al.*, Brain Res Mol Brain Res. 1998 Jun 15;57(2):310-20; U. S. Patent 5,801,154; U.S. Patent 5,789,573; U. S. Patent 5,718,709 and U.S. Patent 5,610,288). Antisense constructs have also been described that inhibit and can be used to treat a variety of abnormal cellular proliferations, *e.g.* cancer (U. S. Patent 5,747,470; U. S.

20 Patent 5,591,317 and U. S. Patent 5,783,683).

Therefore, in certain embodiments, the present invention provides oligonucleotide sequences that comprise all, or a portion of, any sequence that is capable of specifically binding to polynucleotide sequence described herein, or a complement thereof. In one embodiment, the antisense oligonucleotides comprise DNA

25 or derivatives thereof. In another embodiment, the oligonucleotides comprise RNA or derivatives thereof. In a third embodiment, the oligonucleotides are modified DNAs comprising a phosphorothioated modified backbone. In a fourth embodiment, the oligonucleotide sequences comprise peptide nucleic acids or derivatives thereof. In each case, preferred compositions comprise a sequence region that is complementary,

30 and more preferably substantially-complementary, and even more preferably, completely complementary to one or more portions of polynucleotides disclosed herein.

Selection of antisense compositions specific for a given gene sequence is based upon analysis of the chosen target sequence and determination of secondary structure, T_m , binding energy, and relative stability. Antisense compositions may be selected based upon their relative inability to form dimers, hairpins, or other secondary structures that would reduce or prohibit specific binding to the target mRNA in a host cell. Highly preferred target regions of the mRNA, are those which are at or near the AUG translation initiation codon, and those sequences which are substantially complementary to 5' regions of the mRNA. These secondary structure analyses and target site selection considerations can be performed, for example, using v.4 of the OLIGO primer analysis software and/or the BLASTN 2.0.5 algorithm software (Altschul *et al.*, Nucleic Acids Res. 1997, 25(17):3389-402).

The use of an antisense delivery method employing a short peptide vector, termed MPG (27 residues), is also contemplated. The MPG peptide contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain from the nuclear localization sequence of SV40 T-antigen (Morris *et al.*, Nucleic Acids Res. 1997 Jul 15;25(14):2730-6). It has been demonstrated that several molecules of the MPG peptide coat the antisense oligonucleotides and can be delivered into cultured mammalian cells in less than 1 hour with relatively high efficiency (90%). Further, the interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and the ability to cross the plasma membrane.

According to another embodiment of the invention, the polynucleotide compositions described herein are used in the design and preparation of ribozyme molecules for inhibiting expression of the tumor polypeptides and proteins of the present invention in tumor cells. Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim and Cech, Proc Natl Acad Sci U S A. 1987 Dec;84(24):8788-92; Forster and Symons, Cell. 1987 Apr 24;49(2):211-20). For example, a large number of ribozymes accelerate phosphoester transfer reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech *et al.*, Cell. 1981 Dec;27(3 Pt 2):487-96; Michel and Westhof, J Mol Biol. 1990 Dec 5;216(3):585-610; Reinhold-Hurek and Shub, Nature.

1992 May 14;357(6374):173-6). This specificity has been attributed to the requirement that the substrate bind via specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme prior to chemical reaction.

Six basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds *in trans* (and thus can cleave other RNA molecules) under physiological conditions. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

The enzymatic nature of a ribozyme is advantageous over many technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the concentration of ribozyme necessary to affect a therapeutic treatment is lower than that of an antisense oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. Similar mismatches in antisense molecules do not prevent their action (Woolf *et al.*, Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7305-9). Thus, the specificity of action of a ribozyme is greater than that of an antisense oligonucleotide binding the same RNA site.

The enzymatic nucleic acid molecule may be formed in a hammerhead, hairpin, a hepatitis δ virus, group I intron or RNaseP RNA (in association with an RNA

guide sequence) or Neurospora VS RNA motif. Examples of hammerhead motifs are described by Rossi *et al.* Nucleic Acids Res. 1992 Sep 11;20(17):4559-65. Examples of hairpin motifs are described by Hampel *et al.* (Eur. Pat. Appl. Publ. No. EP 0360257), Hampel and Tritz, Biochemistry 1989 Jun 13;28(12):4929-33; Hampel *et al.*, Nucleic
5 Acids Res. 1990 Jan 25;18(2):299-304 and U. S. Patent 5,631,359. An example of the hepatitis δ virus motif is described by Perrotta and Been, Biochemistry. 1992 Dec 1;31(47):11843-52; an example of the RNaseP motif is described by Guerrier-Takada *et al.*, Cell. 1983 Dec;35(3 Pt 2):849-57; Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, Cell. 1990 May 18;61(4):685-96; Saville and
10 Collins, Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8826-30; Collins and Olive, Biochemistry. 1993 Mar 23;32(11):2795-9); and an example of the Group I intron is described in (U. S. Patent 4,987,071). All that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have
15 nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule. Thus the ribozyme constructs need not be limited to specific motifs mentioned herein.

Ribozymes may be designed as described in Int. Pat. Appl. Publ. No. WO 93/23569 and Int. Pat. Appl. Publ. No. WO 94/02595, each specifically
20 incorporated herein by reference) and synthesized to be tested *in vitro* and *in vivo*, as described. Such ribozymes can also be optimized for delivery. While specific examples are provided, those in the art will recognize that equivalent RNA targets in other species can be utilized when necessary.

Ribozyme activity can be optimized by altering the length of the
25 ribozyme binding arms, or chemically synthesizing ribozymes with modifications that prevent their degradation by serum ribonucleases (see *e.g.*, Int. Pat. Appl. Publ. No. WO 92/07065; Int. Pat. Appl. Publ. No. WO 93/15187; Int. Pat. Appl. Publ. No. WO 91/03162; Eur. Pat. Appl. Publ. No. 92110298.4; U. S. Patent 5,334,711; and Int. Pat. Appl. Publ. No. WO 94/13688, which describe various chemical modifications that can
30 be made to the sugar moieties of enzymatic RNA molecules), modifications which

enhance their efficacy in cells, and removal of stem II bases to shorten RNA synthesis times and reduce chemical requirements.

Sullivan *et al.* (Int. Pat. Appl. Publ. No. WO 94/02595) describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles.

Alternatively, the RNA/vehicle combination may be locally delivered by direct inhalation, by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Int. Pat. Appl. Publ. No. WO 94/02595 and Int. Pat. Appl. Publ. No. WO 93/23569, each specifically incorporated herein by reference.

Another means of accumulating high concentrations of a ribozyme(s) within cells is to incorporate the ribozyme-encoding sequences into a DNA expression vector. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, *etc.*) present nearby.

Prokaryotic RNA polymerase promoters may also be used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells. Ribozymes expressed from such promoters have been shown to function in mammalian cells. Such transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated vectors), or viral RNA vectors (such as retroviral, semliki forest virus, sindbis virus vectors).

In another embodiment of the invention, peptide nucleic acids (PNAs) compositions are provided. PNA is a DNA mimic in which the nucleobases are attached to a pseudopeptide backbone (Good and Nielsen, *Antisense Nucleic Acid Drug Dev.* 1997 7(4) 431-37). PNA is able to be utilized in a number methods that traditionally have used RNA or DNA. Often PNA sequences perform better in techniques than the corresponding RNA or DNA sequences and have utilities that are not inherent to RNA or DNA. A review of PNA including methods of making, characteristics of, and methods of using, is provided by Corey (*Trends Biotechnol* 1997 Jun;15(6):224-9). As such, in certain embodiments, one may prepare PNA sequences that are complementary to one or more portions of the ACE mRNA sequence, and such PNA compositions may be used to regulate, alter, decrease, or reduce the translation of ACE-specific mRNA, and thereby alter the level of ACE activity in a host cell to which such PNA compositions have been administered.

PNAs have 2-aminoethyl-glycine linkages replacing the normal phosphodiester backbone of DNA (Nielsen *et al.*, *Science* 1991 Dec 6;254(5037):1497-500; Hanvey *et al.*, *Science*. 1992 Nov 27;258(5087):1481-5; Hyrup and Nielsen, *Bioorg Med Chem.* 1996 Jan;4(1):5-23). This chemistry has three important consequences: firstly, in contrast to DNA or phosphorothioate oligonucleotides, PNAs are neutral molecules; secondly, PNAs are achiral, which avoids the need to develop a stereoselective synthesis; and thirdly, PNA synthesis uses standard Boc or Fmoc protocols for solid-phase peptide synthesis, although other methods, including a modified Merrifield method, have been used.

PNA monomers or ready-made oligomers are commercially available from PerSeptive Biosystems (Framingham, MA). PNA syntheses by either Boc or Fmoc protocols are straightforward using manual or automated protocols (Norton *et al.*, *Bioorg Med Chem.* 1995 Apr;3(4):437-45). The manual protocol lends itself to the production of chemically modified PNAs or the simultaneous synthesis of families of closely related PNAs.

As with peptide synthesis, the success of a particular PNA synthesis will depend on the properties of the chosen sequence. For example, while in theory PNAs can incorporate any combination of nucleotide bases, the presence of adjacent purines

can lead to deletions of one or more residues in the product. In expectation of this difficulty, it is suggested that, in producing PNAs with adjacent purines, one should repeat the coupling of residues likely to be added inefficiently. This should be followed by the purification of PNAs by reverse-phase high-pressure liquid chromatography, providing yields and purity of product similar to those observed during the synthesis of peptides.

Modifications of PNAs for a given application may be accomplished by coupling amino acids during solid-phase synthesis or by attaching compounds that contain a carboxylic acid group to the exposed N-terminal amine. Alternatively, PNAs can be modified after synthesis by coupling to an introduced lysine or cysteine. The ease with which PNAs can be modified facilitates optimization for better solubility or for specific functional requirements. Once synthesized, the identity of PNAs and their derivatives can be confirmed by mass spectrometry. Several studies have made and utilized modifications of PNAs (for example, Norton *et al.*, Bioorg Med Chem. 1995 Apr;3(4):437-45; Petersen *et al.*, J Pept Sci. 1995 May-Jun;1(3):175-83; Orum *et al.*, Biotechniques. 1995 Sep;19(3):472-80; Footer *et al.*, Biochemistry. 1996 Aug 20;35(33):10673-9; Griffith *et al.*, Nucleic Acids Res. 1995 Aug 11;23(15):3003-8; Pardridge *et al.*, Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5592-6; Boffa *et al.*, Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1901-5; Gambacorti-Passerini *et al.*, Blood. 1996 Aug 15;88(4):1411-7; Armitage *et al.*, Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12320-5; Seeger *et al.*, Biotechniques. 1997 Sep;23(3):512-7). U.S. Patent No. 5,700,922 discusses PNA-DNA-PNA chimeric molecules and their uses in diagnostics, modulating protein in organisms, and treatment of conditions susceptible to therapeutics.

Methods of characterizing the antisense binding properties of PNAs are discussed in Rose (Anal Chem. 1993 Dec 15;65(24):3545-9) and Jensen *et al.* (Biochemistry. 1997 Apr 22;36(16):5072-7). Rose uses capillary gel electrophoresis to determine binding of PNAs to their complementary oligonucleotide, measuring the relative binding kinetics and stoichiometry. Similar types of measurements were made by Jensen *et al.* using BIAcore™ technology.

Other applications of PNAs that have been described and will be apparent to the skilled artisan include use in DNA strand invasion, antisense inhibition, mutational analysis, enhancers of transcription, nucleic acid purification, isolation of transcriptionally active genes, blocking of transcription factor binding, genome
5 cleavage, biosensors, *in situ* hybridization, and the like.

Polynucleotide Identification, Characterization and Expression

Polynucleotides compositions of the present invention may be identified, prepared and/or manipulated using any of a variety of well established techniques (see generally, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring
10 Harbor Laboratories, Cold Spring Harbor, NY, 1989, and other like references). For example, a polynucleotide may be identified, as described in more detail below, by screening a microarray of cDNAs for tumor-associated expression (*i.e.*, expression that is at least two fold greater in a tumor than in normal tissue, as determined using a representative assay provided herein). Such screens may be performed, for example,
15 using the microarray technology of Affymetrix, Inc. (Santa Clara, CA) according to the manufacturer's instructions (and essentially as described by Schena et al., *Proc. Natl. Acad. Sci. USA* 93:10614-10619, 1996 and Heller et al., *Proc. Natl. Acad. Sci. USA* 94:2150-2155, 1997). Alternatively, polynucleotides may be amplified from cDNA prepared from cells expressing the proteins described herein, such as tumor cells.

20 Many template dependent processes are available to amplify a target sequences of interest present in a sample. One of the best known amplification methods is the polymerase chain reaction (PCR™) which is described in detail in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,800,159, each of which is incorporated herein by reference in its entirety. Briefly, in PCR™, two primer sequences are prepared which
25 are complementary to regions on opposite complementary strands of the target sequence. An excess of deoxynucleoside triphosphates is added to a reaction mixture along with a DNA polymerase (*e.g.*, *Taq* polymerase). If the target sequence is present in a sample, the primers will bind to the target and the polymerase will cause the primers to be extended along the target sequence by adding on nucleotides. By raising
30 and lowering the temperature of the reaction mixture, the extended primers will

dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction product and the process is repeated. Preferably reverse transcription and PCRTM amplification procedure may be performed in order to quantify the amount of mRNA amplified. Polymerase chain reaction methodologies are well
5 known in the art.

Any of a number of other template dependent processes, many of which are variations of the PCRTM amplification technique, are readily known and available in the art. Illustratively, some such methods include the ligase chain reaction (referred to as LCR), described, for example, in Eur. Pat. Appl. Publ. No. 320,308 and U.S. Patent
10 No. 4,883,750; Qbeta Replicase, described in PCT Intl. Pat. Appl. Publ. No. PCT/US87/00880; Strand Displacement Amplification (SDA) and Repair Chain Reaction (RCR). Still other amplification methods are described in Great Britain Pat. Appl. No. 2 202 328, and in PCT Intl. Pat. Appl. Publ. No. PCT/US89/01025. Other nucleic acid amplification procedures include transcription-based amplification systems
15 (TAS) (PCT Intl. Pat. Appl. Publ. No. WO 88/10315), including nucleic acid sequence based amplification (NASBA) and 3SR. Eur. Pat. Appl. Publ. No. 329,822 describes a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA). PCT Intl. Pat. Appl. Publ. No. WO 89/06700 describes a nucleic acid sequence amplification scheme based
20 on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. Other amplification methods such as "RACE" (Frohman, 1990), and "one-sided PCR" (Ohara, 1989) are also well-known to those of skill in the art.

An amplified portion of a polynucleotide of the present invention may be
25 used to isolate a full length gene from a suitable library (*e.g.*, a tumor cDNA library) using well known techniques. Within such techniques, a library (cDNA or genomic) is screened using one or more polynucleotide probes or primers suitable for amplification. Preferably, a library is size-selected to include larger molecules. Random primed libraries may also be preferred for identifying 5' and upstream regions of genes.
30 Genomic libraries are preferred for obtaining introns and extending 5' sequences.

For hybridization techniques, a partial sequence may be labeled (*e.g.*, by nick-translation or end-labeling with ^{32}P) using well known techniques. A bacterial or bacteriophage library is then generally screened by hybridizing filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe
5 (*see* Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989). Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis. cDNA clones may be analyzed to determine the amount of additional sequence by, for example, PCR using a primer from the partial sequence and a primer from the vector. Restriction maps and
10 partial sequences may be generated to identify one or more overlapping clones. The complete sequence may then be determined using standard techniques, which may involve generating a series of deletion clones. The resulting overlapping sequences can then be assembled into a single contiguous sequence. A full length cDNA molecule can be generated by ligating suitable fragments, using well known techniques.

15 Alternatively, amplification techniques, such as those described above, can be useful for obtaining a full length coding sequence from a partial cDNA sequence. One such amplification technique is inverse PCR (*see* Triglia et al., *Nucl. Acids Res.* 16:8186, 1988), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and
20 used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a known region. The amplified sequences are typically subjected to a second round of amplification with the same linker primer and a second primer specific to the known
25 region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591. Another such technique is known as "rapid amplification of cDNA ends" or RACE. This technique involves the use of an internal primer and an external primer, which hybridizes to a polyA region or vector sequence, to identify sequences that are 5'
30 and 3' of a known sequence. Additional techniques include capture PCR (Lagerstrom et al., *PCR Methods Applic.* 1:111-19, 1991) and walking PCR (Parker et al., *Nucl. Acids.*

Res. 19:3055-60, 1991). Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known programs (*e.g.*, NCBI BLAST searches), and such ESTs may be used to generate a contiguous full length sequence. Full length DNA sequences may also be obtained by analysis of genomic fragments.

In other embodiments of the invention, polynucleotide sequences or fragments thereof which encode polypeptides of the invention, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide.

As will be understood by those of skill in the art, it may be advantageous in some instances to produce polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

Moreover, the polynucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter polypeptide encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. For example, DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. In addition, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of polypeptide activity, it may be useful to encode a chimeric protein that can be
5 recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the polypeptide-encoding sequence and the heterologous protein sequence, so that the polypeptide may be cleaved and purified away from the heterologous moiety.

Sequences encoding a desired polypeptide may be synthesized, in whole
10 or in part, using chemical methods well known in the art (see Caruthers, M. H. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, Horn, T. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of a polypeptide, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques
15 (Roberge, J. Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer, Palo Alto, CA).

A newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) *Proteins, Structures and Molecular Principles*, WH Freeman and Co., New York, N.Y.) or other comparable
20 techniques available in the art. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure). Additionally, the amino acid sequence of a polypeptide, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with
25 sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a desired polypeptide, the nucleotide sequences encoding the polypeptide, or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well
30 known to those skilled in the art may be used to construct expression vectors containing sequences encoding a polypeptide of interest and appropriate transcriptional and

translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described, for example, in Sambrook, J. et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et al. (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York. N.Y.

A variety of expression vector/host systems may be utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (*e.g.*, baculovirus); plant cell systems transformed with virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids); or animal cell systems.

The "control elements" or "regulatory sequences" present in an expression vector are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the pBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or pSPORT1 plasmid (Gibco BRL, Gaithersburg, MD) and the like may be used. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are generally preferred. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding a polypeptide, vectors based on SV40 or EBV may be advantageously used with an appropriate selectable marker.

In bacterial systems, any of a number of expression vectors may be selected depending upon the use intended for the expressed polypeptide. For example, when large quantities are needed, for example for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be

used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as pBLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of .beta.-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S. M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509); and the like. pGEX Vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) *Methods Enzymol.* 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding polypeptides may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L. E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, N.Y.; pp. 191-196).

An insect system may also be used to express a polypeptide of interest. For example, in one such system, *Autographa californica* nuclear polyhedrosis virus

(AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequences encoding the polypeptide may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the polypeptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, *S. frugiperda* cells or *Trichoplusia* larvae in which the polypeptide of interest may be expressed (Engelhard, E. K. et al. (1994) *Proc. Natl. Acad. Sci.* 91 :3224-3227).

In mammalian host cells, a number of viral-based expression systems are generally available. For example, in cases where an adenovirus is used as an expression vector, sequences encoding a polypeptide of interest may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing the polypeptide in infected host cells (Logan, J. and Shenk, T. (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding a polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation.

5 Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, COS, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

10 For long-term, high-yield production of recombinant proteins, stable expression is generally preferred. For example, cell lines which stably express a polynucleotide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction
15 of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

20 Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1990) *Cell* 22:817-23) genes which can be employed in tk.sup.- or aprt.sup.- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can
25 be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin, F. et al (1981) *J. Mol. Biol.* 150:1-14); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*).
30 Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in

place of histidine (Hartman, S. C. and R. C. Mulligan (1988) *Proc. Natl. Acad. Sci.* 85:8047-51). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. et al. (1995) *Methods Mol. Biol.* 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding a polypeptide is inserted within a marker gene sequence, recombinant cells containing sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a polypeptide-encoding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells that contain and express a desired polynucleotide sequence may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include, for example, membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

A variety of protocols for detecting and measuring the expression of polynucleotide-encoded products, using either polyclonal or monoclonal antibodies specific for the product are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on a given polypeptide may be preferred for some applications, but a competitive binding assay may also be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; *Serological Methods, a Laboratory Manual*, APS Press, St Paul, Minn.) and Maddox, D. E. et al. (1983; *J. Exp. Med.* 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides include oligolabeling, nick translation, end-labeling or PCR
5 amplification using a labeled nucleotide. Alternatively, the sequences, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of
10 commercially available kits. Suitable reporter molecules or labels, which may be used include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with a polynucleotide sequence of interest may be cultured under conditions suitable for the expression and recovery of the protein from
15 cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides of the invention may be designed to contain signal sequences which direct secretion of the encoded polypeptide through a prokaryotic or eukaryotic cell membrane. Other
20 recombinant constructions may be used to join sequences encoding a polypeptide of interest to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on
25 immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, Calif.) between the purification domain and the encoded polypeptide may be used to facilitate purification. One such expression vector provides for expression of a fusion
30 protein containing a polypeptide of interest and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues

facilitate purification on IMIAC (immobilized metal ion affinity chromatography) as described in Porath, J. et al. (1992, *Prot. Exp. Purif.* 3:263-281) while the enterokinase cleavage site provides a means for purifying the desired polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D. J. et al. (1993; *DNA Cell Biol.* 12:441-453).

In addition to recombinant production methods, polypeptides of the invention, and fragments thereof, may be produced by direct peptide synthesis using solid-phase techniques (Merrifield J. (1963) *J. Am. Chem. Soc.* 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Alternatively, various fragments may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

Antibody Compositions, Fragments Thereof and Other Binding Agents

According to another aspect, the present invention further provides binding agents, such as antibodies and antigen-binding fragments thereof, that exhibit immunological binding to a tumor polypeptide disclosed herein, or to a portion, variant or derivative thereof. An antibody, or antigen-binding fragment thereof, is said to "specifically bind," "immunologically bind," and/or is "immunologically reactive" to a polypeptide of the invention if it reacts at a detectable level (within, for example, an ELISA assay) with the polypeptide, and does not react detectably with unrelated polypeptides under similar conditions.

Immunological binding, as used in this context, generally refers to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (K_d) of the interaction, wherein a smaller K_d represents a greater affinity. Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen-binding site/antigen complex formation and dissociation, wherein those rates

depend on the concentrations of the complex partners, the affinity of the interaction, and on geometric parameters that equally influence the rate in both directions. Thus, both the "on rate constant" (K_{on}) and the "off rate constant" (K_{off}) can be determined by calculation of the concentrations and the actual rates of association and dissociation.

- 5 The ratio of K_{off}/K_{on} enables cancellation of all parameters not related to affinity, and is thus equal to the dissociation constant K_d . See, generally, Davies et al. (1990) Annual Rev. Biochem. 59:439-473.

An "antigen-binding site," or "binding portion" of an antibody refers to the part of the immunoglobulin molecule that participates in antigen binding. The
10 antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains are referred to as "hypervariable regions" which are interposed between more conserved flanking stretches known as "framework regions," or "FRs". Thus the term "FR" refers to amino acid sequences
15 which are naturally found between and adjacent to hypervariable regions in immunoglobulins. In an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen,
20 and the three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions," or "CDRs."

Binding agents may be further capable of differentiating between patients with and without a cancer, such as colon cancer, using the representative assays provided herein. For example, antibodies or other binding agents that bind to a tumor
25 protein will preferably generate a signal indicating the presence of a cancer in at least about 20% of patients with the disease, more preferably at least about 30% of patients. Alternatively, or in addition, the antibody will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without the cancer. To determine whether a binding agent satisfies this requirement, biological samples (*e.g.*,
30 blood, sera, sputum, urine and/or tumor biopsies) from patients with and without a cancer (as determined using standard clinical tests) may be assayed as described herein

for the presence of polypeptides that bind to the binding agent. Preferably, a statistically significant number of samples with and without the disease will be assayed. Each binding agent should satisfy the above criteria; however, those of ordinary skill in the art will recognize that binding agents may be used in combination to improve
5 sensitivity.

Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome, with or without a peptide component, an RNA molecule or a polypeptide. In a preferred embodiment, a binding agent is an antibody or an antigen-binding fragment thereof. Antibodies may be prepared by any of
10 a variety of techniques known to those of ordinary skill in the art. *See, e.g.,* Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes into
15 suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (*e.g.*, mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier
20 protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a
25 suitable solid support.

Monoclonal antibodies specific for an antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the
30 desired specificity (*i.e.*, reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as

described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

A number of therapeutically useful molecules are known in the art which comprise antigen-binding sites that are capable of exhibiting immunological binding properties of an antibody molecule. The proteolytic enzyme papain preferentially cleaves IgG molecules to yield several fragments, two of which (the "F(ab)" fragments) each comprise a covalent heterodimer that includes an intact antigen-binding site. The enzyme pepsin is able to cleave IgG molecules to provide several fragments, including the "F(ab')₂" fragment which comprises both antigen-binding sites. An "Fv" fragment can be produced by preferential proteolytic cleavage of an IgM, and on rare occasions IgG or IgA immunoglobulin molecule. Fv fragments are, however, more commonly derived using recombinant techniques known in the art. The Fv fragment includes a non-covalent V_H::V_L heterodimer including an antigen-binding site which retains much of the antigen recognition and binding capabilities of the native antibody molecule.

Inbar et al. (1972) Proc. Nat. Acad. Sci. USA 69:2659-2662; Hochman et al. (1976) Biochem 15:2706-2710; and Ehrlich et al. (1980) Biochem 19:4091-4096.

A single chain Fv ("sFv") polypeptide is a covalently linked $V_H::V_L$ heterodimer which is expressed from a gene fusion including V_H - and V_L -encoding genes linked by a peptide-encoding linker. Huston et al. (1988) Proc. Nat. Acad. Sci. USA 85(16):5879-5883. A number of methods have been described to discern chemical structures for converting the naturally aggregated--but chemically separated--light and heavy polypeptide chains from an antibody V region into an sFv molecule which will fold into a three dimensional structure substantially similar to the structure of an antigen-binding site. See, *e.g.*, U.S. Pat. Nos. 5,091,513 and 5,132,405, to Huston et al.; and U.S. Pat. No. 4,946,778, to Ladner et al.

Each of the above-described molecules includes a heavy chain and a light chain CDR set, respectively interposed between a heavy chain and a light chain FR set which provide support to the CDRs and define the spatial relationship of the CDRs relative to each other. As used herein, the term "CDR set" refers to the three hypervariable regions of a heavy or light chain V region. Proceeding from the N-terminus of a heavy or light chain, these regions are denoted as "CDR1," "CDR2," and "CDR3" respectively. An antigen-binding site, therefore, includes six CDRs, comprising the CDR set from each of a heavy and a light chain V region. A polypeptide comprising a single CDR, (*e.g.*, a CDR1, CDR2 or CDR3) is referred to herein as a "molecular recognition unit." Crystallographic analysis of a number of antigen-antibody complexes has demonstrated that the amino acid residues of CDRs form extensive contact with bound antigen, wherein the most extensive antigen contact is with the heavy chain CDR3. Thus, the molecular recognition units are primarily responsible for the specificity of an antigen-binding site.

As used herein, the term "FR set" refers to the four flanking amino acid sequences which frame the CDRs of a CDR set of a heavy or light chain V region. Some FR residues may contact bound antigen; however, FRs are primarily responsible for folding the V region into the antigen-binding site, particularly the FR residues directly adjacent to the CDRs. Within FRs, certain amino residues and certain structural features are very highly conserved. In this regard, all V region sequences contain an

internal disulfide loop of around 90 amino acid residues. When the V regions fold into a binding-site, the CDRs are displayed as projecting loop motifs which form an antigen-binding surface. It is generally recognized that there are conserved structural regions of FRs which influence the folded shape of the CDR loops into certain "canonical" structures--regardless of the precise CDR amino acid sequence. Further, certain FR residues are known to participate in non-covalent interdomain contacts which stabilize the interaction of the antibody heavy and light chains.

A number of "humanized" antibody molecules comprising an antigen-binding site derived from a non-human immunoglobulin have been described, including chimeric antibodies having rodent V regions and their associated CDRs fused to human constant domains (Winter et al. (1991) *Nature* 349:293-299; Lobuglio et al. (1989) *Proc. Nat. Acad. Sci. USA* 86:4220-4224; Shaw et al. (1987) *J Immunol.* 138:4534-4538; and Brown et al. (1987) *Cancer Res.* 47:3577-3583), rodent CDRs grafted into a human supporting FR prior to fusion with an appropriate human antibody constant domain (Riechmann et al. (1988) *Nature* 332:323-327; Verhoeyen et al. (1988) *Science* 239:1534-1536; and Jones et al. (1986) *Nature* 321:522-525), and rodent CDRs supported by recombinantly veneered rodent FRs (European Patent Publication No. 519,596, published Dec. 23, 1992). These "humanized" molecules are designed to minimize unwanted immunological response toward rodent antihuman antibody molecules which limits the duration and effectiveness of therapeutic applications of those moieties in human recipients.

As used herein, the terms "veneered FRs" and "recombinantly veneered FRs" refer to the selective replacement of FR residues from, *e.g.*, a rodent heavy or light chain V region, with human FR residues in order to provide a xenogeneic molecule comprising an antigen-binding site which retains substantially all of the native FR polypeptide folding structure. Veneering techniques are based on the understanding that the ligand binding characteristics of an antigen-binding site are determined primarily by the structure and relative disposition of the heavy and light chain CDR sets within the antigen-binding surface. Davies et al. (1990) *Ann. Rev. Biochem.* 59:439-473. Thus, antigen binding specificity can be preserved in a humanized antibody only wherein the CDR structures, their interaction with each other, and their interaction with the rest of

the V region domains are carefully maintained. By using veneering techniques, exterior (e.g., solvent-accessible) FR residues which are readily encountered by the immune system are selectively replaced with human residues to provide a hybrid molecule that comprises either a weakly immunogenic, or substantially non-immunogenic veneered surface.

The process of veneering makes use of the available sequence data for human antibody variable domains compiled by Kabat et al., in Sequences of Proteins of Immunological Interest, 4th ed., (U.S. Dept. of Health and Human Services, U.S. Government Printing Office, 1987), updates to the Kabat database, and other accessible U.S. and foreign databases (both nucleic acid and protein). Solvent accessibilities of V region amino acids can be deduced from the known three-dimensional structure for human and murine antibody fragments. There are two general steps in veneering a murine antigen-binding site. Initially, the FRs of the variable domains of an antibody molecule of interest are compared with corresponding FR sequences of human variable domains obtained from the above-identified sources. The most homologous human V regions are then compared residue by residue to corresponding murine amino acids. The residues in the murine FR which differ from the human counterpart are replaced by the residues present in the human moiety using recombinant techniques well known in the art. Residue switching is only carried out with moieties which are at least partially exposed (solvent accessible), and care is exercised in the replacement of amino acid residues which may have a significant effect on the tertiary structure of V region domains, such as proline, glycine and charged amino acids.

In this manner, the resultant "veneered" murine antigen-binding sites are thus designed to retain the murine CDR residues, the residues substantially adjacent to the CDRs, the residues identified as buried or mostly buried (solvent inaccessible), the residues believed to participate in non-covalent (e.g., electrostatic and hydrophobic) contacts between heavy and light chain domains, and the residues from conserved structural regions of the FRs which are believed to influence the "canonical" tertiary structures of the CDR loops. These design criteria are then used to prepare recombinant nucleotide sequences which combine the CDRs of both the heavy and light chain of a murine antigen-binding site into human-appearing FRs that can be used to transfect

mammalian cells for the expression of recombinant human antibodies which exhibit the antigen specificity of the murine antibody molecule.

In another embodiment of the invention, monoclonal antibodies of the present invention may be coupled to one or more therapeutic agents. Suitable agents in this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ^{90}Y , ^{123}I , ^{125}I , ^{131}I , ^{186}Re , ^{188}Re , ^{211}At , and ^{212}Bi . Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, *Pseudomonas* exotoxin, *Shigella* toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (*e.g.*, covalently bonded) to a suitable monoclonal antibody either directly or indirectly (*e.g.*, via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (*e.g.*, a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, *e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (*e.g.*, U.S. Patent No. 4,489,710, to Spitler), by irradiation of a photolabile bond (*e.g.*, U.S. Patent No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (*e.g.*, U.S. Patent No. 4,638,045, to Kohn et al.), by serum complement-mediated hydrolysis (*e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (*e.g.*, U.S. Patent No. 4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers that provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (*e.g.*, U.S. Patent No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (*e.g.*, U.S. Patent No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (*e.g.*, U.S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U.S. Patent No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

T Cell Compositions

The present invention, in another aspect, provides T cells specific for a tumor polypeptide disclosed herein, or for a variant or derivative thereof. Such cells may generally be prepared *in vitro* or *ex vivo*, using standard procedures. For example, 5 T cells may be isolated from bone marrow, peripheral blood, or a fraction of bone marrow or peripheral blood of a patient, using a commercially available cell separation system, such as the Isolex™ System, available from Nexell Therapeutics, Inc. (Irvine, CA; see also U.S. Patent No. 5,240,856; U.S. Patent No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). Alternatively, T cells may be derived from related or 10 unrelated humans, non-human mammals, cell lines or cultures.

T cells may be stimulated with a polypeptide, polynucleotide encoding a polypeptide and/or an antigen presenting cell (APC) that expresses such a polypeptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the polypeptide of interest. Preferably, a tumor 15 polypeptide or polynucleotide of the invention is present within a delivery vehicle, such as a microsphere, to facilitate the generation of specific T cells.

T cells are considered to be specific for a polypeptide of the present invention if the T cells specifically proliferate, secrete cytokines or kill target cells coated with the polypeptide or expressing a gene encoding the polypeptide. T cell 20 specificity may be evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen et al., *Cancer Res.* 54:1065-1070, 1994. Alternatively, detection of the 25 proliferation of T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (*e.g.*, by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Contact with a tumor polypeptide (100 ng/ml - 100 µg/ml, preferably 200 ng/ml - 25 µg/ml) for 3 - 7 30 days will typically result in at least a two fold increase in proliferation of the T cells. Contact as described above for 2-3 hours should result in activation of the T cells, as

measured using standard cytokine assays in which a two fold increase in the level of cytokine release (*e.g.*, TNF or IFN- γ) is indicative of T cell activation (*see* Coligan et al., Current Protocols in Immunology, vol. 1, Wiley Interscience (Greene 1998)). T cells that have been activated in response to a tumor polypeptide, polynucleotide or polypeptide-expressing APC may be CD4⁺ and/or CD8⁺. Tumor polypeptide-specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient, a related donor or an unrelated donor, and are administered to the patient following stimulation and expansion.

For therapeutic purposes, CD4⁺ or CD8⁺ T cells that proliferate in response to a tumor polypeptide, polynucleotide or APC can be expanded in number either *in vitro* or *in vivo*. Proliferation of such T cells *in vitro* may be accomplished in a variety of ways. For example, the T cells can be re-exposed to a tumor polypeptide, or a short peptide corresponding to an immunogenic portion of such a polypeptide, with or without the addition of T cell growth factors, such as interleukin-2, and/or stimulator cells that synthesize a tumor polypeptide. Alternatively, one or more T cells that proliferate in the presence of the tumor polypeptide can be expanded in number by cloning. Methods for cloning cells are well known in the art, and include limiting dilution.

T Cell Receptor Compositions

The T cell receptor (TCR) consists of 2 different, highly variable polypeptide chains, termed the T-cell receptor α and β chains, that are linked by a disulfide bond (Janeway, Travers, Walport. *Immunobiology*. Fourth Ed., 148-159. Elsevier Science Ltd/Garland Publishing. 1999). The α/β heterodimer complexes with the invariant CD3 chains at the cell membrane. This complex recognizes specific antigenic peptides bound to MHC molecules. The enormous diversity of TCR specificities is generated much like immunoglobulin diversity, through somatic gene rearrangement. The β chain genes contain over 50 variable (V), 2 diversity (D), over 10 joining (J) segments, and 2 constant region segments (C). The α chain genes contain over 70 V segments, and over 60 J segments but no D segments, as well as one C segment. During T cell development in the thymus, the D to J gene rearrangement of

the β chain occurs, followed by the V gene segment rearrangement to the DJ. This functional VDJ β exon is transcribed and spliced to join to a C β . For the α chain, a V α gene segment rearranges to a J α gene segment to create the functional exon that is then transcribed and spliced to the C α . Diversity is further increased during the
5 recombination process by the random addition of P and N-nucleotides between the V, D, and J segments of the β chain and between the V and J segments in the α chain (Janeway, Travers, Walport. *Immunobiology*. Fourth Ed., 98 and 150. Elsevier Science Ltd/Garland Publishing. 1999).

The present invention, in another aspect, provides TCRs specific for a
10 polypeptide disclosed herein, or for a variant or derivative thereof. In accordance with the present invention, polynucleotide and amino acid sequences are provided for the V-J or V-D-J junctional regions or parts thereof for the alpha and beta chains of the T-cell receptor which recognize tumor polypeptides described herein. In general, this aspect of the invention relates to T-cell receptors which recognize or bind tumor polypeptides
15 presented in the context of MHC. In a preferred embodiment the tumor antigens recognized by the T-cell receptors comprise a polypeptide of the present invention. For example, cDNA encoding a TCR specific for a colon tumor peptide can be isolated from T cells specific for a tumor polypeptide using standard molecular biological and recombinant DNA techniques.

20 This invention further includes the T-cell receptors or analogs thereof having substantially the same function or activity as the T-cell receptors of this invention which recognize or bind tumor polypeptides. Such receptors include, but are not limited to, a fragment of the receptor, or a substitution, addition or deletion mutant of a T-cell receptor provided herein. This invention also encompasses polypeptides or
25 peptides that are substantially homologous to the T-cell receptors provided herein or that retain substantially the same activity. The term "analog" includes any protein or polypeptide having an amino acid residue sequence substantially identical to the T-cell receptors provided herein in which one or more residues, preferably no more than 5 residues, more preferably no more than 25 residues have been conservatively substituted
30 with a functionally similar residue and which displays the functional aspects of the T-cell receptor as described herein.

The present invention further provides for suitable mammalian host cells, for example, non-specific T cells, that are transfected with a polynucleotide encoding TCRs specific for a polypeptide described herein, thereby rendering the host cell specific for the polypeptide. The α and β chains of the TCR may be contained on
5 separate expression vectors or alternatively, on a single expression vector that also contains an internal ribosome entry site (IRES) for cap-independent translation of the gene downstream of the IRES. Said host cells expressing TCRs specific for the polypeptide may be used, for example, for adoptive immunotherapy of colon cancer as discussed further below.

10 In further aspects of the present invention, cloned TCRs specific for a polypeptide recited herein may be used in a kit for the diagnosis of colon cancer. For example, the nucleic acid sequence or portions thereof, of tumor-specific TCRs can be used as probes or primers for the detection of expression of the rearranged genes encoding the specific TCR in a biological sample. Therefore, the present invention
15 further provides for an assay for detecting messenger RNA or DNA encoding the TCR specific for a polypeptide.

Pharmaceutical Compositions

In additional embodiments, the present invention concerns formulation of one or more of the polynucleotide, polypeptide, T-cell, TCR, and/or antibody
20 compositions disclosed herein in pharmaceutically-acceptable carriers for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy.

It will be understood that, if desired, a composition as disclosed herein may be administered in combination with other agents as well, such as, *e.g.*, other
25 proteins or polypeptides or various pharmaceutically-active agents. In fact, there is virtually no limit to other components that may also be included, given that the additional agents do not cause a significant adverse effect upon contact with the target cells or host tissues. The compositions may thus be delivered along with various other agents as required in the particular instance. Such compositions may be purified from

host cells or other biological sources, or alternatively may be chemically synthesized as described herein. Likewise, such compositions may further comprise substituted or derivatized RNA or DNA compositions.

Therefore, in another aspect of the present invention, pharmaceutical
5 compositions are provided comprising one or more of the polynucleotide, polypeptide, antibody, TCR, and/or T-cell compositions described herein in combination with a physiologically acceptable carrier. In certain preferred embodiments, the pharmaceutical compositions of the invention comprise immunogenic polynucleotide and/or polypeptide compositions of the invention for use in prophylactic and therapeutic
10 vaccine applications. Vaccine preparation is generally described in, for example, M.F. Powell and M.J. Newman, eds., "Vaccine Design (the subunit and adjuvant approach)," Plenum Press (NY, 1995). Generally, such compositions will comprise one or more polynucleotide and/or polypeptide compositions of the present invention in combination with one or more immunostimulants.

15 It will be apparent that any of the pharmaceutical compositions described herein can contain pharmaceutically acceptable salts of the polynucleotides and polypeptides of the invention. Such salts can be prepared, for example, from pharmaceutically acceptable non-toxic bases, including organic bases (*e.g.*, salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases (*e.g.*,
20 sodium, potassium, lithium, ammonium, calcium and magnesium salts).

In another embodiment, illustrative immunogenic compositions, *e.g.*, vaccine compositions, of the present invention comprise DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated *in situ*. As noted above, the polynucleotide may be administered within any of a variety of delivery
25 systems known to those of ordinary skill in the art. Indeed, numerous gene delivery techniques are well known in the art, such as those described by Rolland, *Crit. Rev. Therap. Drug Carrier Systems* 15:143-198, 1998, and references cited therein. Appropriate polynucleotide expression systems will, of course, contain the necessary regulatory DNA regulatory sequences for expression in a patient (such as a suitable
30 promoter and terminating signal). Alternatively, bacterial delivery systems may involve

the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope.

Therefore, in certain embodiments, polynucleotides encoding immunogenic polypeptides described herein are introduced into suitable mammalian host cells for expression using any of a number of known viral-based systems. In one illustrative embodiment, retroviruses provide a convenient and effective platform for gene delivery systems. A selected nucleotide sequence encoding a polypeptide of the present invention can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to a subject. A number of illustrative retroviral systems have been described (*e.g.*, U.S. Pat. No. 5,219,740; Miller and Rosman (1989) *BioTechniques* 7:980-990; Miller, A. D. (1990) *Human Gene Therapy* 1:5-14; Scarpa et al. (1991) *Virology* 180:849-852; Burns et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:8033-8037; and Boris-Lawrie and Temin (1993) *Cur. Opin. Genet. Develop.* 3:102-109.

In addition, a number of illustrative adenovirus-based systems have also been described. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus minimizing the risks associated with insertional mutagenesis (Haj-Ahmad and Graham (1986) *J. Virol.* 57:267-274; Bett et al. (1993) *J. Virol.* 67:5911-5921; Mittereder et al. (1994) *Human Gene Therapy* 5:717-729; Seth et al. (1994) *J. Virol.* 68:933-940; Barr et al. (1994) *Gene Therapy* 1:51-58; Berkner, K. L. (1988) *BioTechniques* 6:616-629; and Rich et al. (1993) *Human Gene Therapy* 4:461-476).

Various adeno-associated virus (AAV) vector systems have also been developed for polynucleotide delivery. AAV vectors can be readily constructed using techniques well known in the art. See, *e.g.*, U.S. Pat. Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92/01070 and WO 93/03769; Lebkowski et al. (1988) *Molec. Cell. Biol.* 8:3988-3996; Vincent et al. (1990) *Vaccines* 90 (Cold Spring Harbor Laboratory Press); Carter, B. J. (1992) *Current Opinion in Biotechnology* 3:533-539; Muzyczka, N. (1992) *Current Topics in Microbiol. and Immunol.* 158:97-129; Kotin, R. M. (1994) *Human Gene Therapy* 5:793-801; Shelling and Smith (1994) *Gene Therapy* 1:165-169; and Zhou et al. (1994) *J. Exp. Med.* 179:1867-1875.

Additional viral vectors useful for delivering the polynucleotides encoding polypeptides of the present invention by gene transfer include those derived from the pox family of viruses, such as vaccinia virus and avian poxvirus. By way of example, vaccinia virus recombinants expressing the novel molecules can be constructed as follows. The DNA encoding a polypeptide is first inserted into an appropriate vector so that it is adjacent to a vaccinia promoter and flanking vaccinia DNA sequences, such as the sequence encoding thymidine kinase (TK). This vector is then used to transfect cells which are simultaneously infected with vaccinia. Homologous recombination serves to insert the vaccinia promoter plus the gene encoding the polypeptide of interest into the viral genome. The resulting TK.sup.(-) recombinant can be selected by culturing the cells in the presence of 5-bromodeoxyuridine and picking viral plaques resistant thereto.

A vaccinia-based infection/transfection system can be conveniently used to provide for inducible, transient expression or coexpression of one or more polypeptides described herein in host cells of an organism. In this particular system, cells are first infected in vitro with a vaccinia virus recombinant that encodes the bacteriophage T7 RNA polymerase. This polymerase displays exquisite specificity in that it only transcribes templates bearing T7 promoters. Following infection, cells are transfected with the polynucleotide or polynucleotides of interest, driven by a T7 promoter. The polymerase expressed in the cytoplasm from the vaccinia virus recombinant transcribes the transfected DNA into RNA which is then translated into polypeptide by the host translational machinery. The method provides for high level, transient, cytoplasmic production of large quantities of RNA and its translation products. See, *e.g.*, Elroy-Stein and Moss, Proc. Natl. Acad. Sci. USA (1990) 87:6743-6747; Fuerst et al. Proc. Natl. Acad. Sci. USA (1986) 83:8122-8126.

Alternatively, avipoxviruses, such as the fowlpox and canarypox viruses, can also be used to deliver the coding sequences of interest. Recombinant avipox viruses, expressing immunogens from mammalian pathogens, are known to confer protective immunity when administered to non-avian species. The use of an Avipox vector is particularly desirable in human and other mammalian species since members of the Avipox genus can only productively replicate in susceptible avian species and

therefore are not infective in mammalian cells. Methods for producing recombinant Avipoxviruses are known in the art and employ genetic recombination, as described above with respect to the production of vaccinia viruses. See, *e.g.*, WO 91/12882; WO 89/03429; and WO 92/03545.

5 Any of a number of alphavirus vectors can also be used for delivery of polynucleotide compositions of the present invention, such as those vectors described in U.S. Patent Nos. 5,843,723; 6,015,686; 6,008,035 and 6,015,694. Certain vectors based on Venezuelan Equine Encephalitis (VEE) can also be used, illustrative examples of which can be found in U.S. Patent Nos. 5,505,947 and 5,643,576.

10 Moreover, molecular conjugate vectors, such as the adenovirus chimeric vectors described in Michael et al. *J. Biol. Chem.* (1993) 268:6866-6869 and Wagner et al. *Proc. Natl. Acad. Sci. USA* (1992) 89:6099-6103, can also be used for gene delivery under the invention.

 Additional illustrative information on these and other known viral-based
15 delivery systems can be found, for example, in Fisher-Hoch et al., *Proc. Natl. Acad. Sci. USA* 86:317-321, 1989; Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner et al., *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, *Biotechniques* 6:616-627, 1988; Rosenfeld et al., *Science*
20 252:431-434, 1991; Kolls et al., *Proc. Natl. Acad. Sci. USA* 91:215-219, 1994; Kass-Eisler et al., *Proc. Natl. Acad. Sci. USA* 90:11498-11502, 1993; Guzman et al., *Circulation* 88:2838-2848, 1993; and Guzman et al., *Cir. Res.* 73:1202-1207, 1993.

 In certain embodiments, a polynucleotide may be integrated into the genome of a target cell. This integration may be in the specific location and orientation
25 *via* homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation). In yet further embodiments, the polynucleotide may be stably maintained in the cell as a separate, episomal segment of DNA. Such polynucleotide segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host
30 cell cycle. The manner in which the expression construct is delivered to a cell and

where in the cell the polynucleotide remains is dependent on the type of expression construct employed.

In another embodiment of the invention, a polynucleotide is administered/delivered as "naked" DNA, for example as described in Ulmer et al.,
5 *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.

In still another embodiment, a composition of the present invention can be delivered via a particle bombardment approach, many of which have been described.
10 In one illustrative example, gas-driven particle acceleration can be achieved with devices such as those manufactured by Powderject Pharmaceuticals PLC (Oxford, UK) and Powderject Vaccines Inc. (Madison, WI), some examples of which are described in U.S. Patent Nos. 5,846,796; 6,010,478; 5,865,796; 5,584,807; and EP Patent No. 0500 799. This approach offers a needle-free delivery approach wherein a dry powder
15 formulation of microscopic particles, such as polynucleotide or polypeptide particles, are accelerated to high speed within a helium gas jet generated by a hand held device, propelling the particles into a target tissue of interest.

In a related embodiment, other devices and methods that may be useful for gas-driven needle-less injection of compositions of the present invention include
20 those provided by Bioject, Inc. (Portland, OR), some examples of which are described in U.S. Patent Nos. 4,790,824; 5,064,413; 5,312,335; 5,383,851; 5,399,163; 5,520,639 and 5,993,412.

According to another embodiment, the pharmaceutical compositions described herein will comprise one or more immunostimulants in addition to the
25 immunogenic polynucleotide, polypeptide, antibody, T-cell, TCR, and/or APC compositions of this invention. An immunostimulant refers to essentially any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. One preferred type of immunostimulant comprises an adjuvant. Many adjuvants contain a substance designed to protect the antigen from rapid
30 catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis* derived

proteins. Certain adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

10 Within certain embodiments of the invention, the adjuvant composition is preferably one that induces an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (*e.g.*, IFN- γ , TNF α , IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (*e.g.*, IL-4, IL-5, IL-6 and IL-10) tend to favor the
15 induction of humoral immune responses. Following application of a vaccine as provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using
20 standard assays. For a review of the families of cytokines, see Mosmann and Coffman, *Ann. Rev. Immunol.* 7:145-173, 1989.

Certain preferred adjuvants for eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A, together with an aluminum salt. MPL[®]
25 adjuvants are available from Corixa Corporation (Seattle, WA; *see*, for example, US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and
30 5,856,462. Immunostimulatory DNA sequences are also described, for example, by Sato et al., *Science* 273:352, 1996. Another preferred adjuvant comprises a saponin,

such as Quil A, or derivatives thereof, including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, MA); Escin; Digitonin; or *Gypsophila* or *Chenopodium quinoa* saponins. Other preferred formulations include more than one saponin in the adjuvant combinations of the present invention, for example
5 combinations of at least two of the following group comprising QS21, QS7, Quil A, β -escin, or digitonin.


Alternatively the saponin formulations may be combined with vaccine vehicles composed of chitosan or other polycationic polymers, polylactide and polylactide-co-glycolide particles, poly-N-acetyl glucosamine-based polymer matrix,
10 particles composed of polysaccharides or chemically modified polysaccharides, liposomes and lipid-based particles, particles composed of glycerol monoesters, etc. The saponins may also be formulated in the presence of cholesterol to form particulate structures such as liposomes or ISCOMs. Furthermore, the saponins may be formulated together with a polyoxyethylene ether or ester, in either a non-particulate solution or
15 suspension, or in a particulate structure such as a paucilamellar liposome or ISCOM. The saponins may also be formulated with excipients such as Carbopol^R to increase viscosity, or may be formulated in a dry powder form with a powder excipient such as lactose.

In one preferred embodiment, the adjuvant system includes the
20 combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPL[®] adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations comprise an oil-in-water emulsion and tocopherol. Another particularly preferred adjuvant formulation employing QS21, 3D-
25 MPL[®] adjuvant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of CpG and QS21 is disclosed in WO 00/09159. Preferably the formulation additionally
30 comprises an oil in water emulsion and tocopherol.

Additional illustrative adjuvants for use in the pharmaceutical compositions of the invention include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (*e.g.*, SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), Detox (Enhanzyn[®]) (Corixa, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. Patent Application Serial Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene ether adjuvants such as those described in WO 99/52549A1.

Other preferred adjuvants include adjuvant molecules of the general formula



wherein, n is 1-50, A is a bond or $-\text{C}(\text{O})-$, R is C_{1-50} alkyl or Phenyl C_{1-50} alkyl.

One embodiment of the present invention consists of a vaccine formulation comprising a polyoxyethylene ether of general formula (I), wherein n is between 1 and 50, preferably 4-24, most preferably 9; the R component is C_{1-50} , preferably $\text{C}_4\text{-C}_{20}$ alkyl and most preferably C_{12} alkyl, and A is a bond. The concentration of the polyoxyethylene ethers should be in the range 0.1-20%, preferably from 0.1-10%, and most preferably in the range 0.1-1%. Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether, polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether. Polyoxyethylene ethers such as polyoxyethylene lauryl ether are described in the Merck index (12th edition: entry 7717). These adjuvant molecules are described in WO 99/52549.

The polyoxyethylene ether according to the general formula (I) above may, if desired, be combined with another adjuvant. For example, a preferred adjuvant combination is preferably with CpG as described in the pending UK patent application GB 9820956.2.

According to another embodiment of this invention, an immunogenic composition described herein is delivered to a host via antigen presenting cells (APCs),

such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-tumor effects *per se* and/or to be
5 immunologically compatible with the receiver (*i.e.*, matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

Certain preferred embodiments of the present invention use dendritic
10 cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, *Nature* 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (*see* Timmerman and Levy, *Ann. Rev. Med.* 50:507-529, 1999). In general, dendritic cells may be identified based on their typical shape (stellate *in situ*,
15 with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency and their ability to activate naïve T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex vivo*, and such modified dendritic cells are contemplated by the present invention. As
20 an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (*see* Zitvogel et al., *Nature Med.* 4:594-600, 1998).

Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph
25 nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated *ex vivo* by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF α to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into
30 dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNF α ,

CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

Dendritic cells are conveniently categorized as "immature" and "mature" cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fcγ receptor and mannose receptor. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (*e.g.*, CD54 and CD11) and costimulatory molecules (*e.g.*, CD40, CD80, CD86 and 4-1BB).

APCs may generally be transfected with a polynucleotide of the invention (or portion or other variant thereof) such that the encoded polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a pharmaceutical composition comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., *Immunology and cell Biology* 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the tumor polypeptide, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (*e.g.*, vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (*e.g.*, a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier

will typically vary depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, mucosal, intravenous, intracranial, intraperitoneal, subcutaneous and intramuscular administration.

5 Carriers for use within such pharmaceutical compositions are biocompatible, and may also be biodegradable. In certain embodiments, the formulation preferably provides a relatively constant level of active component release. In other embodiments, however, a more rapid rate of release immediately upon administration may be desired. The formulation of such compositions is well within the
10 level of ordinary skill in the art using known techniques. Illustrative carriers useful in this regard include microparticles of poly(lactide-co-glycolide), polyacrylate, latex, starch, cellulose, dextran and the like. Other illustrative delayed-release carriers include supramolecular biovectors, which comprise a non-liquid hydrophilic core (*e.g.*, a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer
15 comprising an amphiphilic compound, such as a phospholipid (*see e.g.*, U.S. Patent No. 5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

20 In another illustrative embodiment, biodegradable microspheres (*e.g.*, polylactate polyglycolate) are employed as carriers for the compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763; 5,814,344, 5,407,609 and 5,942,252. Modified hepatitis B core protein carrier systems.
25 such as described in WO/99 40934, and references cited therein, will also be useful for many applications. Another illustrative carrier/delivery system employs a carrier comprising particulate-protein complexes, such as those described in U.S. Patent No. 5,928,647, which are capable of inducing a class I-restricted cytotoxic T lymphocyte responses in a host.

30 In another illustrative embodiment, calcium phosphate core particles are employed as carriers, vaccine adjuvants, or as controlled release matrices for the

compositions of this invention. Exemplary calcium phosphate particles are disclosed, for example, in published patent application No. WO/0046147.

The pharmaceutical compositions of the invention will often further comprise one or more buffers (*e.g.*, neutral buffered saline or phosphate buffered saline); carbohydrates (*e.g.*, glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (*e.g.*, aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate.

The pharmaceutical compositions described herein may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are typically sealed in such a way to preserve the sterility and stability of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

The development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including *e.g.*, oral, parenteral, intravenous, intranasal, and intramuscular administration and formulation, is well known in the art, some of which are briefly discussed below for general purposes of illustration.

In certain applications, the pharmaceutical compositions disclosed herein may be delivered *via* oral administration to an animal. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.

The active compounds may even be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (see, for example, Mathiowitz *et al.*, Nature 1997 Mar 27;386(6623):410-4; Hwang *et al.*, Crit Rev Ther Drug Carrier Syst

1998;15(3):243-84; U. S. Patent 5,641,515; U. S. Patent 5,580,579 and U. S. Patent 5,792,451). Tablets, troches, pills, capsules and the like may also contain any of a variety of additional components, for example, a binder, such as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, 5 such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as 10 coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations.

15 Typically, these formulations will contain at least about 0.1% of the active compound or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared is such 20 a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

25 For oral administration the compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, oral spray, or sublingual orally-administered formulation. Alternatively, the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a 30 dentifrice, or added in a therapeutically-effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.

Alternatively the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.

In certain circumstances it will be desirable to deliver the pharmaceutical compositions disclosed herein parenterally, intravenously, intramuscularly, or even
5 intraperitoneally. Such approaches are well known to the skilled artisan, some of which are further described, for example, in U. S. Patent 5,543,158; U. S. Patent 5,641,515 and U. S. Patent 5,399,363. In certain embodiments, solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be
10 prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations generally will contain a preservative to prevent the growth of microorganisms.

Illustrative pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous
15 preparation of sterile injectable solutions or dispersions (for example, see U. S. Patent 5,466,468). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium
20 containing, for example, water, ethanol, polyol (*e.g.*, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and/or by the use of surfactants. The prevention of the action of microorganisms can be
25 facilitated by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate
30 and gelatin.

In one embodiment, for parenteral administration in an aqueous solution, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. Moreover, for human administration, preparations will of course preferably meet sterility, pyrogenicity, and the general safety and purity standards as required by FDA Office of Biologics standards.

In another embodiment of the invention, the compositions disclosed herein may be formulated in a neutral or salt form. Illustrative pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.

The carriers can further comprise any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. The phrase

"pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.

In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles.

5 Methods for delivering genes, nucleic acids, and peptide compositions directly to the lungs *via* nasal aerosol sprays has been described, *e.g.*, in U. S. Patent 5,756,353 and U. S. Patent 5,804,212. Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga *et al.*, J Controlled Release 1998 Mar 2;52(1-2):81-7) and lysophosphatidyl-glycerol compounds (U. S. Patent 5,725,871) are also well-known in

10 the pharmaceutical arts. Likewise, illustrative transmucosal drug delivery in the form of a polytetrafluoroethylene support matrix is described in U. S. Patent 5,780,045.

In certain embodiments, liposomes, nanocapsules, microparticles, lipid particles, vesicles, and the like, are used for the introduction of the compositions of the present invention into suitable host cells/organisms. In particular, the compositions of

15 the present invention may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like. Alternatively, compositions of the present invention can be bound, either covalently or non-covalently, to the surface of such carrier vehicles.

The formation and use of liposome and liposome-like preparations as

20 potential drug carriers is generally known to those of skill in the art (see for example, Lasic, Trends Biotechnol 1998 Jul;16(7):307-21; Takakura, Nippon Rinsho 1998 Mar;56(3):691-5; Chandran *et al.*, Indian J Exp Biol. 1997 Aug;35(8):801-9; Margalit, Crit Rev Ther Drug Carrier Syst. 1995;12(2-3):233-61; U.S. Patent 5,567,434; U.S. Patent 5,552,157; U.S. Patent 5,565,213; U.S. Patent 5,738,868 and U.S. Patent

25 5,795,587, each specifically incorporated herein by reference in its entirety).

Liposomes have been used successfully with a number of cell types that are normally difficult to transfect by other procedures, including T cell suspensions, primary hepatocyte cultures and PC 12 cells (Renneisen *et al.*, J Biol Chem. 1990 Sep 25;265(27):16337-42; Muller *et al.*, DNA Cell Biol. 1990 Apr;9(3):221-9). In addition,

30 liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce genes, various drugs,

radiotherapeutic agents, enzymes, viruses, transcription factors, allosteric effectors and the like, into a variety of cultured cell lines and animals. Furthermore, the use of liposomes does not appear to be associated with autoimmune responses or unacceptable toxicity after systemic delivery.

5 In certain embodiments, liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)).

 Alternatively, in other embodiments, the invention provides for pharmaceutically-acceptable nanocapsule formulations of the compositions of the present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way (see, for example, Quintanar-Guerrero *et al.*, Drug Dev Ind Pharm. 1998 Dec;24(12):1113-28). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μm) may be designed using polymers able to be degraded *in vivo*. Such particles can be made as described, for example, by Couvreur *et al.*, Crit Rev Ther Drug Carrier Syst. 1988;5(1):1-20; zur Muhlen *et al.*, Eur J Pharm Biopharm. 1998 Mar;45(2):149-55; Zambaux *et al.* J Controlled Release. 1998 Jan 2;50(1-3):31-40; and U. S. Patent 5,145,684.

Cancer Therapeutic Methods

 Immunologic approaches to cancer therapy are based on the recognition that cancer cells can often evade the body's defenses against aberrant or foreign cells and molecules, and that these defenses might be therapeutically stimulated to regain the lost ground, *e.g.* pgs. 623-648 in Klein, Immunology (Wiley-Interscience, New York, 1982). Numerous recent observations that various immune effectors can directly or indirectly inhibit growth of tumors has led to renewed interest in this approach to cancer therapy, *e.g.* Jager, *et al.*, Oncology 2001;60(1):1-7; Renner, *et al.*, Ann Hematol 2000 Dec;79(12):651-9.

 Four basic cell types whose function has been associated with antitumor cell immunity and the elimination of tumor cells from the body are: i) B-lymphocytes which secrete immunoglobulins into the blood plasma for identifying and labeling the nonself invader cells; ii) monocytes which secrete the complement proteins that are

responsible for lysing and processing the immunoglobulin-coated target invader cells; iii) natural killer lymphocytes having two mechanisms for the destruction of tumor cells, antibody-dependent cellular cytotoxicity and natural killing; and iv) T-lymphocytes possessing antigen-specific receptors and having the capacity to recognize
5 a tumor cell carrying complementary marker molecules (Schreiber, H., 1989, in Fundamental Immunology (ed). W. E. Paul, pp. 923-955).

Cancer immunotherapy generally focuses on inducing humoral immune responses, cellular immune responses, or both. Moreover, it is well established that induction of CD4⁺ T helper cells is necessary in order to secondarily induce either
10 antibodies or cytotoxic CD8⁺ T cells. Polypeptide antigens that are selective or ideally specific for cancer cells, particularly colon cancer cells, offer a powerful approach for inducing immune responses against colon cancer, and are an important aspect of the present invention.

Therefore, in further aspects of the present invention, the pharmaceutical
15 compositions described herein may be used to stimulate an immune response against cancer, particularly for the immunotherapy of colon cancer. Within such methods, the pharmaceutical compositions described herein are administered to a patient, typically a warm-blooded animal, preferably a human. A patient may or may not be afflicted with cancer. Pharmaceutical compositions and vaccines may be administered either prior to
20 or following surgical removal of primary tumors and/or treatment such as administration of radiotherapy or conventional chemotherapeutic drugs. As discussed above, administration of the pharmaceutical compositions may be by any suitable method, including administration by intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal, intradermal, anal, vaginal, topical and oral routes.

25 Within certain embodiments, immunotherapy may be active immunotherapy, in which treatment relies on the *in vivo* stimulation of the endogenous host immune system to react against tumors with the administration of immune response-modifying agents (such as polypeptides and polynucleotides as provided herein).

30 Within other embodiments, immunotherapy may be passive immunotherapy, in which treatment involves the delivery of agents with established

tumor-immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate antitumor effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T cells as discussed above, T lymphocytes (such as CD8⁺ cytotoxic T lymphocytes and CD4⁺ T-helper tumor-infiltrating lymphocytes), killer cells (such as Natural Killer cells and lymphokine-activated killer cells), B cells and antigen-presenting cells (such as dendritic cells and macrophages) expressing a polypeptide provided herein. T cell receptors and antibody receptors specific for the polypeptides recited herein may be cloned, expressed and transferred into other vectors or effector cells for adoptive immunotherapy. The polypeptides provided herein may also be used to generate antibodies or anti-idiotypic antibodies (as described above and in U.S. Patent No. 4,918,164) for passive immunotherapy.

Monoclonal antibodies may be labeled with any of a variety of labels for desired selective usages in detection, diagnostic assays or therapeutic applications (as described in U.S. Patent Nos. 6,090,365; 6,015,542; 5,843,398; 5,595,721; and 4,708,930, hereby incorporated by reference in their entirety as if each was incorporated individually). In each case, the binding of the labelled monoclonal antibody to the determinant site of the antigen will signal detection or delivery of a particular therapeutic agent to the antigenic determinant on the non-normal cell. A further object of this invention is to provide the specific monoclonal antibody suitably labelled for achieving such desired selective usages thereof.

Effector cells may generally be obtained in sufficient quantities for adoptive immunotherapy by growth *in vitro*, as described herein. Culture conditions for expanding single antigen-specific effector cells to several billion in number with retention of antigen recognition *in vivo* are well known in the art. Such *in vitro* culture conditions typically use intermittent stimulation with antigen, often in the presence of cytokines (such as IL-2) and non-dividing feeder cells. As noted above, immunoreactive polypeptides as provided herein may be used to rapidly expand antigen-specific T cell cultures in order to generate a sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage, monocyte, fibroblast and/or B cells, may be pulsed with immunoreactive polypeptides

or transfected with one or more polynucleotides using standard techniques well known in the art. For example, antigen-presenting cells can be transfected with a polynucleotide having a promoter appropriate for increasing expression in a recombinant virus or other expression system. Cultured effector cells for use in therapy
5 must be able to grow and distribute widely, and to survive long term *in vivo*. Studies have shown that cultured effector cells can be induced to grow *in vivo* and to survive long term in substantial numbers by repeated stimulation with antigen supplemented with IL-2 (*see*, for example, Cheever et al., *Immunological Reviews* 157:177, 1997).

Alternatively, a vector expressing a polypeptide recited herein may be
10 introduced into antigen presenting cells taken from a patient and clonally propagated *ex vivo* for transplant back into the same patient. Transfected cells may be reintroduced into the patient using any means known in the art, preferably in sterile form by intravenous, intracavitary, intraperitoneal or intratumor administration.

Routes and frequency of administration of the therapeutic compositions
15 described herein, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions and vaccines may be administered by injection (*e.g.*, intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (*e.g.*, by aspiration) or orally. Preferably, between 1 and 10 doses may be administered over a 52 week period.
20 Preferably, 6 doses are administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response, and is at least 10-50% above the basal (*i.e.*, untreated) level. Such response
25 can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells *in vitro*. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (*e.g.*, more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-
30 vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose

ranges from about 25 µg to 5 mg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (e.g., more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. Increases in preexisting immune responses to a tumor protein generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which may be performed using samples obtained from a patient before and after treatment.

Cancer Detection and Diagnostic Compositions, Methods and Kits

In general, a cancer may be detected in a patient based on the presence of one or more colon tumor proteins and/or polynucleotides encoding such proteins in a biological sample (for example, blood, sera, sputum urine and/or tumor biopsies) obtained from the patient. In other words, such proteins may be used as markers to indicate the presence or absence of a cancer such as colon cancer. In addition, such proteins may be useful for the detection of other cancers. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the biological sample.

Polynucleotide primers and probes may be used to detect the level of mRNA encoding a tumor protein, which is also indicative of the presence or absence of a cancer. In general, a tumor sequence should be present at a level that is at least two-fold, preferably three-fold, and more preferably five-fold or higher in tumor tissue than in normal tissue of the same type from which the tumor arose. Expression levels of a particular tumor sequence in tissue types different from that in which the tumor arose are irrelevant in certain diagnostic embodiments since the presence of tumor cells can be confirmed by observation of predetermined differential expression levels, e.g., 2-fold, 5-fold, etc, in tumor tissue to expression levels in normal tissue of the same type.

Other differential expression patterns can be utilized advantageously for diagnostic purposes. For example, in one aspect of the invention, overexpression of a tumor sequence in tumor tissue and normal tissue of the same type, but not in other normal tissue types, *e.g.* PBMCs, can be exploited diagnostically. In this case, the presence of metastatic tumor cells, for example in a sample taken from the circulation or some other tissue site different from that in which the tumor arose, can be identified and/or confirmed by detecting expression of the tumor sequence in the sample, for example using RT-PCR analysis. In many instances, it will be desired to enrich for tumor cells in the sample of interest, *e.g.*, PBMCs, using cell capture or other like techniques.

There are a variety of assay formats known to those of ordinary skill in the art for using a binding agent to detect polypeptide markers in a sample. *See, e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, the presence or absence of a cancer in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined cut-off value.

In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such assays include full length colon tumor

proteins and polypeptide portions thereof to which the binding agent binds, as described above.

The solid support may be any material known to those of ordinary skill in the art to which the tumor protein may be attached. For example, the solid support
5 may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support
10 using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent).
15 Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or
20 polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 μ g, and preferably about 100 ng to about 1 μ g, is sufficient to immobilize an adequate amount of binding agent.

Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with
25 both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (*see, e.g.,* Pierce Immunotechnology Catalog and Handbook, 1991, at
30 A12-A13).

In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody.

5 Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a detection reagent (preferably a second antibody capable of binding to a different site on the polypeptide) containing a reporter group is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

10 More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20™ (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to

15 bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (*i.e.*, incubation time) is a period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with colon cancer at least about 95% of that achieved at equilibrium between bound and unbound polypeptide.

20 Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support

25 with an appropriate buffer, such as PBS containing 0.1% Tween 20™. The second antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include those groups recited above.

The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide.

30 An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed

and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

10 To determine the presence or absence of a cancer, such as colon cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value for the detection of a cancer is the average mean signal obtained when the immobilized antibody is incubated with samples from
15 patients without the cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for the cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., *Clinical Epidemiology: A Basic Science for Clinical Medicine*, Little Brown and Co., 1985,
20 p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (*i.e.*, sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (*i.e.*, the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a
25 signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for a cancer.

30 In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the binding agent is immobilized on a membrane, such as

nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized binding agent as the sample passes through the membrane. A second, labeled binding agent then binds to the binding agent-polypeptide complex as a solution containing the second binding agent flows through the membrane. The detection of bound second binding agent may then be performed as described above. In the strip test format, one end of the membrane to which binding agent is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second binding agent and to the area of immobilized binding agent. Concentration of second binding agent at the area of immobilized antibody indicates the presence of a cancer. Typically, the concentration of second binding agent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of binding agent immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferred binding agents for use in such assays are antibodies and antigen-binding fragments thereof. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 μ g, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

Of course, numerous other assay protocols exist that are suitable for use with the tumor proteins or binding agents of the present invention. The above descriptions are intended to be exemplary only. For example, it will be apparent to those of ordinary skill in the art that the above protocols may be readily modified to use tumor polypeptides to detect antibodies that bind to such polypeptides in a biological sample. The detection of such tumor protein specific antibodies may correlate with the presence of a cancer.

A cancer may also, or alternatively, be detected based on the presence of T cells that specifically react with a tumor protein in a biological sample. Within certain methods, a biological sample comprising CD4⁺ and/or CD8⁺ T cells isolated from a patient is incubated with a tumor polypeptide, a polynucleotide encoding such a

polypeptide and/or an APC that expresses at least an immunogenic portion of such a polypeptide, and the presence or absence of specific activation of the T cells is detected. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by
5 Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with polypeptide (*e.g.*, 5 - 25 µg/ml). It may be desirable to incubate another aliquot of a T cell sample in the absence of tumor polypeptide to serve as a control. For CD4⁺ T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8⁺ T cells,
10 activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a cancer in the patient.

As noted above, a cancer may also, or alternatively, be detected based on the level of mRNA encoding a tumor protein in a biological sample. For example, at
15 least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify a portion of a tumor cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for (*i.e.*, hybridizes to) a polynucleotide encoding the tumor protein. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel
20 electrophoresis.

Similarly, oligonucleotide probes that specifically hybridize to a polynucleotide encoding a tumor protein may be used in a hybridization assay to detect the presence of polynucleotide encoding the tumor protein in a biological sample.

To permit hybridization under assay conditions, oligonucleotide primers
25 and probes should comprise an oligonucleotide sequence that has at least about 60%, preferably at least about 75% and more preferably at least about 90%, identity to a portion of a polynucleotide encoding a tumor protein of the invention that is at least 10 nucleotides, and preferably at least 20 nucleotides, in length. Preferably, oligonucleotide primers and/or probes hybridize to a polynucleotide encoding a
30 polypeptide described herein under moderately stringent conditions, as defined above. Oligonucleotide primers and/or probes which may be usefully employed in the

diagnostic methods described herein preferably are at least 10-40 nucleotides in length. In a preferred embodiment, the oligonucleotide primers comprise at least 10 contiguous nucleotides, more preferably at least 15 contiguous nucleotides, of a DNA molecule having a sequence as disclosed herein. Techniques for both PCR based assays and
5 hybridization assays are well known in the art (*see*, for example, Mullis et al., *Cold Spring Harbor Symp. Quant. Biol.*, 51:263, 1987; Erlich ed., *PCR Technology*, Stockton Press, NY, 1989).

One preferred assay employs RT-PCR, in which PCR is applied in conjunction with reverse transcription. Typically, RNA is extracted from a biological
10 sample, such as biopsy tissue, and is reverse transcribed to produce cDNA molecules. PCR amplification using at least one specific primer generates a cDNA molecule, which may be separated and visualized using, for example, gel electrophoresis. Amplification may be performed on biological samples taken from a test patient and from an individual who is not afflicted with a cancer. The amplification reaction may be
15 performed on several dilutions of cDNA spanning two orders of magnitude. A two-fold or greater increase in expression in several dilutions of the test patient sample as compared to the same dilutions of the non-cancerous sample is typically considered positive.

In another aspect of the present invention, cell capture technologies may
20 be used in conjunction, with, for example, real-time PCR to provide a more sensitive tool for detection of metastatic cells expressing colon tumor antigens. Detection of colon cancer cells in biological samples, e.g., bone marrow samples, peripheral blood, and small needle aspiration samples is desirable for diagnosis and prognosis in colon cancer patients.

Immunomagnetic beads coated with specific monoclonal antibodies to
25 surface cell markers, or tetrameric antibody complexes, may be used to first enrich or positively select cancer cells in a sample. Various commercially available kits may be used, including Dynabeads® Epithelial Enrich (Dynal Biotech, Oslo, Norway), StemSep™ (StemCell Technologies, Inc., Vancouver, BC), and RosetteSep (StemCell
30 Technologies). A skilled artisan will recognize that other methodologies and kits may also be used to enrich or positively select desired cell populations. Dynabeads®

Epithelial Enrich contains magnetic beads coated with mAbs specific for two glycoprotein membrane antigens expressed on normal and neoplastic epithelial tissues. The coated beads may be added to a sample and the sample then applied to a magnet, thereby capturing the cells bound to the beads. The unwanted cells are washed away
5 and the magnetically isolated cells eluted from the beads and used in further analyses.

RosetteSep can be used to enrich cells directly from a blood sample and consists of a cocktail of tetrameric antibodies that targets a variety of unwanted cells and crosslinks them to glycophorin A on red blood cells (RBC) present in the sample, forming rosettes. When centrifuged over Ficoll, targeted cells pellet along with the free
10 RBC. The combination of antibodies in the depletion cocktail determines which cells will be removed and consequently which cells will be recovered. Antibodies that are available include, but are not limited to: CD2, CD3, CD4, CD5, CD8, CD10, CD11b, CD14, CD15, CD16, CD19, CD20, CD24, CD25, CD29, CD33, CD34, CD36, CD38, CD41, CD45, CD45RA, CD45RO, CD56, CD66B, CD66e, HLA-DR, IgE, and TCR $\alpha\beta$.

15 Additionally, it is contemplated in the present invention that mAbs specific for colon tumor antigens can be generated and used in a similar manner. For example, mAbs that bind to tumor-specific cell surface antigens may be conjugated to magnetic beads, or formulated in a tetrameric antibody complex, and used to enrich or positively select metastatic colon tumor cells from a sample. Once a sample is enriched
20 or positively selected, cells may be lysed and RNA isolated. RNA may then be subjected to RT-PCR analysis using colon tumor-specific primers in a real-time PCR assay as described herein. One skilled in the art will recognize that enriched or selected populations of cells may be analyzed by other methods (*e.g. in situ* hybridization or flow cytometry).

25 In another embodiment, the compositions described herein may be used as markers for the progression of cancer. In this embodiment, assays as described above for the diagnosis of a cancer may be performed over time, and the change in the level of reactive polypeptide(s) or polynucleotide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter
30 performed as needed. In general, a cancer is progressing in those patients in whom the level of polypeptide or polynucleotide detected increases over time. In contrast, the

cancer is not progressing when the level of reactive polypeptide or polynucleotide either remains constant or decreases with time.

Certain *in vivo* diagnostic assays may be performed directly on a tumor. One such assay involves contacting tumor cells with a binding agent. The bound
5 binding agent may then be detected directly or indirectly via a reporter group. Such binding agents may also be used in histological applications. Alternatively, polynucleotide probes may be used within such applications.

As noted above, to improve sensitivity, multiple tumor protein markers may be assayed within a given sample. It will be apparent that binding agents specific
10 for different proteins provided herein may be combined within a single assay. Further, multiple primers or probes may be used concurrently. The selection of tumor protein markers may be based on routine experiments to determine combinations that results in optimal sensitivity. In addition, or alternatively, assays for tumor proteins provided herein may be combined with assays for other known tumor antigens.

15 The present invention further provides kits for use within any of the above diagnostic methods. Such kits typically comprise two or more components necessary for performing a diagnostic assay. Components may be compounds, reagents, containers and/or equipment. For example, one container within a kit may contain a monoclonal antibody or fragment thereof that specifically binds to a tumor protein.
20 Such antibodies or fragments may be provided attached to a support material, as described above. One or more additional containers may enclose elements, such as reagents or buffers, to be used in the assay. Such kits may also, or alternatively, contain a detection reagent as described above that contains a reporter group suitable for direct or indirect detection of antibody binding.

25 Alternatively, a kit may be designed to detect the level of mRNA encoding a tumor protein in a biological sample. Such kits generally comprise at least one oligonucleotide probe or primer, as described above, that hybridizes to a polynucleotide encoding a tumor protein. Such an oligonucleotide may be used, for example, within a PCR or hybridization assay. Additional components that may be
30 present within such kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate the detection of a polynucleotide encoding a tumor protein.

The following Examples are offered by way of illustration and not by way of limitation.

EXAMPLES

EXAMPLE 1

PREPARATION OF COLON TUMOR SUBTRACTION LIBRARIES AND IDENTIFICATION OF COLON TUMOR PROTEIN cDNAs

This Example illustrates the identification of cDNA molecules encoding colon tumor proteins. PolyA mRNA was prepared from a pool of three colon tumor cell lines (adenocarcinomas) grown in SCID mice were subtracted with a set of transcripts from normal lung, adrenal gland, bone marrow, small intestine, stomach, pancreas, normal colon, HMEC (human mammary epithelial cell line) and SCID mouse liver/spleen samples. The cDNA synthesis, hybridizations, and PCR amplifications were performed according to standard procedures (Clontech), with modifications at the cDNA digestion steps and in the tester to driver hybridization ratios. Following the PCR amplification steps, the cDNAs were cloned into the pCR2.1 plasmid vector. To analyze the efficiency of the subtraction, the housekeeping gene, actin, was PCR amplified from dilutions of subtracted as well as unsubtracted PCR samples. This results suggest that the library was enriched for genes overexpressed in colon tumor samples.

The Clontech PCR-based cDNA subtraction approach was utilized to prepare two cDNA libraries from pools of tester mRNA collected from three Dukes B stage colon tumor samples. Eight normal tissues, including lung, adrenal gland, bone marrow, small intestine, heart, pancreas, colon, and liver were represented in the driver mRNA pool. The two libraries, CS/B1105 and CS/B1605, shared the same tester and driver mRNA samples but differed in their tester:driver ratios (1:5 and 1:30, respectively). To analyze the efficiency of the subtraction, the housekeeping gene, actin, was PCR amplified from dilutions of subtracted as well as unsubtracted PCR samples. This results suggest that the library was enriched for genes overexpressed in colon tumor samples. 172 randomly selected clones were subjected to DNA sequencing and are presented herein as SEQ ID NO: 57-229. Additional sequence data was

generated by bulk sequencing clones isolated from the CS/B1105 and CS/B1605 subtraction libraries and are presented herein as SEQ ID NO: 230-1660.

Further disclosed herein are sequences derived from a fourth colon tumor expression library which sequences are presented herein as SEQ ID NO: 1661-1704.

5 Antigens obtained from this colon PCR subtracted cDNA libraries may be used for immunotherapeutic purposes in individuals with colon adenocarcinoma and/or as diagnostic markers for colon adenocarcinoma.

10

EXAMPLE 2

ANALYSIS OF CDNA EXPRESSION USING MICROARRAY TECHNOLOGY

In additional studies, sequences disclosed herein were evaluated for overexpression in specific tumor tissues by microarray analysis. Using this approach, cDNA sequences were PCR amplified and their mRNA expression profiles in tumor
15 and normal tissues were examined using cDNA microarray technology essentially as described (Skena *et al.*, *Science* 270(5235):467-70 (1995). In brief, the clones were arrayed onto glass slides as multiple replicas, with each location corresponding to a unique cDNA clone (as many as 5500 clones can be arrayed on a single slide, or chip). Each chip was hybridized with a pair of cDNA probes that were fluorescence-labeled
20 with Cy3 and Cy5, respectively. Typically, 1µg of polyA⁺ RNA was used to generate each cDNA probe. After hybridization, the chips were scanned and the fluorescence intensity recorded for both Cy3 and Cy5 channels. There were multiple built-in quality control steps. First, the probe quality was monitored using a panel of ubiquitously expressed genes. Secondly, the control plate also includee yeast DNA fragments of
25 which complementary RNA were spiked into the probe synthesis for measuring the quality of the probe and the sensitivity of the analysis. Currently, this methodology offers a sensitivity of 1 in 100,000 copies of mRNA. Finally, the reproducibility of this technology was ensured by including duplicated control cDNA elements at different locations.

30 Table 2 identifies 27 clones found to be at least two-fold overexpressed in colon tumor cells as compared to a panel of normal tissues by microarray analysis.

Table 2

array	Clone Sequence Identifier	Ratio	clone I.D.
p0175r03c18	R0676 F9	2.62	72239,
p0174r13c21	R0675 A11	2.16	72237,
p0174r09c13	R0674 A7	2.67	72236,
p0176r01c22	R0680 B11	2.3	72244,
p0174r05c17	R0673 A9	2.09	72234,
p0174r08c24	R0673 H12	2.06	71574, 72235
p0174r16c17	R0675 G9	2.46	72238,
p0175r07c22	R0677 F11	3.21	72241,
p0176r03c02	R0680 F1	2.93	72245,
p0176r04c06	R0680 H3	2.09	72246,
p0177r07c22	R0685 F11	2.27	71675, 72247, 72902, 71041
p0177r13c06	R0687 B3	3.43	72249, 72904, 70985
p0175r10c04	R0678 D2	2.05	70424, 72899
p0176r16c05	R0683 G3	2.03	70426, 72900
p0174r07c23	R0673 E12	2.58	72901,
p0174r03c05	R0672 E3	2.09	72233
p0175r06c13	R0677 C7	2.13	72240
p0175r11c19	R0678 E10	3.44	72242
p0175r14c21	R0679 C11	2.75	72243
p0174r10c20	R0674 D10	2.58	71575
p0172r01c06	R0664 B3	2.05	71569
p0173r09c05	R0670 A3	2.35	71571
p0172r05c18	R0665 B9	2.36	70580
p0175r04c07	676_G4 & 678_H12 & 681_B5 & 682_E4	3.94	70581, 70582, 70586, 70589
p0176r07c14	R0681 F7	2.27	70587
p0176r08c22	R0681 H11	2.02	70584
p0176r08c06	R0681 H3	2.25	70588

In addition, the following clones (Table 3) were repeatedly identified by microarray analysis as being at least two-fold overexpressed in colon tumor cells as compared to a panel of normal tissues.

Table 3

70971	70973	70974	71049
70975	70977	70980	71058
70981	70982	70986	71063
70987	70988	70997	71051
70998	70999	71006	71059
71008	71009	71011	71065
71012	71018	71021	71055
71022	71024	71028	71062
71029	71032	71036	71066
71037	71039	71045	

EXAMPLE 3

5 ANALYSIS OF CDNA EXPRESSION USING REAL-TIME PCR

Two clones isolated from the subtraction library described in Example 1 and that showed at least 2-fold overexpression in colon tumors by microarray, were selected for further mRNA expression analysis by real-time PCR. The first clone, C1490P (SEQ ID NO:1660; also referred to as clone R0680 B11 and 72244), showed
 10 no significant similarity to any known sequences when searched against the Genbank nucleic acid database. The second clone, C1491P (SEQ ID NO:1681; also referred to as clone R0683 G3 and 70426), has some similarity to adenovirus E1A enhancer binding protein (set forth in SEQ ID NO:1788 (cDNA) and 1789 (amino acid)).

The first-strand cDNA used in the quantitative real-time PCR was
 15 synthesized from 20 µg of total RNA that was treated with DNase I (Amplification Grade, Gibco BRL Life Technology, Gaithersburg, MD), using Superscript Reverse Transcriptase (RT) (Gibco BRL Life Technology, Gaithersburg, MD). Real-time PCR was performed with a GeneAmp™ 5700 sequence detection system (PE Biosystems, Foster City, CA). The 5700 system uses SYBR™ green, a fluorescent dye that only
 20 intercalates into double stranded DNA, and a set of gene-specific forward and reverse primers. The increase in fluorescence was monitored during the whole amplification process. The optimal concentration of primers was determined using a checkerboard approach and a pool of cDNAs from breast tumors was used in this process. The PCR reaction was performed in 25 µl volumes that include 2.5 µl of SYBR green buffer, 2 µl
 25 of cDNA template and 2.5 µl each of the forward and reverse primers for the gene of

interest. The cDNAs used for RT reactions were diluted 1:10 for each gene of interest and 1:100 for the β -actin control. In order to quantitate the amount of specific cDNA (and hence initial mRNA) in the sample, a standard curve was generated for each run using the plasmid DNA containing the gene of interest. Standard curves were generated using the Ct values determined in the real-time PCR which were related to the initial cDNA concentration used in the assay. Standard dilution ranging from $20\text{-}2 \times 10^6$ copies of the gene of interest was used for this purpose. In addition, a standard curve was generated for β -actin ranging from 200fg-2000fg. This enabled standardization of the initial RNA content of a tissue sample to the amount of β -actin for comparison purposes. The mean copy number for each group of tissues tested was normalized to a constant amount of β -actin, allowing the evaluation of the over-expression levels seen with each of the genes.

The real-time analysis confirmed previous microarray results and showed that C1490P is overexpressed in the majority of colon tumor samples in comparison to normal samples. Overexpression of C1490P was also seen in lymph nodes and thymus. Some C1490P expression was observed in normal colon but at a much lower level than was seen in tumor samples. Likewise, some low levels of expression were observed in breast, esophagus, small intestine, stomach, trachea, thymus, and bone marrow. C1491P is overexpressed in the majority of colon tumor samples when compared to normal colon and a panel of other normal tissue. Low expression of this gene was observed in normal pancreas, pituitary, and low expression in some salivary and adrenal gland samples. Thus, the results indicate that these 2 candidates may be used for immunotherapeutic purposes in individuals with colon cancer and/or as diagnostic markers for colon cancer.

EXAMPLE 4

PEPTIDE PRIMING OF T-HELPER LINES

Generation of CD4⁺ T helper lines and identification of peptide epitopes derived from tumor-specific antigens that are capable of being recognized by CD4⁺ T cells in the context of HLA class II molecules, is carried out as follows:

Fifteen-mer peptides overlapping by 10 amino acids, derived from a tumor-specific antigen, are generated using standard procedures. Dendritic cells (DC) are derived from PBMC of a normal donor using GM-CSF and IL-4 by standard protocols. CD4⁺ T cells are generated from the same donor as the DC using MACS beads (Miltenyi Biotec, Auburn, CA) and negative selection. DC are pulsed overnight with pools of the 15-mer peptides, with each peptide at a final concentration of 0.25 µg/ml. Pulsed DC are washed and plated at 1×10^4 cells/well of 96-well V-bottom plates and purified CD4⁺ T cells are added at 1×10^5 /well. Cultures are supplemented with 60 ng/ml IL-6 and 10 ng/ml IL-12 and incubated at 37°C. Cultures are restimulated as above on a weekly basis using DC generated and pulsed as above as antigen presenting cells, supplemented with 5 ng/ml IL-7 and 10 U/ml IL-2. Following 4 *in vitro* stimulation cycles, resulting CD4⁺ T cell lines (each line corresponding to one well) are tested for specific proliferation and cytokine production in response to the stimulating pools of peptide with an irrelevant pool of peptides used as a control.

20

EXAMPLE 5

GENERATION OF TUMOR-SPECIFIC CTL LINES USING IN VITRO WHOLE-GENE PRIMING

Using *in vitro* whole-gene priming with tumor antigen-vaccinia infected DC (see, for example, Yee et al, *The Journal of Immunology*, 157(9):4079-86, 1996), human CTL lines are derived that specifically recognize autologous fibroblasts transduced with a specific tumor antigen, as determined by interferon-γ ELISPOT analysis. Specifically, dendritic cells (DC) are differentiated from monocyte cultures derived from PBMC of normal human donors by growing for five days in RPMI medium containing 10% human serum, 50 ng/ml human GM-CSF and 30 ng/ml human IL-4. Following culture, DC are infected overnight with tumor antigen-recombinant vaccinia virus at a multiplicity of infection (M.O.I) of five, and matured overnight by

30

the addition of 3 µg/ml CD40 ligand. Virus is then inactivated by UV irradiation. CD8+ T cells are isolated using a magnetic bead system, and priming cultures are initiated using standard culture techniques. Cultures are restimulated every 7-10 days using autologous primary fibroblasts retrovirally transduced with previously identified
5 tumor antigens. Following four stimulation cycles, CD8+ T cell lines are identified that specifically produce interferon-γ when stimulated with tumor antigen-transduced autologous fibroblasts. Using a panel of HLA-mismatched B-LCL lines transduced with a vector expressing a tumor antigen, and measuring interferon-γ production by the CTL lines in an ELISPOT assay, the HLA restriction of the CTL lines is determined.

10

EXAMPLE 6

GENERATION AND CHARACTERIZATION OF ANTI-TUMOR ANTIGEN MONOCLONAL ANTIBODIES

Mouse monoclonal antibodies are raised against *E. coli* derived tumor
15 antigen proteins as follows: Mice are immunized with Complete Freund's Adjuvant (CFA) containing 50 µg recombinant tumor protein, followed by a subsequent intraperitoneal boost with Incomplete Freund's Adjuvant (IFA) containing 10µg recombinant protein. Three days prior to removal of the spleens, the mice are immunized intravenously with approximately 50µg of soluble recombinant protein. The
20 spleen of a mouse with a positive titer to the tumor antigen is removed, and a single-cell suspension made and used for fusion to SP2/O myeloma cells to generate B cell hybridomas. The supernatants from the hybrid clones are tested by ELISA for specificity to recombinant tumor protein, and epitope mapped using peptides that spanned the entire tumor protein sequence. The mAbs are also tested by flow cytometry
25 for their ability to detect tumor protein on the surface of cells stably transfected with the cDNA encoding the tumor protein.

EXAMPLE 7

SYNTHESIS OF POLYPEPTIDES

30 Polypeptides are synthesized on a Perkin Elmer/Applied Biosystems Division 430A peptide synthesizer using Fmoc chemistry with HPTU (O-

Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence is attached to the amino terminus of the peptide to provide a method of conjugation, binding to an immobilized surface, or labeling of the peptide. Cleavage of the peptides from the solid support is carried out using the following cleavage
5 mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides are precipitated in cold methyl-t-butyl-ether. The peptide pellets are then dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of 0%-
10 60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) is used to elute the peptides. Following lyophilization of the pure fractions, the peptides are characterized using electrospray or other types of mass spectrometry and by amino acid analysis.

From the foregoing it will be appreciated that, although specific
15 embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

What is Claimed:

1. An isolated polynucleotide comprising a sequence selected from the group consisting of:
 - (a) sequences provided in SEQ ID NO:1-1788;
 - (b) complements of the sequences provided in SEQ ID NO:1-1788;
 - (c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NO:1-1788;
 - (d) sequences that hybridize to a sequence provided in SEQ ID NO:1-1788, under moderately stringent conditions;
 - (e) sequences having at least 75% identity to a sequence of SEQ ID NO:1-1788;
 - (f) sequences having at least 90% identity to a sequence of SEQ ID NO:1-1788; and
 - (g) degenerate variants of a sequence provided in SEQ ID NO:1-1788.
2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) sequences encoded by a polynucleotide of claim 1; and
 - (b) sequences having at least 70% identity to a sequence encoded by a polynucleotide of claim 1;
 - (c) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1;
 - (d) sequences set forth in SEQ ID NO:1789;
 - (e) sequences having at least 70% identity to a sequence set forth in SEQ ID NO:1789; and
 - (f) sequences having at least 90% identity to a sequence set forth in SEQ ID NO:1789.

3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.
4. A host cell transformed or transfected with an expression vector according to claim 3.
5. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2.
6. A method for detecting the presence of a cancer in a patient, comprising the steps of:
 - (a) obtaining a biological sample from the patient;
 - (b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 2;
 - (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and
 - (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.
7. A fusion protein comprising at least one polypeptide according to claim 2.
8. An oligonucleotide that hybridizes to a sequence recited in SEQ ID NO:1-1788 under moderately stringent conditions.
9. A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:
 - (a) polypeptides according to claim 2;
 - (b) polynucleotides according to claim 1; and

(c) antigen-presenting cells that express a polypeptide according to claim 2,

under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

10. An isolated T cell population, comprising T cells prepared according to the method of claim 9.

11. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1;
- (c) antibodies according to claim 5;
- (d) fusion proteins according to claim 7;
- (e) T cell populations according to claim 10; and
- (f) antigen presenting cells that express a polypeptide according to claim 2.

12. A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 11.

13. A method for the treatment of a cancer in a patient, comprising administering to the patient a composition of claim 11.

14. A method for determining the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with an oligonucleotide according to claim 8;

(c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and

(d) compare the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

15. A diagnostic kit comprising at least one oligonucleotide according to claim 8.

16. A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.

17. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(a) incubating CD4⁺ and/or CD8⁺ T cells isolated from a patient with at least one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; and (iii) antigen presenting cells that express a polypeptide of claim 2, such that T cell proliferate;

(b) administering to the patient an effective amount of the proliferated T cells,

and thereby inhibiting the development of a cancer in the patient.

SEQUENCE LISTING

<110> Corixa Corporation
King, Gordon E.
Meagher, Madeleine Joy
Xu, Jiangchun
Secrist, Heather

<120> COMPOSITIONS AND METHODS FOR THE THERAPY
AND DIAGNOSIS OF COLON CANCER

<130> 210121.547PC

<140> PCT

<141> 2001-07-31

<160> 1789

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 656

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> 544, 560, 627, 635

<223> n = A,T,C or G

<400> 1

```
cctccacaaa gtgtctgtgc tgttctgtgt ctccaagcca gtcttcatgt gtaggggtggg 60
gggtgaggac acactttcgg gctctgcagg gaggccagaa gtattcttcc ctccatcaat 120
agctttcttg ttggaaagga gggaatcctt ttttcagag tcaataacaa tcttaaggac 180
atctggctca gaggtgggtt ctgcaagttg tttttcattc tcagaaaagt catcgtcttc 240
caagtgcagg aggaggggac tgatagagtc actctccctc tgaacatcag gcaactcttt 300
caaaccagtt cccaagtgtc caacctggaa agttgtctctg cttccaggag gaaccttact 360
aataaaaagc cgcagagcat cccctgggaa ctctgtatcc atagagctgg gtagttcagc 420
caggccaaca gtagtcatcat ttagttgttg attaagaaag gcaatttcat tgagcagtga 480
agtcagtgtc tcatcagtat catctcatc ttccatgtta ggtcagcagt tcaactggaat 540
caanactgct tctctatan ctgatgttac tttcctcagt tccatctcta tgctttgaa 600
cccttgaaaa ctttcatctt ttatttntga aaaangaaga atcctttgaa tttcac 656
```

<210> 2

<211> 373

<212> DNA

<213> Homo sapiens

<400> 2

```
ctgtcccatg gggtccttat tgtaatctag accatcttgt tctagatggg cacttaagcc 60
ctgtttcttc atagtctgtt atgctgtcat ttggacctgg atgcttcttg tttcttccag 120
caatttttgt ttgtgttttt tgtgttgaa gagaggaaca ttttaaggagt tagataaact 180
ggtaattttc agatgtgtag aaaattgcat aggtgggtgaa agccaatgcc ataggctctg 240
aaatttttact atttctaca tcaggaaatg tgtacaaaaa gtgctaaaaat gccagaata 300
attttgagta tctaaagata gataaatctt ttcactctgag tggaaatggc attatgactt 360
tatattctca tgg
```

<210> 3

<DIR>
<DIR>

547pc.app.txt	1093 KB	7/31/01
---------------	---------	---------

1 file(s)
Total filesize 1093 KB
2 folder(s)
0 kilobytes free



THIS PAGE BLANK (USPTO)